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ABSTRACT 
 
Clinical observation suggest that bone formation is influenced by the environmental 
niche where it takes place and specifically that soft connective tissues may inhibit the 
bone healing process. The aim of the studies described in this thesis is to test the 
hypothesis that fibroblasts inhibit the differentiation and function of osteoblasts in vitro. 
To address this aim the ability of fibroblasts and their supernatants to inhibit osteoblast 
differentiation was investigated. In addition, the inhibitory effects of gingival and 
periodontal ligament fibroblasts were compared. Next Bone Morphogenetic Proteins 
(BMPs) and their antagonists were tested for their ability to modulate the activity of 
fibroblast supernatants. Finally the effects of fibroblast supernatants on osteoblast 
chemotactic responses were investigated. 
 
Primary fibroblasts were isolated from rat gingivae, skin, oral mucosa and periodontal 
ligament (PDL) using explant cultures. Primary osteoblast cultures were established by 
enzymatic digestion of neonatal rat calvariae. In other experiments the osteoblastic cell 
line ROS 17/2.8 was used. Osteoblast differentiation was assessed by measuring 
alkaline phosphatase (ALP). 
 
In co-culture experiments using 3-D collagen gels and diffusion chamber inserts 
fibroblasts strongly inhibited osteoblast differentiation. Furthermore conditioned medium 
from superficial connective tissues fibroblasts consistently inhibited osteoblast 
differentiation (greater than 50% inhibition of ALP expression. In contrast, PDL cells 
strongly stimulated ALP expression (greater than 100% increase). Stimulation of ROS 
17/2.8 cells with BMP-2 increased ALP expression (more than 3 fold increase with 
10ng/ml BMP-2), and this effect could be completely blocked by the BMP-antagonist 
100ng/ml noggin. Similarly conditioned media from gingival, oral mucosal and skin 
fibroblasts totally suppressed the effects of BMP-2. In contrast, PDL conditioned media 
stimulated ALP expression in additively with BMP-2, and his effect could also be 
blocked by noggin.   
 
Using a micro-well Boyden Chamber both PDGF and BMP-2 caused a dose-dependent 
increase in chemotaxis. However fibroblast conditioned medium totally blocked the 
chemotactic effects on BMP-2, but had no effect on PDGF-induced chemotaxis. 
 
Overall these studies demonstrate that fibroblasts from superficial connective tissues 
(gingival, oral mucosa and skin) can inhibit osteoblast function by secretion of BMP-
antagonists and that superficial connective tissues and PDL are distinct in respect to 
their role in bone healing. Further studies are needed to identify the specific molecular 
identity of this inhibitory activity and to extend these observations to an in vitro model. 
However in the longer term it is proposed that information on the regional expression of 
BMP inhibitors may lead to novel therapeutic interventions to promote bone growth in 
periodontal and implant related bone regeneration procedures. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 BONE 
Bone is a highly specialized form of connective tissue. It is distinguished from 
other forms of connective tissue by the fact that it is extremely strong and yet 
can respond to mechanical loading. These mechanical properties result from the 
deposition within a relatively soft organic matrix of a complex mineral substance, 
largely composed of calcium, phosphate, and carbonate.  Embryologically, bone 
is formed by two separate developmental processes described as 
intramembranous and endochondral ossification (Bortell, et al., 1990; Craft & 
Sargent, 1989). When ossification has occurred directly by direct mineralization 
of an osteoid matrix, it is classified as being intramembranous in character. In 
intramembranous ossification, mesenchymal cells with an abundant vascular 
supply develop foci of extracellular collagen deposition. Osteoblasts begin 
secreting osteoid into which calcium salts are deposited. Such direct bone 
formation is responsible for the genesis of the cranial vault, the facial skeleton 
and parts of the mandible, scapula and clavicle.  Endochondral bone formation 
involves a cartilaginous phase, where mesenchymal stem cells differentiate into 
a primitive hyaline cartilage. Blood vessels and bone forming units resorb the 
cartilage and replace it with osteoid while invading this matrix. Weight-bearing 
bones and those terminating in joints comprise most of this group of bones. In 
addition, most of the cranial base and a portion of the mandible are 
endochondral in character (Frost & Jee, 1994a; Frost & Jee, 1994b). 
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1.2 STRUCTURE OF BONE 
1.2.1 Macroscopic Structure 
 
Bone varies according to local architecture but can be broadly divided into two 
categories: compact (Burchardt, 1983) and trabecular (or cancellous) bone. 
Bone can be further classified according to its shape: long, short and flat bone. 
Long bones are subdivided into epiphysis, metaphysis, and diaphysis regions:  
Epiphyses and metaphyses are characterized by a compact layer that surrounds 
a body of spongy bone consisting of trabeculae, either in the shape of rods or 
plates. Towards the diaphysis the cortical bone becomes thicker and the 
trabeculae are replaced by a coherent marrow cavity. In small bones such as 
vertebrae, carpal and tarsal bones, there is no diaphysis and the metaphyses 
have merged. Ribs, the mandible, and certain parts of the skull also consist of 
cancellous bone surrounded by a cortical layer. The mineralized structure of 
bone is enclosed by the periosteal and endosteal envelopes. The vascular 
canals within compact bone are continuations of the periosteal or endosteal 
envelopes (endocortical or haversian envelope). All three envelopes share two 
important features: osteogenic potential and abundant vascularization. These 
functions enable the envelopes to participate in modelling and remodelling 
activities, as well as in bone repair. The periosteum covers the outer surface of 
the bones, with the exception of the articular surfaces and tendon and ligament 
insertions.  
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Figure 1.1: Main features of a long bone. (Clifton, 2008).  
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1.2.2 Microscopic Structure 
 
Based on the orientation of the collagen fibrils, two types of bone tissues are 
distinguished: woven bone and lamellar bone (Palumbo, et al., 1990)  
 
 
Woven bone 
In woven bone the collagen fibrils are oriented in a random or felt-like manner. 
Woven bone is formed predominantly in embryos and growing children, and is 
later replaced by lamellar bone. In the adult, it appears when accelerated bone 
formation is required, as in the bony callus during fracture repair and in 
pathologic conditions like Paget’s disease, renal osteodystrophy, 
hyperparathyroidism, or fluorosis. Besides its interlacing fibrils, woven bone is 
characterized by more numerous and larger osteocytes and, in 
microradiographs, by its high mineral density (Berkovitz, 2002).  
 
 
Lamellar bone 
Lamellar bone is characterized by 3-5 µm wide layers of parallel collagen fibrils. 
The orientation of the fibrils changes from lamella to lamella, a construction that 
is often compared to plywood. This fibrillar arrangement was first analyzed by 
polarized light and later confirmed by electron microscopy.  
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1.3 BONE CELLS 
1.3.1 Osteoblasts  
Osteoblasts are of mesenchymal origin, arising primarily from stromal cells 
found in bone marrow. These multipotent stromal stem cells have an endless 
capacity for renewal but do not synthesize many of the proteins necessary for 
bone formation. Some of these stromal precursors, under the influence of 
growth factors and other stimuli, evolve into more differentiated osteoblasts. The 
periosteum serves as an important but not exclusive reservoir of osteoblasts for 
skeletal repair (Tenenbaum, 1990). 
 
The differentiation process induces activation of new genes while expression of 
others is suppressed as cells adopt their final phenotypes. From the 
undifferentiated multi-potent stromal stem cells arises a group of mesenchymal 
cells that have been termed "inducible osteoprogenitor cells" (IOPCs). The 
IOPCs respond to Bone Morphogenetic Protein (BMP) and other growth factors, 
eventually differentiating into "determined osteoprogenitor cells" (DOPCs) (Forell 
1983; Urist, et al., 1983). The DOPCs, under the influence of a variety of 
systemic and bone-derived growth factors, mature into osteoblasts. Interestingly, 
both the IOPC and DOPC populations appear to have a limited capacity to 
divide and therefore, unlike the multipotent stem cells, can not self-renew (Dixon 
1982). Both the IOPCs and DOPCs are found within the bone marrow and give 
rise to orthotopic (intraskeletal) bone formation. However, IOPCs are also found 
in other connective tissues and therefore can be a source of heterotopic 
(extraskeletal) bone formation (Forell 1983). Dysregulation of these precursor 
cells may manifest clinically in diseases such as fibrodyplasia ossificans 
progressiva, a genetic disease characterized by the ossification of skeletal 
muscle and other connective tissues, or in the periarticular heterotopic 
ossification that can complicate skeletal trauma (Browner 1992). 
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Synthetic function of osteoblasts 
The principal role of osteoblasts is to form new bone via the synthesis of various 
proteins and glycoproteins. Other functions include the regulation of bone 
remodelling and mineral metabolism. Studies of osteoblastic cells isolated from 
trabecular bone, embryonic calvaria, and osteosarcoma have established a set 
of secreted molecules that have been considered phenotypic markers of 
osteoblastic function (Rodan 1983; Stein, et al., 1990). These include the 
synthesis of type I collagen, the expression of alkaline phosphatase (ALP), the 
secretion of osteocalcin, and the production of mineralized matrix (Manolagas & 
Jilka, 1995; Rodan, 1992). The phenotype of osteoblasts can be modulated by 
several factors including 1, 25-(OH)2 D3 (vitamin D3), parathyroid hormone 
(PTH), glucocorticoids, prostanoids, and a number of cytokine growth factors 
(Beresford, et al., 1984; Bonewald, et al., 1992; Fang & Hahn, 1991; McSheehy 
& Chambers, 1986; Owen, et al., 1991; Price & Baukol, 1980).  
 
Type I Collagen 
Type I collagen is the single most abundant protein in the human body and the 
major organic component of bone matrix. The production of type I collagen by 
osteoblasts heralds their differentiation into a more mature phenotype (Risteli & 
Risteli, 1993). Abundant type I collagen is produced during the proliferative 
phase of osteoblast development and is the first recognizable marker of 
differentiation. In mesenchymal precursor cells, type I collagen synthesis is 
always linked with that of type III collagen. However, once cells are committed to 
the osteoblast lineage, type III collagen is no longer expressed (Risteli & Risteli, 
1993). Disordered type I collagen synthesis by osteoblasts is seen in a variety of 
diseases. Errors in processing can give rise to abnormalities in collagen 
structure. For example, osteogenesis imperfecta (brittle bone syndrome) results 
from a defect in either the coding or processing of collagen and gives rise to a 
heterogeneous group of genetic diseases characterized by increased bone 
fragility (Whyte, 1993). 
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Alkaline Phosphatase 
The most widely measured osteoblast marker is alkaline phosphatase (ALP), an 
enzyme which catalyzes the hydrolysis of phosphate esters at an alkaline pH 
(Harris, 1989). In humans, three isoenzymes are currently known: (i) tissue non-
specific, (ii) intestinal, and (iii) placental. The tissue non-specific isoenzymes has 
three isoforms, expressed in bone, liver, and kidney, which contain different 
carbohydrate moieties on the same polypeptide backbone (Cole 1990). The 
skeletal isoform of ALP is a glycoprotein found on the cell membrane of 
osteoblasts (Harris, 1989). Several studies have demonstrated the importance 
of ALP in bone matrix mineralization. For example, a mis-sense mutation in the 
ALP gene results in the potentially lethal clinical syndrome known as 
hypophosphatasia, a disease characterized by reduced mineralization of the 
skeleton (Whyte, 1993). Total ALP activity has been recognized as a reliable 
indicator of osteoblast differentiation. For example, several human 
osteosarcoma cell lines have been characterized as osteoblastic by their ability 
to express ALP in culture (Fedde, 1992; Rodan, et al., 1987).  
 
Osteocalcin 
Osteocalcin is the major non-collagenous late specific marker of bone. It is a low 
molecular weight vitamin K-dependent protein that is synthesized exclusively by 
osteoblasts and odontoblasts. When osteocalcin was first discovered, it was 
called bone Gla protein (BGP) because it contained three carboxyglutamic acid 
(Gla) residues (Poser, et al., 1980). Osteocalcin is produced by mature 
osteoblasts during the mineralization phase and is only marginally detectable 
during the earlier phases of proliferation and matrix maturation (Price, 1985). 
Some investigators have suggested that osteocalcin may act either as a 
cytokine or as a chemoattractant for osteoblasts, osteoclasts, and blood 
monocytes. It has been shown that serum and synovial fluid osteocalcin levels 
reflect the activity of fully differentiated non-dividing osteoblasts and correlate 
with the extent of new bone formation. As a result, osteocalcin levels are 
elevated in infants, children, and in patients with conditions characterized by 
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increased bone metabolism, such as Paget's disease, osteomalacia, 
pathological bone resorption, and osteitis fibrosa cystica (Malone, et al., 1982). 
Analysis of mice lacking osteocalcin showed that osteocalcin is a negative 
regulator of bone formation. These mice had normal bones at birth but had 
significantly increased bone density and thickness at 6 months. Their 
osteoblasts deposited more bone matrix than those of wild-type mice, though 
mineralization was not affected. (Holbauer & Heufelder, 1997; Wolf, 1996) 
 
Other Osteoblast Products 
There are several other non-collagenous proteins found in the organic bone 
matrix, including osteonectin, osteopontin, bone sialoprotein, biglycan, decorin, 
matrix Gla-protein, and bone acidic glycoprotein that are believed to play an 
important role in the regulation of bone growth and mineralization. Osteonectin 
is produced by osteoblasts and may mediate the deposition of hydroxyapatite, 
bind to growth factors, and influence the cell cycle. Studies by Delany and co-
workers indicate that osteonectin is important for osteoblast formation, 
maturation, and survival. They found that marrow stroma from osteonectin-null 
mice contains fewer osteoblastic precursors than that of control mice. The 
mutant cells exhibited decreased formation of mineralized nodules, as well as 
diminished expression of osteocalcin mRNA and response to PTH (Delany, et 
al., 2003). Osteopontin, although not found exclusively in bone, may be 
implicated in regulating mineralization. Similarly, bone sialoprotein, which is 
bone specific, and bone acidic glycoprotein are also thought to play a role in 
mineralization. Biglycan and decorin are proteoglycans that may bind to collagen 
and various growth factors in the matrix. Finally, matrix Gla-protein may be 
involved in cartilage metabolism (Manolagas & Jilka, 1995; Rodan, 1992).  
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1.3.2 Osteocytes 
Osteoblasts that have become encased in mineralized matrix are termed 
osteocytes. Morphologically, osteocytes resemble osteoblasts in every respect, 
having prominent nuclei, and a perinuclear Golgi apparatus. Biochemically, they 
produce the same proteins as fully mature osteoblasts. However, as more 
mineral is laid down and osteocytes become encased deeper within the matrix, 
biochemical and morphological changes gradually occur that distinguish them 
from their precursors. As a result of the decreased synthetic capacity and 
cytoplasmic volume, the nuclei become the most prominent osteocytic cellular 
feature (Scherft & Heersche, 1975). Although recent studies have shown that 
osteocytes support osteoclast formation and activation when co-cultured with 
osteoclast precursors, other experiments demonstrate that mechanically 
stimulated osteocytes release soluble factors that can inhibit osteoclastogenesis 
induced by other supporting cells including bone marrow stromal cells, which 
indicates that osteocytes may be responsible for detecting and responding to 
mechanical loading and initiating the bone adaptation process (You, et al., 
2008).  
 
1.3.3 Osteoclasts 
Osteoclasts, the body’s sole bone-resorbing cells, are multinucleated giant cells 
that differentiate from cells of the haematopoietic lineage. In the 1960’s, 
osteoclasts were thought to arise by fusion of osteoblasts. Many studies since 
then have shown decisively that the osteoclast is haematopoietic in origin and 
unrelated to the stromal lineage. The elucidation of the origin of osteoclasts 
facilitated the investigation of the molecular mechanisms underlying osteoclast 
differentiation. Now it has been established that osteoclast differentiation 
involves several critical stages. First, the haematopoietic stem cells give rise to 
circulating mononuclear cells called colony forming unit-
granulocyte/macrophages (CFU-GM). M-CSF supports the proliferation of CFU-
GM to create and sustain a pool of mononuclear cells in the 
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monocyte/macrophage lineage. The mononuclear precursors are attracted to 
prospective resorption sites by an unknown mechanism (presumably by 
chemotaxis) and attach onto bone matrix to further differentiate into pre-fusion 
osteoclasts with the stimulation of two critical factors: M-CSF and RANKL. With 
the continuous presence of M-CSF and RANKL these pre-fusion osteoclasts 
continue to differentiate by fusion to become multinucleated and functional cells 
(Teitelbaum & Ross, 2003).  
 
Osteoclasts work by establishing a functional resorption compartment that has 
two important features. First, osteoclasts attach to bone through a special 
structure called a sealing zone, which seals the resorption site from its 
surroundings. The second feature is the formation of a ruffled border membrane 
facing the bone. The ruffled border membrane plays an important role in the 
degradation of bone matrix. The ruffled border membrane is rich in proton 
pumps which transport protons into the resorption compartment to maintain a 
low-pH environment that is critical for the dissolution of inorganic components of 
bone matrix (Teitelbaum, 2000). Although recent studies have revealed that 
osteoblasts express cytokines essential for osteoclastogenesis receptor 
activator of nuclear factor kappa B ligand (RANKL) and macrophage colony-
stimulating factor (M-CSF) (Bostanci, 2006; Hofbauer, et al., 2000), It appears 
possible to induce osteoclasts from cells of the monocyte-macrophage lineage 
in vitro even in the absence of osteoblasts (Takahashi, et al., 2007).  
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1.4 BONE REMODELLING 
Besides its excellent mechanical properties, bone has an extensive capacity for 
regeneration, where it is able to heal fractures or local defects. The mechanism 
of this healing pattern is often considered as the recapitulation of embryonic 
osteogenesis and growth. Disorders of bone remodelling can lead to skeletal 
problems of either too much or, more commonly, too little bone. Many factors 
influence bone remodelling by their direct action on osteoblasts. These factors 
include the systemic hormones vitamin D3, PTH and growth hormone, and 
locally acting cytokines.  
1.4.1 Vitamin D3 
The activated molecule 1,25(OH)2 Vitamin D3 is an important physiological 
regulator of mineral metabolism. It is a steroid hormone synthesized in response 
to hypocalcaemia and hypophosphatemia (Reichel, et al., 1989). The target 
tissues of vitamin D3 are the intestine, bone, kidney, and parathyroid glands. It 
has been shown that activated vitamin D3 influences a spectrum of osteoblastic 
cellular functions and acts as an important cell differentiation factor. The effects 
of Vitamin D3 on cultured osteoblasts include the inhibition of cell proliferation 
(Bonewald, et al., 1992; Owen, et al., 1991), the stimulation of ALP (Farley, et 
al., 1994; Fedde, 1992) and osteocalcin production (Beresford, et al., 1984; 
Price & Baukol, 1980), the modulation of type I collagen production and the 
release of cytokines and matrix proteins (Franceschi, et al., 1988). Vitamin D3 
also has potent bone resorbing effects that are mediated through the osteoblast. 
The physiological importance of its effects becomes readily apparent during 
states of either vitamin D3 deficiency or resistance. Rickets and osteomalacia 
are two examples that illustrate the physiological role of vitamin D3. Inadequate 
mineralization of bone is the hallmark pathological feature of both processes 
(Reichel, et al., 1989).  
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1.4.2 Parathyroid Hormone (PTH) 
PTH, an 84-amino acid peptide hormone synthesized by the parathyroid glands, 
is an important modulator of calcium homeostasis. The principal target organs 
for PTH are the kidneys and bone. In bone, PTH causes an increase in 
osteoclastic bone resorption and bone remodelling. PTH mediates its effect by 
binding to extracellular membrane-bound receptors on osteoblasts that activate 
an intracellular adenylate cyclase-dependent signal transduction system. When 
activated, adenylate cyclase causes an increase in intracellular cyclic adenosine 
monophosphate (cAMP). As osteoclasts are devoid of PTH receptors, their 
response to PTH is dependent on PTH binding to the membrane-bound 
receptors on osteoblasts, which then indirectly mediate the osteoclastic 
resorption through secondary coupling factors. Through this mechanism, PTH 
can modulate both bone resorption and bone formation (Risteli & Risteli, 1993). 
1.4.3 Growth Hormone 
Growth hormone (GH) is a peptide hormone released by the anterior pituitary 
gland. It’s secretion is regulated by two hypothalamic regulatory hormones, 
growth hormone releasing hormone (GHRH) and somatostatin, which stimulate 
and inhibit its release, respectively. Evidence from pathological conditions of 
either GH excess or deficiency shows that GH promotes skeletal growth by 
binding to membrane-bound GH receptors on the activated osteoblasts (Wilson, 
1992). There has been interest in the use of exogenous GH as a possible 
osteoinductive agent that could be used clinically to stabilize prosthetic skeletal 
implants by stimulating new bone formation. It has been shown that GH-loaded 
biomaterials can increase osteoblastic bone formation around implants (Clifford, 
1994). 
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1.4.4 Cytokines 
Cytokines and growth factors are important mediators of cell-to-cell 
communication. They can also mediate the effects of many systemic hormones 
locally. Acting in autocrine and paracrine ways, they can promote cell 
proliferation, cell differentiation, bone formation, and bone resorption. 
Prostaglandins, especially PGE2, are produced by osteoblasts, stimulate 
osteoclastic bone resorption, and may play a central role in the skeletal 
response to physical stress. This is supported by the finding that cultured 
osteoblasts release PGE2 when physiological strains are applied (Kawaguchi, et 
al., 1995; Murray & Rushton, 1990). 
 
The osteotropic factors include cytokines that can affect the recruitment and 
differentiation of osteoprogenitor cells and the function of the mature osteoblast. 
Bone Morphogenetic Proteins (BMPs) stimulate IOPCs to differentiate into the 
DOPCs (Forell 1993; Urist, et al., 1983). BMPs are discussed in more details in 
section 1.6. TGF-ß and IGF-1 are reported to have stimulatory effects on both 
osteoprogenitor cells and mature osteoblasts (Gowen, 1991). Fibroblast growth 
factors (FGFs), including FGF1 (acidic) and FGF2 (basic), stimulate the 
proliferation of osteoblasts in culture, while platelet derived growth factor 
(PDGF) acts as a potent mitogen for all cells of mesenchymal origin (Hauschka, 
et al., 1986; Mohan, et al., 1990). Moreover, both BMP and TGF-ß have been 
shown to promote bone formation in animals. For example, experimental work 
has shown that TGF-ß can hasten fracture healing in a rat model (Nielson, 
1994).  
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1.5 ALVEOLAR BONE 
1.5.1 Alveolar bone anatomy and healing process 
Alveolar bone is that specialized part of the maxillofacial skeleton that forms the 
primary support for the teeth. It is composed of bundles of bone that are built up 
in layers in a parallel orientation to the coronal-apical direction of the tooth. This 
bone is made up of the thickened inner and outer dense cortical plate with less 
dense trabecular bone sandwiched in between. Trabecular bone is composed of 
many plate-like bone partitions that separate the irregularly shaped marrow 
spaces located within the bone. Nerve branches and vessels pass through the 
trabecular bone to supply teeth. The Lamina Dura is the much thinner, compact 
bony layer that lines the wall of each tooth alveolus. The space between the 
outer layer of tooth root and the alveolar bone is occupied by the periodontal 
ligament of between 0.12-0.33 mm thickness. Bundle bone is that part of the 
alveolar bone where the fibres of the periodontal ligament (Sharpey's fibers) are 
inserted (Figure 1.2). It has been observed that the course of the Sharpey's 
fibres traverse the alveolar process, particularly towards the apical region, and 
continue to mingle buccally with the fibres of the periosteum covering the 
alveolar process (Ranjith, 2004). 
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Figure 1.2: Histological section of alveolar bundle bone, and periodontal ligament. (Bath-Balogh, 
2005)  
 
 
The relationship between alveolar bone, teeth and periodontal ligament have 
been the subjects of interest to many researchers. Recent studies by Hosoya et 
al (2008) have suggested that periodontal ligament tissue contains 
osteoprogenitor cells that have the ability to regenerate alveolar bone. They 
transplanted transgenic rat molars into the subcutaneous tissues of wild-type 
rats, and after 10 days, bone-like tissue was formed in the connective tissue 
between the branches of the bifurcated roots. This hard tissue expanded to 
encompass the entire bifurcation area without osseous ankylosis after 20 days. 
Their model also suggests that these regeneration processes might be similar to 
normal alveolar bone formation (Hosoya, et al., 2008).  
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1.5.2 Resorption of alveolar bone 
Alveolar bone loss occurs as a consequence of tooth loss, periodontal disease 
or mass loss of bone after trauma or tumour. However, following tooth extraction 
bone resorbs most rapidly during the first years. Non-traumatic loss of anterior 
maxillary teeth is followed by a progressive loss of bone mainly from the labial 
side (Atwood, 1973; Cawood & Howell, 1988). The magnitude of bone loss is 
estimated to be 40–60% during the first 3 years following extraction and then 
decreases to 0.25–0.5% annual loss thereafter (Ashman, 2000a; Ashman, 
2000b). This resorption does not involve the permanent dentition only; it has 
been observed that after the extraction of retained second deciduous molar 
(which has no permanent tooth to replace it), bone loss occurs. The rates of 
bone loss at these sites have manifested as alveolar ridge width decreases of 
25% within 3 years after extraction of the retained primary molars, and this 
continues to diminish by a further 4% over the next 3 years (Ostler & Kokich, 
1994). The cause of resorption of alveolar bone after extraction has been 
assumed to be due to disuse atrophy, decreased blood supply, localized 
inflammation or unfavourable prosthesis pressure (Ashman, 2000a; Mackay, 
1979).  
 
In periodontal disease it seems that many factors contribute to bone resorption; 
however it has been shown that the host derived bone resorption mediators are 
the major determinant of the bone loss (Williams & Howell, 1993). One of the 
important factors is the receptor activator of nuclear factor kappa B ligand 
(RANKL), which is a cell surface protein present on osteoblastic cells and an 
absolute requirement for osteoclast differentiation and bone resorption (Kong & 
Penninger, 2000). This molecule can bind to RANK; a transmembranous 
receptor expressed on osteoclast precursor cells. Interaction between RANKL 
and RANK initiates a signalling and gene expression cascade resulting in the 
promotion of osteoclast formation from the precursor pool. Another important 
molecule is the osteoprotegerin (OPG), a secreted transmembranous receptor 
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produced by osteoblasts and immune cells. OPG is secreted by osteoblasts and 
acts as a soluble competitive binding partner for RANKL, which inhibits 
osteoclast formation and, consequentially, bone resorption (Bostanci et al, 2006; 
Hofbauer, et al., 2000). 
 
Bone tissue can only be resorbed by osteoclasts and, therefore, if bone loss is 
to occur in periodontitis a local stimulation of osteoclast formation and activity is 
required. A number of molecules present in exudates of inflamed periodontal 
tissues can stimulate bone resorption in vitro and in vivo, including interleukin-1 
(IL-1), IL- 6, IL-11, IL-17, oncostatin M (OSM), leukaemia inhibitory factor (LIF), 
tumour necrosis factor (TNF-α, TNF-ß), macrophage colony-stimulating stimuli 
factor (M-CSF), bradykinin, thrombin and prostaglandins (PGs) (Horowitz & 
Lorenzo, 2004). 
 
1.5.3 Current methods used in alveolar bone regeneration 
For decades, bone grafting has been used to repair skeletal defects. Autografts 
harvested extraorally (Brawley & Simpson, 2006; Catone, 1992; Donovan 1994; 
Kinsel & Turbow, 2004) or intraorally appear to represent the gold standard in 
bone grafting (Proussaefs 2002). They can maintain an adequate space under 
the membrane for sufficient period of time and can be completely resorbed and 
replaced by vital bone with the normal turnover of bone tissue (Burwell, 1964; 
Cushing, 1969). The disadvantages of autogenous bone grafts include the 
additional surgical incision, increased post-operative morbidity (Sasso, et al., 
2005), weakened donor site and increased potential for complications 
(Burchardt, 1987; Emsen & Benlier, 2008). The choice of intraoral or extraoral 
donor sites is dependent on the extent of the defect, the amount of bone 
available at the donor site and the compliance of the patient. Iliac crest and 
calvaria are usually chosen for larger defects when intraoral sites cannot provide 
a sufficient quantity of bone. Common intraoral donor sites include the 
mandibular symphysis (Zerbo, et al., 2003), the ramus, retromolar area, 
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mandibular lower border (Garg, et al., 1998) and maxillary tuberosity 
(Raghoebar 1996). Studies reviewing results of cleft palate repairs show that, in 
respect of bone resorption, intraorally harvested grafts show better results than 
grafts from iliac crest or rib (Borstlap, et al., 1990; Koole, et al., 1989; Sindet-
Pedersen & Enemark, 1990). 
 
Guided bone regeneration (GBR) techniques can be successfully applied to 
augment the width and height of atrophic alveolar ridges prior to implant 
placement (Buser, et al., 1990; Buser, et al., 1996; Yeh & Hsu, 2003). This 
consists of placing a thin barrier membrane between the osseous defect and the 
overlying soft tissues presumably allowing only cells from the bone tissue 
compartment to re-colonize the defect and form new bone. Buser et al tested 
GBR on lateral ridge augmentation and encountered the complications of 
membrane exposure, membrane displacement during closure of the wound and 
membrane collapse during the healing period. Subsequent modifications of the 
surgical protocol have included the use of autogenous bone graft to support the 
membrane (Buser, et al., 1993; Buser, et al., 1995; Buser, Dula, Hirt, & Schenk, 
1996). Although non-resorbable membranes have been used as barriers, 
resorbable membranes present the advantage of circumventing a re-entry 
procedure for membrane removal after healing period (Buser, et al., 1996; 
Chiapasco, et al., 1999; Simion, et al., 1997) and resorbable (Eickholz, et al., 
2006; von Arx & Buser, 2006; Chiapasco, et al., 1999; Kirkland, et al., 2000; 
Parodi, et al., 1998; Proussaefs & Lozada, 2003). 
 
The application of tissue engineering techniques has more recently been 
directed towards bone regeneration. Cells with proliferative and differentiation 
potential have been used in addition to growth factors, scaffolds and bone 
substitutes (Calvert, Weiss, & Sundine, 2003; Tabata, 2003) to engineer bone 
tissue. This type of therapy has shown potential for clinical bone and cartilage 
repair that could replace autogenous grafts (Hallman & Thor, 2008). BMPs have 
a strong promising effect on bone and cartilage growth and can act as powerful 
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bone-inducing components in diverse tissue-engineering products (Barboza, et 
al., 2004). However BMPs need a delivery carrier. Synthetic polymers, natural 
origin polymers, inorganic materials and composites have all been used as 
carriers for the delivery of BMPs. There are prospects of a successful future in 
the field of regenerative medicine of bone and cartilage with the use of BMPs. 
Bone Morphogenetic Proteins will be discussed in more detail later in this 
chapter. 
1.5.4 Limitations in alveolar bone regeneration 
Although major progress has been made in the field of bone regenerative 
medicine in recent years, current therapies such as bone grafts still have many 
limitations. Moreover, in spite of the fact that materials science technology has 
resulted in clear improvements in the field of bone substitution medicine, the 
available techniques and materials have been generally successful in 
regenerating bone in lateral directions but all the available techniques show 
significant limitations for the induction of coronal bone growth (Hallman & Thor, 
2008; Stenport, et al., 2003) and hence induction of coronal bone still represent 
a major challenge for reconstructive surgeons and periodontists. Roos-Jansaker 
et al (2002) failed to induce any supracrestal bone formation around partially 
inserted titanium implants in a dog model study (Roos-Jansaker, et al., 2002). In 
a similar experiment, Stenport et al failed also to show any coronal bone growth, 
despite the use of BMPs, cortical perforation, insoluble decalcified bone matrix, 
and titanium mesh covered with a membrane to maintain space for bone growth 
(Stenport, et al., 2003). Cortical perforation was used to ensure sufficient blood 
supply, however, it is possible that the failure to induce any significant bone 
growth might be the result of insufficient blood supply during the initial phase of 
healing. He concluded that coronal bone growth beyond the crestal limit may not 
be possible in a large space. It is worth noting that other investigators have 
shown positive coronal bone formation and even new bone formation beyond 
the crestal limit obtained by placing bone fragments mixed with blood around 
partially inserted implants (Renvert, et al., 1996). In this study, a dome shaped 
	   
35 	  
	  
Chapter	  One	  Literature	  Review	  
perforated titanium space maintainer was used around the partially inserted 
implant to protect the clot and maintain the space for bone in growth. There was 
significant coronal bone growth about 1.9 mm beyond the crestal margin. 
Interestingly, when the dome was covered with ePTFE membrane more bone 
growth was found. It seems that that the membrane may act as a barrier 
isolating the flap tissue cells from competing with the bone growth through the 
perforated dome. 
 
It is generally accepted that the induction of bone tissue requires at least three 
elements that must interact in a highly regulated process. These elements are 
the presence of osteoprogenitor cells, osteoinductive factors, and a supporting 
extracellular matrix (ECM) (Burchardt, 1983). However, in alveolar bone 
regeneration many other local factors are also crucial. Clot protection, space 
maintenance, and exclusion of the overlying connective tissue are likely to be 
key determinants of the extent of periodontal regeneration and coronal bone 
growth. In a study by Polimeni et al (2005), a positive correlation between the 
width of the alveolar ridge at the base of the defect and bone formation was 
found to be important to get space maintenance for new bone growth (Polimeni, 
et al., 2005). Moreover, the complex anatomical arrangement of the periodontal 
tissues makes the alveolar bone unique in terms of regeneration. The 
communication with the oral cavity and bacterial contamination, the presence of 
neighbouring overhanging dental restorations (Jeffcoat & Howell, 1980), 
physiological tooth movement and occlusal loading during healing period, in 
addition to the interaction between multiple different cell types are all believed to 
be major factors which may complicate the bone healing process in this region 
(Jeffcoat & Howell, 1980; McCulloch, 1993; Needleman, et al., 2006; Trombelli, 
et al., 2002). The observation that the soft connective tissue complicates bone 
healing suggests that soft connective tissue might express antagonistic factors 
to inhibit the bone regeneration process. For example, BMPs and their inhibitors 
are reported to have a major influence on the bone remodelling process, and are 
therefore discussed further below. 
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1.6 BMPs AND BMP INHIBITORS 
1.6.1 Introduction and discovery of BMPs 
Bone regeneration is regulated by a number of growth factors, among which the 
BMPs have received considerable attention because of their potential clinical 
applications and unique biological activity.  
 
The first ‘hints’ of the existence of such ‘factors in bone’ were the observations 
from researchers made decades prior to the discovery of BMPs. In 1889, Senn 
demonstrated that decalcified bone could be used in the treatment of 
osteomylitis (Senn, 1889). In 1938, Levander observed that an acid alcohol 
extract of bone and callus induced heterotopic cartilage and bone when injected 
intramuscularly in rabbits. He concluded that bone regeneration occurs as the 
result of some specific bone-forming substance activating the non-specific 
mesenchymal tissue (Lavender, 1938). In 1945, Lacroix hypothesised the role of 
an osteogenic inducer in bone, called osteogenin (Lacroix, 1945). However, the 
seminal observations were made by Urist in 1965, and as he commented: ‘it was 
one single experiment that mapped the road to BMP’. Urist was the first to report 
that protein extracts from de-mineralized bone matrix were able to induce bone 
formation at ectopic sites in rodents and that the process initiated by the 
implantation of these extracts closely resembled the cellular progression seen 
during endochondral bone formation and fracture healing. Urist called this bone-
forming activity bone morphogenetic protein (BMP), and this seminal discovery 
marked the beginning of BMP research (Urist, 1965b).  
 
After Urist's key discovery, BMP became the topic of extensive research, which 
revealed that it was not only one protein but rather a group of proteins (BMPs) in 
the bone matrix that were responsible for osteoinduction. Subsequent 
purification of these proteins from bovine bone resulted in the identification and 
cloning of the different BMP-members and, with the use of recombinant gene 
technology, recombinant human BMPs (rhBMPs) could be produced (Celeste, et 
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al., 1990; Nussenbaum, et al., 2003; Wang, et al., 1988; Wang, et al., 1990a; 
Wozney, et al., 1988). BMPs were classified as a subfamily within the 
transforming growth factor-beta (TGF-β) superfamily, which is a large family of 
growth and differentiation factors including BMPs, TGF-βs, growth and 
differentiation factors (GDFs), activins, inhibins and the Mullerian inhibiting 
substance (ten Dijke, et al., 2003). Since their discovery, BMPs have been 
perhaps one of the most intensively studied groups of factors in various 
physiological processes. Major advances in our understanding of BMP biology 
were made by Dr. Harri Reddi and his group who determined that BMP activity 
is not species specific and demonstrated that the delivery matrix used to implant 
BMPs was a key regulator of its biological activity. Coarse powders of (74-
420µm) demineralized diaphyseal bone matrix were able to induce local 
differentiation of endochondral bone after they were implanted in subcutaneous 
tissues, while the same matrix with particle size of 44-74 µm (Fine matrix) did 
not (Sampath & Reddi, 1983; Sampath & Reddi, 1984). Reddi also began to 
dissect the cellular events initiated at the site of BMP implantation and it was this 
work that attracted many cell and molecular biologists to the BMP field (Reddi, 
1981).  
 
BMPs are proteins that are expressed as large precursor polypeptide chains 
containing a hydrophobic signal sequence, a long and poorly conserved N-
terminal pro-region sequence, a mature domain with a highly conserved C-
terminal region and an N-terminal region that varies among the different BMPs. 
BMPs are biologically active as either homo- or heterodimers (Israel, et al., 
1996). BMPs contain a conserved motif of seven cysteine residues, which are 
involved in the formation of six intrachain disulphide bonds and a single 
interchain bond, necessary for dimer formation. The three-dimensional structure 
conferred by the location of six of the seven cysteines makes BMP molecules 
highly resistant to heat, denaturants, and extremes of pH. These unique 
properties were of fundamental importance in the discovery and subsequent 
purifications of native BMP activity from bone (Wozney, et al., 1988). 
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In humans, there are many recognized BMPs, from BMP-2 to BMP-18 (Table 
1.1). BMP-1 is not a member of the BMP family. It is a misidentified and 
misnamed protein with chordinase and procollagen proteinase activities, 
implicated in embryonic patterning (Kessler, et al., 1996), but unrelated to other 
BMPs. Usually only BMP-2 to BMP-11 are considered to be BMPs by their 
bone-inductive properties. BMP-12, -13 and -14 are also named as cartilage-
derived morphogenetic proteins (CDMPs), as these induce chondrogenic 
phenotypes rather than osteogenesis (Reddi, 2003) (Table 1.1). 
 
BMP Other names Main Physiological roles Reference 
Bone Morphogenetic Proteins 
BMP-2 BMP-2a Cartilage and bone 
morphogenesis/ heart 
formation 
(Callis, et al., 2005; Kang, et al., 
2004; Wang, et al., 1990a) 
BMP-3 Osteogenin Negative regulator of 
bone morphogenesis 
(Hino, et al., 2004) 
BMP-3b GDF-10 Negative regulator of 
bone morphogenesis 
(Hino, et al., 2004) 
BMP-4 BMP-2b Cartilage and bone 
morphogenesis/ kidney 
formation 
(Luyten, et al., 1994; Oxburgh, et 
al., 2005) 
BMP-5  Limb development/ bone 
morphogenesis 
(Cho, et al., 2002; Zuzarte-Luis, et 
al., 2004) 
BMP-6 Vrg1, Dvr6 Hypertrophy of cartilage/ 
bone morphogenesis/ 
oestrogen mediation 
(Gitelman, et al., 1994; Kang, et 
al., 2004; Rickard, et al., 1998) 
BMP-7 OP-1 Cartilage and bone 
morphogenesis/ kidney 
formation 
(Kang, et al., 2004; Reddi, 1998; 
Simic & Vukicevic, 2005) 
BMP-8 OP-2 Bone morphogenesis/ 
spermatogenesis 
(Cho, Gerstenfeld, & Einhorn, 
2002; Zhao, et al., 1996) 
BMP-9 GDF-2 Bone morphogenesis/ 
development of 
(Chen, et al., 2003; Kang, et al., 
2004; Lopez-Coviella, et al., 2006) 
	   
39 	  
	  
Chapter	  One	  Literature	  Review	  
cholinergic neurons/ 
glucose metabolism 
BMP-11 GDF-11 Axial skeleton patterning/ 
eye development/ 
pancreas development/ 
kidney formation 
(Andersson, et al., 2006; Esquela 
& Lee, 2003; Harmon, et al., 2004; 
Kim, et al., 2005) 
Cartilage-derived morphogenetic proteins 
BMP-12 CDMP-3, GDF-7 Ligament and tendon 
development/ 
development of sensory 
neurons 
(Lo, et al., 2005; Reddi, 2003) 
BMP-13 CDMP-2, GDF-6 Cartilage development 
and hypertrophy 
(Reddi, 2003) 
BMP-14 CDMP-1, GDF-5 Chondrogenesis/ 
angiogenesis 
(Reddi, 2003; Yamashita, et al., 
1997; Zeng, et al., 2007) 
Others 
BMP-8b OP-3 Spermatogenesis (Zhao, et al., 1996) 
BMP-10  Heart morphogenesis (Chen, et al., 2004a) 
BMP-15 GDF-9b Ovary physiology (Knight & Glister, 2006) 
BMP-16 Nodal Embryonic patterning (Bessa, et al., 2008) 
BMP-17 Lefty Embryonic patterning (Bessa, et al., 2008) 
BMP-18 Lefty Embryonic patterning (Bessa, et al., 2008) 
Table 1.1: BMP members in humans and their main physiological roles. (Bessa, et al., 2008) 
 
 
Activins are BMP-like proteins that belong to the TGF-β superfamily, and they 
act via intracellular signalling molecules (Itoh, et al., 2000). Activins and their 
relatives, inhibins, were initially purified from gonadal fluids and characterized on 
the basis of their ability to modulate FSH secretion from pituitary gonadotropes 
(Bilezikjian, et al., 2004; Chen, et al., 2006). Increasing evidence suggests the 
involvement of activin in the regulation of bone formation and metabolism. In 
neonatal rat calvaria, activin promotes ectopic bone formation induced by BMP 
(Ogawa, et al., 1992), can enhance proliferation of osteoblastic cells and 
collagen synthesis (Centrella, et al., 1991) and is found to be released from the 
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bone matrix of calvaria undergoing resorption (Sakai, et al., 2000). 
 
Activin A, a homodimer of inhibin bA subunits, has been isolated from bone 
matrix (Ogawa, et al., 1992) and found to enhance both ectopic endochondral 
bone formation by BMPs and intramembranous bone formation in rats (Oue, et 
al., 1994). It has also been reported that activin A promotes osteoblastogenesis 
and enhances osteoclast-like cell formation in murine bone marrow cultures 
(Gaddy-Kurten, et al., 2002; Sakai, et al., 1993), and can promote bone 
formation and fracture healing in rodents in vivo (Ogawa, et al., 1992; Sakai, et 
al., 1999). However, other reports have demonstrated an inhibitory effect of 
activin on osteoblast differentiation in rat and murine osteoblasts (Hashimoto, et 
al., 1992).  
 
Figure 1.3: The structure of the TGF-ß family cysteine knot monomer. Consists of two finger-like 
anti-parallel beta-strand projections (Simank, et al. 2001), and an alpha-helical heel region 
(green). Two disulfide bridges complete a ring of covalent bonds that is penetrated by a third 
disulfide bond to form the knot (PeproTech, 2005). 
 
1.6.2 Functions and activities of BMPs 
BMPs play very important role in bone physiology influencing bone growth, 
turnover, bone formation and cartilage induction (Chen, et al., 2004). Their 
influence is not restricted to bone tissue. BMPs regulate apoptosis in various 
types of tissues (Botchkarev, 2003). As BMPs were able to induce the formation 
of bone and cartilage, researchers have hypothesised their involvement in the 
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normal processes of bone formation during skeletogenesis (Hall, 1987; Lyons, et 
al., 1989; Rosen, et al., 1989) and bone regeneration in adult life including 
fracture healing (Bostrom, et al., 1995; Hulth, et al., 1988; Luyten, et al., 1992). 
Moreover, the potential role of BMPs not only in skeletal development, but also 
in other physiological processes during embryogenesis, is supported by the 
detection of BMPs in various tissues including brain, heart, lung, kidney, spleen, 
and liver (Wozney, et al., 1990). BMPs are also involved in embryonic patterning 
(Kishigami & Mishina, 2005), skeletal formation (Tsumaki & Yoshikawa, 2005) 
and organogenesis of other tissues as well as bone. For example, BMP-2 plays 
a role in heart morphogenesis (Callis, et al., 2005) and in neural stem cells 
(White, et al., 2001) and BMP-7 is required for the normal formation of the 
kidney (Simic & Vukicevic, 2005). During gastrulation a BMP gradient in 
signalling established by BMP antagonists is responsible for directing cells into 
forming organs such as bone, cartilage, kidney or heart, depending on the levels 
of BMP activity and of other cytokines (Yamamoto & Oelgeschlager, 2004). 
During the events of early embryogenesis, BMPs are involved in dorsal–ventral 
patterning with each factor playing specific roles, e.g. BMP-2 and -4 induce 
embryo ventral differentiation, while BMP-3 and -3b oppose the ventralizing 
effect by inducing tail and head formation, respectively (Hino, et al., 2004).  
 
In vitro, BMPs are potent differentiation factors, inducing the differentiation of 
multipotent mesenchymal cells into osteochondrogenic lineage cells and 
osteoblast precursor cells (Katagiri, et al., 1994b; Shea, et al., 2003; Wan & 
Cao, 2005). Researchers have used rhBMP-2 to induce differentiation of 
mesenchymal stem cells into osteoblast and chondroblast cells and to prevent 
the former cells from differentiating into other cell phenotypes such as 
myoblasts. Vaes et al (2002) induced murine C2C12 mesenchymal progenitor 
cells to differentiate into mature osteoblasts by treatment with bone 
morphogenetic protein 2 (BMP-2) (Vaes, et al., 2002). In another study on 
C2C12 cells, high concentrations of OP-1 (BMP-7) (200 ng/ml) elevated the 
alkaline phosphatase (ALP) activity dramatically, completely inhibited myotube 
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formation and induced the formation of cells displaying osteoblastic morphology, 
which indicates that OP-1 is a potent inducer of differentiation, at least in C2C12 
cells into osteoblasts (Yeh, et al., 2002). The differentiation stage of multipotent 
cell populations appears to be an important determinant of the effects of BMPs 
(Li, et al., 1996; Shibano, et al., 1998; Yamaguchi, et al., 1996; Yamaguchi, et 
al., 1991). Whilst myoblasts retained the ability to change their differentiation 
pathway to express osteoblast parameters (Jortikka, et al., 1998; Katagiri, et al., 
1997; Katagiri, et al., 1994b), several studies have shown that BMPs do not 
stimulate mature osteoblasts (Kim, et al., 1997; Knutsen, et al., 1993; 
Yamaguchi, et al., 1991); moreover, mature fibroblasts could not be induced to 
express osteogenic parameters after treatment with BMP-2 (Katagiri, et al., 
1990). These results indicate that the osteogenic influence of BMPs is directed 
towards immature and multi-potent cells. Mature cells seem to loose their 
responsiveness. 
 
Although the induction process caused by BMPs involves both proliferation and 
differentiation (Wildemann, et al., 2007), it has been shown that it also involves 
chemotaxis of mesenchymal progenitor cells (Fiedler, et al., 2002). The role of 
BMPs in osteoblast chemotaxis is discussed in chapter 7. Whilst the main 
biological functions of BMPs are related to bone and cartilage formation as 
shown later, BMP-8b, -10 and -15 do not have any proven roles in the biology of 
bone or cartilage. However, BMP-10 is known to be involved in cardiac 
development and BMP-15 in ovarian physiology (Chen, et al., 2004a; Knight & 
Glister, 2006). Similarly the role of BMP-8b appears to be restricted to the 
growth of reproductive cells (Zhao, et al., 1996). BMPs have been implicated in 
tooth development, and the expression of BMP-2 is increased during the 
terminal differentiation of odontoblasts (Nakashima, et al., 1994; Nakashima & 
Reddi, 2003). Beads soaked in human recombinant BMP-2 induce the mRNA 
expression of Dspp, the differentiation marker of odontoblasts after implantation 
onto dental papilla in organ culture. BMP-2 also induces a large amount of 
reparative dentine on the amputated pulp in vivo (Nakashima & Akamine, 2005). 
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It has been suggested that BMP-2 may regulate the differentiation of pulp cells 
into the odontoblastic lineage and stimulate reparative dentin formation 
(Nakashima & Reddi, 2003). 
 
The study of different BMP has shown unexpected but important activities of 
these proteins. In one of the publication by Piccirillo et al (2006), it was shown 
that BMP-4 elicits a strong effect in triggering a reduction in tumour-initiating 
precursors of human glioblastoma (Piccirillo, et al., 2006). The biological activity 
of different BMPs can differ considerably (Sykaras & Opperman, 2003). High 
activity of heterodimers BMP-4–7 and BMP-2–7 was established in vitro and in 
vivo (Sakou, 1998). High osteoinductive potency has been shown for 
heterodimers of BMP-2–6 in comparison with respective homodimers (Kugimiya, 
et al., 2005; Westerhuis, et al., 2005). Other studies show that different BMPs 
vary in their mitogenic capacity in cultures of periosteal cells and epiphyseal and 
sternal chondrocytes derived from chick embryos. DNA synthesis increased 
more after treatment with BMP-2 and -4 than after BMP-5 or -6 treatment; in 
contrast the effects of OP-7 were marginal, and BMP-3 had no effect (Mayer, et 
al., 1996). Takuwa et al showed that BMP-2 was able to stimulate alkaline 
phosphatase activity and collagen synthesis in MC3T3- E1 cells, whereas BMP-
3 stimulated collagen synthesis only (Takuwa, et al., 1991). BMP-6 was found to 
increase the osteoblastic phenotype in secondary rat calvarial cell cultures more 
than twice as much as BMPs-2 or -4, and BMP-2 was more potent than BMP-4 
(Boden, et al., 1996). BMP-6 was a more potent stimulator of bone formation 
than BMPs-2 and -4 in rat osteoblasts (Israel, et al., 1996). However, in several 
bone marrow cell lines, BMP-6 showed less osteogenic potential than BMPs-2 
and -4 (Yamaguchi, et al., 1996). Some studies have shown that heterodimers 
are much more osteoinductive than homodimers. For example, BMPs-2/7 and 
BMP-4/7 heterodimers were found to be more active than BMPs-2, -4 and -7 
homodimers (Hazama, et al., 1995; Hughes, et al., 1995; Israel, et al., 1996). 
However, the Xenopus BMP-4/7 heterodimer was less inductive than the 
homodimeric recombinant human BMP-2 (Kusumoto, et al., 1997). 
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The pleiotropic effect of the different BMPs is of considerable importance for 
possible tissue engineering applications. For instance, in addition to being used 
for differentiation of cartilage and bone, BMP-4 is being studied for a role in 
preserving the undifferentiated state of embryonic stem cell cultures (Qi, et al., 
2004). A clear bone-inducing role is observed for BMP-2, -4, -6, -7 and -9, and 
these BMPs have been shown to induce bone mineralization and increase in 
osteocalcin levels in C2C12 cells (Chen, et al., 2003) and orthotopic ossification 
in mice (Kang, et al., 2004). BMP-3 and -3b are possibly inhibitors or negative 
regulators of osteogenesis, as these downregulate the expression of ALP in 
bone cells (Hino, et al., 2004) During fracture healing different BMPs follow 
specific defined temporal sequences. BMP-2 appears to be an early factor 
peaking at day 1 after fracture while BMP-14 peaks at day 7 during cartilage 
formation and BMP-3, -4, -7 and -8 are expressed mainly after 2 weeks (Cho, et 
al., 2002). 
 
In summary, BMPs can regulate many aspects of embryonic development, 
including cartilage and bone formation, mesoderm patterning, and craniofacial 
and limb development, and bone formation and repair in postnatal life, by 
regulating growth, differentiation, and apoptosis of various cell types, including 
mesenchymal cells, osteoblasts, chondroblasts, neural and epithelial cells 
(Sakou, 1998; Termaat, et al., 2005; Wan & Cao, 2005). Moreover, preclinical 
and clinical studies have shown that BMP-2 can be used in various therapeutic 
interventions such as bone defects, non-union fractures, spinal fusion, 
osteoporosis and root canal surgery (Chen, et al., 2004). Rutherford et al 
demonstrated that implantation of gingival or dermal fibroblasts transfected with 
BMP genes ex vivo, using a recombinant adenovirus (AdCMVBMP) attached to 
porous biodegradable scaffolds, can form bone in vivo. They showed that BMP-
7-transfected fibroblasts suspended in injectable thermoset hydrogels form 
complete ossicles following subcutaneous injection and can repair segmental 
defects in rat femurs. Bone formation was preceded by an intermediate cartilage 
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stage revealing that BMP transduction induces osteoblastic conversion of these 
cells (Rutherford, et al., 2002).  
1.6.3 BMP Receptors 
Transduction of TGF-β signals involves two distinct kinds of transmembrane 
serine /threonine kinase receptors, type I and type II. The prevailing view is that 
TGF-β ligands bind to the type II receptor, which then recruits a type I receptor. 
Following formation of a ligand/type II/type I ternary complex, the type II receptor 
phosphorylates serine and threonine residues within the intracellular GS 
(glycine–serine-rich) domain of the type I receptor subunit (Wrana, et al., 1994). 
The activated type I receptor kinase, in turn, phosphorylates particular members 
of the Smad family of proteins, called receptor-regulated Smads (R-Smads), at 
serines in a conserved C-terminal SSXS motif, to elicit cellular responses. Three 
type I BMP receptors have been identified; Alk3 binds only to BMPs, Alk6 binds 
to BMPs and anti-mullerian hormone (AMH), and Alk2 recognizes BMPs and 
activin. Type II receptors that exhibit BMP binding are BMP RII, a receptor that 
recognizes only BMPs, and Act RII and IIb that are shared by BMPs and activin 
(Miyazono & Miyazawa, 2002).  
 
Unlike TGF-β, both type I and type II BMP receptors can bind BMPs in the 
absence of the other receptor (Greenwald, et al., 2003; Sun, 2003). BMP ligand 
binding to type I receptor triggers the intracellular association of type I and type 
II receptors, allowing the constitutively phosphorylated type II receptor to 
phosphorylate the type I receptor. Once activated, type I receptors can 
phosphorylate pathway-specific R-Smads that reside in the cell cytoplasm. 
Phosphorylation of an R-Smad releases it from the receptor complex and allows 
it to associate with Smad 4. The R-Smad/Smad4 complex then translocates to 
the nucleus where it recognizes regulatory elements in target genes with the 
help of associated DNA-binding co-factors (Attisano & Wrana, 2002). In the 
BMP–Smad pathway, BMP-2, -4, or -7 dimers bind to the receptor complex, 
leading to phosphorylation of the type I receptor by the type II receptor, which in 
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turn phosphorylates an appropriate R-Smad (Smad1, -5, or -8). This 
phosphorylation enables the R-Smad to complex with the Co- Smad, Smad4, 
and the R-Smad/Smad4 complex enters the nucleus to activate or repress target 
genes depending on which nuclear cofactors are present. 
1.6.4 Role of BMPs in bone regeneration 
BMPs are involved in many processes, which take place during bone formation, 
bone induction, and bone regeneration such as callus formation. A full 
understanding of bone turnover is not yet completed, although many factors and 
interactions are well described. The bone turnover involves a complex interplay 
of at least 200 factors that can be modulated in various physiological and/or 
pathological situations. PDGF (platelet derived growth factor) and TGF-β 
(transforming growth factor – beta) together with the BMPs are the most 
important factors in the process of bone healing (Huang, et al., 2007; Lee, et al., 
2007). 
 
Numerous preclinical studies have demonstrated very encouraging results after 
BMP application with different delivery methods in several clinical situations in 
animal models (rat, rabbit, dog, pig, sheep, and primates). These situations 
include fracture healing (Einhorn, et al., 2003) and vertebral fusion (Cook, et al., 
1994b). Sandhu used BMP-2 in spinal fusion treatment in dogs and obtained 
excellent results (Sandhu, et al., 1996). Also BMPs have been used in the 
healing of critical sized bone defects including long bone (Cook, et al., 1994a). 
Studies on sheep femoral defects showed new bone formation one month after 
grafting with BMP-2 and complete radiographic bone healing after 3 months 
(Kirker-Head, et al., 1995). BMP-2 was also used to treat defects in rat femurs 
and gave similar results (Yasko, et al., 1992). BMPs have been tested to repair 
osteochondral or chondral defects (Cook, et al., 2003), to assist bone healing in 
the presence of infection (Chen, et al., 2004b) or other adverse situations such 
as radiotherapy (Nussenbaum, et al., 2003) or osteonecrosis (Simank, et al., 
2001), and to aid the osseo-integration of orthopaedic implants (Jennissen, 
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2002; Zhang, et al., 2004). The described situations represent basically two 
categories: those in which the acceleration of bone regeneration is anticipated 
such as in fracture healing and vertebral fusion and those in which bone 
formation might not normally occur without further intervention such as in 
recalcitrant fracture non-union and critical sized bone defects. 
 
In healing fractures, which contain many immature cells, expression of native 
BMPs has been demonstrated. Studies on rat models have found that during the 
early stages of fracture healing, the presence of BMP 2, 4 and 7 increases 
dramatically (Bostrom, et al., 1995; Onishi, et al., 1998), indicating that these 
proteins have a local regulatory role during fracture repair.  As cells derived from 
non-healing fractures show an osteogenic response to BMPs (Boyan, et al., 
1992) it is possible that failure of fracture healing may derive from an insufficient 
supply of BMPs.  Various studies have shown that BMPs may be useful in the 
management of fractures for delayed unions and recalcitrant non-unions.  BMPs 
can also initiate faster healing, resulting in less pain and infection at the fracture 
site in open fractures (Vaibhav, et al., 2007).  In a study by Garrison et al (2007) 
it was found that the use of BMPs was associated with a reduced operating 
time, improvement in clinical outcomes and a shorter hospital stay as compared 
with autograft. It was also found that adding BMP to the conventional treatment 
is more effective than conventional intervention alone for union of acute open 
tibial fractures. However the use of BMP for this purpose is unlikely to be cost-
effective if the price of BMP protein stay at this current level (Garrison, et al., 
2007).  
 
In the craniofacial region, BMPs have been used to assist healing and 
regeneration of bone (Higuchi, et al., 1999; Wikesjo, et al., 1999). In a study by 
Marden et al, critical-size defects in rat calvariae were grafted with collagen 
soaked in BMP-2 solution and resulted in re-mineralization of the collagen within 
one week followed by rapid bone formation (Marden, et al., 1994). Also studies 
on dental extractions in chimpanzees showed that OP-1 aided bone formation in 
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the extraction sockets (Cook, et al., 1995). BMP-2 has also been used in 
maxillary sinus elevation in goats and showed increased radio-opacity, bone 
marrow and dense trabeculae (Nevins, et al., 1996). 
 
BMP-2 has been shown to improve the quantity and quality of implant-bone 
osseointegration (Lan, et al., 2007). In this study on rabbits, 16 implants were 
applied with 1.0 mg rhBMP-2 compared to 16 implants without rhBMP-2. At 12 
weeks implants binding strength was measured by pull-out test, and the 
extracted implants were observed under a scanning electronic microscope. The 
pull out strengths of BMP-2 group were greater by 32% than that of the control 
group. Scanning electronic microscopy showed more calcified substance (15%) 
on the surface of the implants of the BMP-2 group than control group (11%). 
Another study in pigs showed that direct application of the BMP-2 gene using a 
liposomal vector enhanced bone regeneration in a bony defect and gene 
delivery combined with bone graft could induce a rapid osseointegration of the 
bone-implant interface at earlier stage (Park, et al., 2007). 
1.6.5 Clinical applications of BMPs in maxillofacial region  
The use of BMP proteins in clinical practice in humans has been approved by 
the FDA as an alternative to autografts in recalcitrant long bone non-unions 
where use of autograft is unfeasible and alternative treatments have failed. 
Within the oral cavity BMPs are approved for constructing new bone in sinus 
elevation and alveolar augmentation procedures. However, the first studies in 
humans using BMP-2 or OP-1 in 1997 showed large variations in term of the 
results and individuals responses. Boyne et al implanted collagen sheets soaked 
in BMP-2 solution in the maxillary sinuses of 12 edentulous or partially 
edentulous patients with severe atrophy of the maxilla (Boyne, et al., 2005). The 
subsequent increase in height of the treated maxilla varied between 2.3 and 
15.7 mm. However, in another study, a histological evaluation of the effect of 
OP-1 coupled to a collagen carrier, grafted in the maxillary sinuses of three 
patients with maxillary atrophy showed excellent bone formation in one of the 
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three patients, but the two other patients had little or no bone formation after 6 
months. In those patients soft tissues were found surrounding the graft remnants 
(Groeneveld, et al., 1999). In the mandible, BMP-2 grafts were unable to form 
bone when applied in ridge augmentation (Howell, et al., 1997a). However, in a 
recent study on ten patients with major mandibular defects following resection of 
biopsy-proven ameloblastoma lesions or osteomylitis of the mandibular body or 
ramus, bioimplants containing BMP-7 in a demineralized bone matrix (DBM) 
were used. The resection defects were spanned with rigid reconstruction plates 
to hold the remaining mandibular segments in the correct position. Radiographic 
evidence of mandibular bone formation was found in all cases within few weeks, 
and after 1 year, functional and esthetic reconstruction of the mandible was 
complete (Clokie & Sandor, 2008).  
 
BMPs were originally discovered in bone tissue, and currently their main clinical 
use lies in promoting bone growth. Although the use of BMPs in animal 
experiments has been successful, it has been shown that their effects are 
concentration dependent and this depends on the local kinetics of the carrier, 
therefore a carrier material is needed that can release a slow BMP concentration 
within a longer period of time.  
1.6.6 BMP Inhibitors  
It has become clear in recent years that the amount of BMP available for 
signalling is controlled by the presence of several structurally distinct BMP 
antagonists that alter the ability of BMPs to bind to their receptors, effectively 
blocking BMP action. These antagonists can be loosely divided into three 
classes: BMP pro-regions that are able to complex with mature BMP, creating 
an inactive molecule, ligand antagonists that bind to BMPs and sequester them 
as inactive and receptor antagonists that prevent BMPs from occupying 
receptors (Gregory, et al., 2005). It is known that in the embryonic skeleton 
these antagonists serve an important physiological role and are responsible for 
tightly regulating BMP activity so that normal skeletal development occurs 
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(Canalis, Economides, & Gazzerro, 2003). In postnatal animals, pertubation of 
where, when, and the extent of BMP signalling through the misexpression of 
these same antagonists results in the alteration of bone formation, allowing us to 
hypothesize that BMP activity is required for the maintenance of bone mass 
(Gazzerro, et al., 2005; Sutherland, et al., 2004; Winkler, et al., 2004; Wu, et al., 
2003). The need to temper BMP activity is confirmed by the demonstration that 
lymphoblastic cell lines from patients with fibrodysplasia ossificans progressiva, 
a disease characterized by extraskeletal ossification, have increased levels of 
BMP-4 (Shafritz, et al., 1996). Mutational analysis in these patients failed to 
demonstrate alterations in the noggin gene (Xu, et al., 2000). 
 
To date, noggin, gremlin, ectodin, follistatin, and sclerostin (Brunet, et al., 1998; 
Gazzerro, et al., 1998; Pereira, et al., 2000), chordin, growth differentiation 
factor 3 (GDF3) (Levine & Brivanlou, 2006), GDF5 & 7 (Niikura, et al., 2006), 
twisted gastrulation (Tsg) (Chang, et al., 2001; Xie & Fisher, 2005), have all 
been identified as osteoblast products that bind and sequester BMPs. Three 
molecules have been identified to date as BMP receptor antagonists; BMP-3, an 
osteoblast product that is stored in bone matrix and acts locally to block BMP 
signalling through Act RII. Inhibin, a circulating molecule that makes its way to 
the bone through the vascular system and antagonizes BMP activity in the 
presence of betaglycan by blocking BMP binding to type II BMP receptors 
(Gamer, et al., 2005) and BAMBI (BMP and activin membrane bound inhibitor), 
a non-signalling BMP pseudoreceptor that causes silencing of BMP receptor 
signalling (Onichtchouk, et al., 1999). These molecules are known to be 
transcriptionally regulated and can be induced by BMP stimulation, acting as a 
negative feedback loop mechanism for BMP activity. The signalling pathways 
involved in induction of BMP inhibitor expression have not yet been fully 
described. However in the case of sclerostin, expression has been described in 
bone cells, and for ectodin, expression has been described in ectodermal 
structures such as the enamel organ of developing tooth germs, raising the 
likelihood that different BMP inhibitors have distinct roles and are expressed in a 
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tissue specific pattern (Laurikkala, et al., 2003). Furthermore, it has also been 
shown that noggin and sclerostin can bind each other with high affinity, resulting 
in a further level of regulation whereby dual expression of multiple inhibitors 
might paradoxically promote BMP signalling (Winkler, et al., 2004)  
 
Noggin 
Noggin cDNA was first isolated by Smith and Harland (1992). They 
demonstrated that this novel polypeptide contains a single reading frame 
encoding a 26 kd protein with a hydrophobic amino-terminal sequence which is 
capable of inducing dorsal development in Xenopus embryos (Smith & Harland, 
1992). Noggin binds several BMPs with various affinities, with a marked 
preference for BMP-2 and BMP-4 over BMP-7. By binding tightly to BMPs, 
Noggin prevents BMPs from binding their receptors (Aspenberg, et al., 2001; 
Zimmerman, De Jesus-Escobar, & Harland, 1996). 
In addition to binding to BMP-2, 4, 7 it binds to several other BMP family 
members including BMP-13 (growth differentiation factor-6), and -14 (growth 
differentiation factor-5) (Chang & Hemmati-Brivanlou, 1999; Merino, et al., 
1999). 
 
In studies by Gazzerro et al, untreated cultures of osteoblasts  did not express 
clearly detectable levels of noggin mRNA by Northern blot analysis. However 
treatment of OB cells with BMP-2 caused a time- and dose dependent induction 
of noggin mRNA expression. BMP-2 at 3.3 nM induced noggin transcripts of 2.5 
kb after 2 h. The effect was nearly maximal after 6 h and was sustained for 24 h. 
The stimulatory effect of BMP-2 was observed at concentrations of 0.3–3.3 nM 
(10–100 ng/ml) after 6 h and 24 h (Gazzerro, et al., 1998). Noggin blocks the 
effect of BMPs in undifferentiated and differentiated cells of the osteoblastic 
lineage, and the addition of noggin to osteoblasts in culture blocks the 
stimulatory effect of BMPs on collagen, noncollagen protein synthesis, and 
alkaline phosphatase activity (Aspenberg, et al., 2001). 
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Loss of Noggin in mutant mice resulted in a recessive lethal phenotype at birth. 
There were multiple defects including a failure of neural tube closure, broad 
club-shaped limbs, loss of caudal vertebrae, a shortened body axis, and 
retention of a small vestigial tail. When examined on an inbred (129/Sv) or F1 
hybrid (129/Sv; C57BL6/J) background, there was a pronounced variability in 
cranial neural tube closure. The brain was almost always open in Noggin 
mutants on the inbred background but most often closed in mutants on the 
hybrid background (McMahon, et al., 1998). In mice lacking Noggin, cartilage 
condensations initiated normally but developed hyperplasia, and initiation of joint 
development failed as measured by the expression of growth and differentiation 
factor-5. Therefore, excess BMP activity in the absence of Noggin antagonism 
may enhance the recruitment of cells into cartilage, resulting in oversized growth 
plates (Brunet, et al., 1998). 
 
In humans, it was found that heterozygous mis-sense mutations in the human 
noggin gene cause two similar, but clinically distinct, skeletal dysplasias, 
proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1). 
SYM1 and SYNS1 have apical joint fusions as their principal feature (Gong, et 
al., 1999), but SYNS1 is distinguished from SYM1 by also having hip and 
vertebral fusions (Krakow, et al., 1998). 
 
Since noggin expression in osteoblasts is limited, and its mRNA and protein 
levels are induced after exposure of the cells to BMP-2, -4, or -6, it has been 
suggested that this may be a protective mechanism to prevent excessive 
exposure of skeletal cells to BMPs (Aspenberg, et al., 2001). 
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Chordin 
Chordin also binds BMPs and antagonizes their activity (Piccolo, et al., 1996; 
Sasai, et al., 1994). Chordin binds BMPs in a specific manner, preventing their 
receptor signalling, and does not bind to other members of the TGF-ß family of 
peptides. Chordin inactivation results in stillborn mice, which exhibit normal early 
development but show later defects in inner and outer ear development and 
abnormalities in pharyngeal, anal and cardiovascular organization (Bachiller, et 
al., 2000). Petryk et al examined the effects of chordin on osteoblast 
differentiation and mineralization using MC3T3-E1 osteoblast-like cells. Their 
results show that chordin reduces the expression of markers of osteoblast 
differentiation and inhibit mineralization, similar to noggin, indicating that chordin 
may act as negative regulators of osteoblast differentiation in MC3T3-E1 cells 
(Petryk, et al., 2005). 
 
Follistatin 
Follistatin was initially identified as an activin binding protein that precluded 
activin signalling, but it can also repress BMP-4 expression and signalling by 
binding BMP-4 (Iemura, et al., 1998). Activin plays a role in anteroposterior 
patterning during embryogenesis, and follistatin, like noggin, can induce 
dorsalization (Thisse, et al., 2000). Unlike noggin, follistatin expression is down-
regulated by BMPs and induced by TGF-ß, indicating that different signalling 
pathways can regulate specific BMP antagonists, such as follistatin (Shibanuma, 
et al., 1993; Zhang, et al., 1997). Activin can induce endochondral bone 
formation in vivo, and the effect is delayed by follistatin (Funaba, et al., 1996; 
Hashimoto, et al., 1992). Some studies have classified follistatin as a specific 
inhibitor to activin and not BMP-2 (Pierre, et al., 2005); however, it has been 
reported that it can bind to BMP-4 (Fainsod, et al., 1997). Follistatin is expressed 
by both osteoblasts and osteocytes in the developing mouse mandible (Inoue, et 
al., 1994; Sakai, et al., 1999) and in fibula fracture callus (Sakai, et al., 1999). In 
vitro, follistatin mRNA has been detected in calvarial-derived MC3T3-E1 
osteoblast-like cells (Hashimoto, et al., 1992). However, the in vivo role of 
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follistatin in bone marrow is may be to act as a feedback mechanism to limit 
activin action, as has been shown in the pituitary (Bilezikjian, et al., 1996; 
Mather, et al., 1993). 
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1.7 SUMMARY AND BACKGROUNG OF THE STUDY 
Studies on the cell and molecular biology of bone formation over the past two 
decades have greatly improved our understanding of the fundamental processes 
required for bone regeneration, normal bone turnover, wound healing and 
therapeutically during bone regeneration procedures. Cells of the osteoblast 
linage are controlled by a variety of signals, such as polypeptide growth and 
differentiation factors, cell-matrix interactions, and cell-cell signalling. In addition, 
bone formation is also profoundly influenced by the environmental niche where 
this process takes place. The effect of the environmental niche on the ability to 
recruit and differentiate cells of the osteoblast linage to give rise to new bone 
formation is possibly one of the more under-researched areas in the study of the 
mechanisms of bone formation. 
 
It is evident that the formation of new bone is biologically dependent on the 
availability of the appropriate undifferentiated cells, the signals, which may 
regulate osteoblast differentiation, and the environmental niche in which this 
process occurs. In respect of the extra-cellular signalling, a wide range of 
molecules has been shown to have potential roles in the control of osteoblast 
recruitment and differentiation. These factors include BMPs, factors which may 
regulate proliferation and amplification of undifferentiated progenitor cells such 
as the fibroblast growth factors (FGFs) and factors that may regulate matrix 
stimulation and late stage differentiation such as transforming growth factor-ß. 
BMPs have attracted particular attention because of their unique and 
remarkable ability to induce heterotopic bone formation when injected into extra 
skeletal sites such as rat muscle (Wang, et al., 1990b). Although BMPs are 
growth and differentiation factors and have a number of critical roles in 
patterning and tissue differentiation in both skeletal and non-skeletal tissues 
during embryogenesis, their role in bone induction appears to be their main 
function in the adult organism. This has attracted considerable interest for 
therapeutic application in bone regeneration. Critical for their action, BMPs 
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appear to be able to regulate the osteoblastic commitment of multipotent 
mesenchymal cells resulting in previously uncommitted cells undergoing 
differentiation along osteoblast or chondrocytic differentiation pathways 
(Katagiri, et al., 1994a; Wang, et al., 1993). This somewhat unique activity on 
stem cells is thought to account for the ability of the BMPs to induce heterotopic 
ossification. 
 
There has been significant progress in novel approaches to therapeutic bone 
regeneration including augmentation techniques and GTR with and without 
growth factors. However, there are a number of questions in the subject of using 
growth factors which remain poorly addressed and which may have therapeutic 
implications in the future. The understanding of many of the biological process 
mentioned above has contributed significantly to the development of therapeutic 
techniques of bone regeneration. Such techniques may be considered to be 
either permissive (osteoconduction) whereby the technique provides the 
environment for osteogenic cells to recolonise and differentiate normally in a 
wound, or may be inductive (osteoinduction) where new bone formation is 
actively stimulated typically by the introduction of exogenous cells, matrix or 
inductive signalling molecules. Inductive methods of bone formation include 
autogenous bone grafting, and, more experimentally, the pharmacological 
application of growth factors. The most successful permissive technique is 
probably guided bone regeneration, whereby space creation provides an 
environmental niche, which permits new bone formation. 
 
We demonstrated above that BMP antagonists regulate osteoblast 
differentiation and adult bone formation. The exogenous application of the 
antagonists also limits in vitro osteogenesis. Since BMPs are important in driving 
and sustaining osteogenic differentiation in many in vitro models, these effects 
can be blunted by the BMP inhibitors. To date, biological methods of enhancing 
bone regeneration in clinical use have centred on the promotion of 
osteoinduction via the delivery of BMPs. However, targeting BMP inhibitors may 
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provide a novel means of improving bone regeneration and fulfilling other 
relevant osteogenic needs. Directly relevant to this are the studies of Kwong et 
al (2008) that showed that endogenously produced chordin constrains the 
osteogenic differentiation of human MSCs. Conversely chordin knockdown 
accelerates early osteogenesis and leads to increased deposition of mineral at 
late time points. Presumably the suppression of chordin led to an increase in the 
bioavailability of endogenously produced BMP-2 to drive the differentiation of 
osteoprogenitors (Kwong, et al., 2008). 
 
This is of particular interest to the implantologist and periodontist as well as the 
reconstructive surgeon of what is the influence of the inductive growth factors or 
their inhibitors on the alveolar bone growth and its relationship to the local 
environmental niche, and a key factor for new bone formation is the coronal 
extent for potential bone formation that is encroaching to the soft gingival 
tissues. During bone augmentation procedures in implantology (and in 
periodontal regeneration procedures) the environmental niche for bone 
formation is unusual compared with (e.g.) orthopaedic procedures because it 
tends to encroach on the superficial soft connective tissues of the overlying 
gingivae. However, these unique features in the alveolar bone can cause 
considerable difficulties for the surgeon during bone augmentation procedures, 
which, are typically managed using space maintenance devices including 
membranes and grafts. Whilst these techniques can often be used successfully, 
and have the effect of creating space for bone growth, clinical techniques are 
not without their limitations. Therefore, a better understanding of the 
mechanisms which limit the amount of coronal bone growth in this environment 
has been looked in this project. When considering the unique features of the 
alveolar bone, the potential role of superficial gingival connective tissues may be 
a key factor in determining the extent and capacity for coronal bone 
regeneration. In the proposed study we plan to investigate the mechanisms by 
which the gingival connective tissue may limit the extent of bone formation. 
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1.7.1 Evidence for the role of soft connective tissues in regulating 
bone formation 
Although this area of research has not been widely studied, a wide range of 
clinical, developmental and experimental observations provides evidence that 
bone formation is inhibited from occurring by superficial connective tissues. 
Studies of the interaction of tissues during embryogenesis suggest that 
mesenchymal tissues can define the boundary of bone formation by the 
expression of both soluble molecules such as the BMP inhibitor noggin, and by 
matrix molecules such as tenascin and syndecan (Hall & Miyake, 2000). 
 
New bone formation readily occurs in suitable environmental niches such as at a 
properly reduced fracture site or indeed within alveolar bone following implant 
placement. However, the extent of new bone formation is generally limited by 
the different environment surrounding the site of bone formation, in particular the 
presence of the adjacent sub-connective tissues. However, it has also been 
shown that in certain circumstances there is the potential to obtain heterotopic 
bone growth within deep connective tissues, which are not normally mineralized. 
A classic example of this is following the implantation of bone graft or 
recombinant BMPs, new bone formation can be induced in a range of sites 
including rat muscles, and subcutaneous fibrous tissues (Urist, 1965a; Wang, et 
al., 1990b). Similarly in some pathological processes ossification may occur in 
ectopic sites such as within a mature fibroepithelial polyp. It is thought that the 
inflammatory processes that occur in these conditions may alter the behaviour of 
the connective tissue which results in it becoming permissive to bone formation 
or possibly even inductive. In support of this idea it is known that inflammatory 
cytokines can alter the expression and production of other signalling molecules 
which are involved in mesenchymal-epithelial interactions, such as KGF and 
scatter factor (McKeown, et al., 2003). 
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Although the evidence supports the potential for heterotopic bone formation in 
deep connective tissues as described, in such circumstances bone formation 
still does not extend into the superficial connective tissues (dermis and mucosal 
lamina propria). The nearest exceptions to this are in the rare genetically 
inherited conditions of fibrodysplasia ossificans progressiva (FOP) and 
progressive osseous heteroplasia (POH) (Kaplan, et al., 2004). These 
disfiguring conditions might potentially offer some insight into the mechanisms 
which ossification in superficial connective tissues normally. In FOP the 
condition is characterised by progressive ossification in the sub dermal layer, 
which occurs in sheets typically following minor trauma. It was shown that there 
is an up regulation of BMP-4 expression in cells, and possibly critically, there is 
no concomitant up regulation of the BMP inhibitors noggin and gremlin (Ahn, et 
al., 2003; Olmsted, et al., 2003). Normally expression of BMP-4 results in a 
negative feedback loop by stimulation of expression of these BMP inhibitors but 
in FOP this pathway appears to be defective. Furthermore, it has been shown 
that in a transgenic mouse model over-expression of noggin was able to block 
the induction of BMP-4 induced heterotopic ossification (Glaser, et al., 2003).  
 
Another extremely rare human condition that results in ectopic ossification is 
progressive osseous heteroplasia (POH) that is characterised by progressive 
heterotopic ossification of subcutaneous and deep connective tissues. It is 
distinguished from FOP partly by the presence of cutaneous ossification and 
other patterns of heterotopic ossification. The genetic defect for POH has been 
shown to be an inactivating mutation of the GNAS1 gene which encodes the 
alpha subunit of a stimulatory G protein involved in activation of the enzyme 
adnylyl cyclase (Eddy, et al., 2000). In these patients it has been shown that in 
the presence of this mutation the osteogenic transcription factor runx 2 is 
expressed in high levels in dermal fibroblasts. Although the full implications of 
these observation are not entirely clear, overall the data suggests the 
importance of the combined regulation of BMPs and their inhibitors in preventing 
ectopic bone formation, and also demonstrate the importance of intact signalling 
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pathways for the regulation of tissue specific transcription factors.  
 
Although little is known about the interaction between soft connective tissues 
and bone formation in the mature organism, there is considerable evidence 
demonstrating the importance of the superficial connective tissues in regulating 
epithelial cell phenotype. Of direct relevance to the hypothesis presented here, 
Mackenzie has previously elegantly demonstrated that whilst dermal connective 
tissues support the outgrowth and normal epithelial differentiation of 
keratinocytes, these processes are inhibited when keratinocytes are placed in 
contact with “deep” connective tissues (Mackenzie, et al., 1993; Mackenzie, 
1987; Mackenzie & Dabelsteen, 1987). With the advent of tissue engineering 
approaches to skin grafting, the importance of the dermal connective tissues in 
regulating keratinocyte growth and differentiation has been clearly demonstrated 
(Navsaria, et al., 1995).  
 
Overall these studies will demonstrate the regulatory role of connective tissues 
to support the idea that these tissues are regionally distinct, and regulate 
adjacent tissues by release of soluble factors such as growth factors, and 
probably matrix factors. 
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1.8 HYPOTHESIS AND AIMS OF THE PROJECT  
The aim of the research in this proposal is to test the hypothesis that superficial 
soft connective tissues inhibit bone formation by specific and identifiable 
molecular signalling mechanisms. This project is designed to provide information 
that leads to further studies to identify the inhibitory molecules to bone growth 
into superficial connective tissues. Specifically, this project investigates: 
1. The interaction between connective tissues fibroblasts and osteoblasts in 
vitro and whether superficial tissue fibroblasts inhibit osteoblasts 
differentiation measured by ALP, osteocalcin and osteopontin synthesis 
and compare it to deep tissue fibroblasts. 
2. The nature of this inhibition and whether the factors involved in this 
influence are dependent on direct cell contact, attached to cell matrix or 
are released factors. 
3. Whether the inhibition behaves as an inhibitor of BMPs. BMPs and their 
inhibitors were tested for their influence on osteoblasts differentiation and 
whether this influence can be modulated by the fibroblasts. 
4. Does the inhibitory activity in the media conditioned by the fibroblasts 
block BMP-induced osteoblasts chemotaxis as well as differentiation.  
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CHAPTER TWO 
MATERIAL AND METHODS 
2.1 OVERVIEW OF EXPERIMENTS 
To test the hypothesis that soft connective tissue can influence bone growth, 
fibroblasts from soft connective tissue were tested for their effects on osteoblast 
functions in vitro. Cells used in this study were either primary rat cells or 
established cell lines. Fibroblast cultures used were primary gingival, skin or oral 
mucosa fibroblasts explanted from adult rat tissues. Primary osteoblasts were 
obtained by collagenase digestion of calvarial bones from newborn wistar rats. 
Primary gingival and periodontal ligament fibroblasts were characterized in 
chapter 3 using direct visualization under light microscope and observing the 
formation of bone nodules, assessment of alkaline phosphatase expression and 
immunocytochemical staining. Although many of the initial experiments were 
carried out with primary cell cultures, later experiments used established 
osteoblastic cell lines, given the increased reproducibility of these cultures. 
Generally, osteoblasts were assessed for their differentiation, proliferation and 
migration functions in response to treatment.  Differentiation was generally 
assessed by measuring osteoblasts total alkaline phosphatase (ALP) activity, 
measuring expression of osteocalcin and osteopontin by ELISA, and 
measurement of gene expression of ALP, osteocalcin and osteopontin; 
proliferation was assessed by performing MTT viability assay and the migration 
of osteoblasts was measured using a Boyden chamber assay. 
 
The experiments in this study are divided into three main stages, which were 
designed to provide definitive information to allow further studies for 
identification of specific mechanisms acting to inhibit bone growth into superficial 
connective tissues. 
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2.1.1 Studies to test the inhibition of osteoblast activity by fibroblast 
cultures. 
The first set of experiments involved a series of studies to establish reliable and 
reproducible models to investigate and characterise the interaction between 
connective tissues cells and bone osteoblasts in vitro. A very wide range of in 
vitro models and cell lines have been described for the study of osteoblast 
biology in vitro (Hughes & Aubin, 1998). In this study we used three models: 
 
Three-dimensional cultures 
To test the ability of different fibroblasts from regionally defined sites to inhibit 
bone formation, 3D cultures of fibroblasts grown in contracted collagen gels 
were established that allowed fibroblasts and osteoblasts to grow and interact in 
a more in vivo like model. Primary cell cultures (gingival and calvarial 
osteoblasts) were seeded into collagen gels using techniques described below. 
Differentiation of osteoblasts was assessed by measuring the total alkaline 
phosphatase activity (ALP) to the mixed culture and compared to the ALP 
activity of osteoblasts grown alone.  
 
Osteoblasts cultured on the top of fibroblast matrices 
To test whether the activity caused by the fibroblasts required living cells to 
cause the effects, the cell matrix was assessed for its activity on osteoblasts 
differentiation. Cells were grown for 72 hours, they were then killed by radiation 
or freezing; and the matrix was kept on the surface. Osteoblasts were cultured 
on the top of the different matrices (test and control) and their ALP activity was 
measured to assess the difference in the differentiation. 
 
Combined culture based on insert system (no cell contact) 
To test whether cell contact is needed to affect the osteoblasts, fibroblasts and 
osteoblasts were cultured on different surfaces sharing the same medium. This 
ensured that fibroblasts and osteoblasts did not have direct contact. Osteoblasts 
were cultured on the lower surface of the well and fibroblasts were cultured on 
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the surface of inserts located 0.8mm above the osteoblasts. Osteoblast 
differentiation was assessed by measuring total ALP activity.  
 
Assessing influence of fibroblast supernatants on osteoblasts 
Serum free supernatants (conditioned media) of fibroblasts (gingival, oral 
mucosa and skin) were harvested and were used to treat osteoblasts. 
Conditioned media from osteoblasts was also collected to be tested for the 
same effects. Total ALP activity was then measured in osteoblasts treated with 
different conditioned media and compared to control. MTT viability assay was 
performed to correct for cell number differences and to assess the influence of 
the treatment on cell proliferation. In this chapter, conditioned media from 
gingival and PDL fibroblast were tested for effects on expression pattern of 
osteocalcin and osteopontin in ROS cells by ELISA and real-time PCR assays. 
Also, the effects of the gingival and PDL conditioned media were tested for the 
effects on ALP protein expression by real-time PCR. Conditioned media of 
gingival and PDL fibroblasts was characterised for their effects on ROS cells 
using trypsin, heat inactivation and molecular weight cut off. 
 
2.1.2 Studies to investigate the effects of fibroblasts on BMP activity  
The second stage of studies were designed to investigate the effects of potential 
candidate factors (BMP inhibitors: noggin, chordin and follistatin), which could 
be involved in this process including the manipulation of these factors for their 
ability to inhibit their antagonists (BMP-2 and activin) in our in vitro systems. 
Total ALP activity of osteoblasts was measured as the differentiation marker in 
this system also. Media conditioned by different cell types were tested for their 
synergy or antagonism to the stimulators (BMPs) or their inhibitors. 
 
2.1.3 Studies to investigate the effects of fibroblast conditioned 
medium on osteoblast migration and chemotaxis.  
The third stage was by performing Boyden chamber chemotactic assays with 
the osteoblasts.  Osteoblasts were tested for their chemotactic responses to 
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PDGF and BMP-2, and whether the media conditioned by different fibroblasts 
antagonized the influence of those factors.  
2.2 MATERIALS  
2.2.1 Media 
 
Transport Medium (TM): Dulbecco’s MEM with 25 mM HEPES buffer 
(Invitrogen #22320), supplemented with penicillin G 500units/ml (GbicoBRL), 
streptomycin 500µg/ml (GbicoBRL) and 3µg/ml amphotericin B (GbicoBRL). 
 
Culture Medium (ME): αMEM with nucleotides (GibcoBRL 22571), with 
Ribonucleosides and Deoxyribonucleosides, supplemented with penicillin G 50 
unit/ml, streptomycin 50 µg/ml and amphotericin B 0.3 µg/ml. 
 
Conditioned media (CM): Early passage (< 5 passages) skin, gingival and 
periodontal ligament fibroblasts in addition to calvarial osteoblasts were grown in 
75cm2 flasks at initial density of 106 cells/ flask with ME supplemented with 10% 
new-born calf serum for 24 hours. The medium was then replaced by 5ml of 
serum free ME and allowed to condition over 48 hours.  CM was filtered using 
4µm filters to remove cell debris. 
 
Serum 
Newborn Calf Serum (NBCS): PAA Laboratories Ltd, batch No A03122-531 
 
2.2.2 Growth factors 
BMP-2: rhBMP-2 was a gift from Dr J Wozney, was reconstituted in sterile 4mM 
Hcl with 1% NBCS at concentration of 10µg/ml and frozen at -20° C. 
 
Activin-A: recombinant human/mouse/rat Activin-A was purchased from R&D 
systems (338-CF), was reconstituted in sterile PBS with 1% NBCS at 
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concentration of 50µg/ml and frozen at -20° C. 
 
Noggin: recombinant mouse noggin was purchased from R&D systems (1967-
NG), was reconstituted in sterile PBS with 1% NBCS at concentration of 
10µg/ml and frozen at -20° C. 
 
Chordin: recombinant mouse chordin was purchased from R&D systems (758-
CF), was reconstituted in sterile PBS with 1% NBCS at concentration of 
100µg/ml and frozen at -20° C. 
 
Follistatin: recombinant mouse follistatin (FS-288) was purchased from R&D 
systems (769-CF), was reconstituted in sterile PBS with 1% NBCS at 
concentration of 100µg/ml and frozen at -20° C. 
 
2.2.3 Total ALP reagent  
For 10 ml solution: 8.4ml distilled water, 2.4ml reaction buffer (Sigma N0221), 
30mg p-nitrophenylphosphate (Sigma No 104) and 2.7mg MgCl2. To stop the 
reaction we used 0.5M NaOH as a stop solution.  
2.2.4 Collagenase solution 
The collagenase solution used in rat calvarial bone digestion was made up as 
follows: 
1.5 mg collagenase/ml (sigma type II #C6885)   100mg 
9.7 units DNAse/ml (Sigma # DNEP)   0.25 mg 
0.12 mM chondroitin sulphate (sigma #C3788)     79mg 
100 mM sorbitol      1200mg 
111.2 mM Kcl      500mg 
1.3 mM MgCl2       17.4mg 
13 mM glucose      170 mg 
0.5 mM ZnCl2      4.5mg 
50 mM TRIS Hcl buffer pH 7.4    66ml 
The mix was filter-sterilized using a 0.45µm pore filter and placed in 4ml aliquots 
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and stored at -20º C.  
2.2.5 Preparation of 3-D culture system 
Rat-tail collagen type I (BD Biosciences 354236) was used to create the 3-
dimensional culture system, and was prepared according to the manufacturer‘s 
instructions as follows:  
All material were placed on ice: the stock gel, sterile 10x αMEM medium, sterile 
dH2O and sterile 1M NaOH.  
Stock collagen volume to be added was determined by the formula: 
 
Final volume x 3 (final collagen concentration mg/ml) 
 
Stock volume = 
4.5 (collagen stock concentration mg/ml) 
                 
Volume of (1M NaOH) was calculated according to the formula: 
Volume 1M NaOH (ml) = volume stock collagen to be added (calculated above) 
X 0.023  
 
Sterile ice-cold 10 x αMEM medium was measured by the formula: 
Final volume of working collagen 10 x αMEM medium= 
10 
 
Volume dH2O was measured by the formula: 
Sterile dH2O (ml) = final working volume – stock collagen volume to be added – 
volume of (10 x αMEM medium) – volume of (1M NaOH)  
 
The mixture was made as follows: sterile 10x αMEM, the sterile ice cold 1M 
NaOH, the sterile dH2O, and finally the collagen stock. The mixture was 
prepared on ice to prevent gelling. 
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2.2.6  Osteocalcin ELISA assay 
Rat osteocalcin ELISA kit from biomedical technologies Inc (Cat no: BT-490) 
was used in this assay that contains the following reagents: 
Working sample buffer. 
Phosphate saline concentrate (was used as a wash buffer) 
Osteocalcin standard was reconstituted with resample buffer to make 
concentrations of 20, 10, 5, 2.5, 1, 0.5, 0.25 and 0 ng/ml of standards. 
Osteocalcin antiserum. 
Donkey anti-Goat IgG Peroxidase Conjugatge that was diluted 1/800 using 
sample buffer. 
Peroxidase substrate TMB (3,3 ,5,5 –tetramethyl benzidine) that is mixed with 
hydrogen peroxide solution at one volume each. 
Stop solution 
96 well plate coated with osteocalcin antibody. 
2.2.7  Ostepontin ELISA assay 
Rat osteopontin ELISA kit from Stressgen (Cat no: 900-090A) was used in this 
experiment that contain the following reagents: 
Assay buffer (tris buffer saline with BSA and detergent) 
Osteopontin standard that was reconstituted to concentrations of: 100, 50, 25, 
12.5, 6.25 and 3.13 ng/ml 
Osteopontin ELISA plate coated with monoclonal antibody specified for 
osteopontin 
Osteopontin polyclonal secondary antibody 
Osteopontin conjugate (streptavidin conjugated to horseradish peroxidase) 
Wash buffer (tris buffered saline containing detergents) 
TMB solution (3,3 ,5,5 –tetramethyl benzidine) and hydrogen peroxide 
Stop solution (1N solution of hydrochloric acid in H2O) 
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2.2.8 Real-time PCR 
RNA extraction 
Qiagen RNeasy mini kit (Cat no: 74104) was used in this experiment that 
contain the following: 
Qiashredder columns 
RNeasy mini-spin columns 
Collection tubes 
Buffer RLT 
Buffer RW1 
Buffer RPE 
RNase-Free water 
 
Reverse Transcription (cDNA synthesis) 
RNase-free H2O  
Oligo dT15 primer (Promega) 
M-MLV RT reaction buffer (Promega) 
10 mM dNTPs (Promega) 
M-MLV RT, Rnase H minus (Promega) 
PCR machine 
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific) 
 
Real-Time PCR 
TaqMan master mix (No 4324018) 
MicroAmpTM Optical 384-well reaction plates (Applied Biosystems) 
Distilled deionised water 
Optical adhesive films 
Applied Biosystems 7900HT real-time PCR System 
Applied Biosystems SDS2.3 software 
GeNorme software 
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Primers 
In order to select two control primers, six primers were tested for their stability: 
18sRNA_ Hs99999901_s1, small ribosomal subunit of eukaryotic ribosome 
Gapdh- Rn99999916_s1, glyceraldehyde 3-phosphate dehydrogenase 
Eif4a2_ Rn01404755_gH, eukaryotic translation initiation factor 4A, isoform 2 
Ubc_ Rn01789612_g1, ubiquitin c 
Atp5b_ Rn01756316_g1, ATP Synthase, H+transporting, mitochondrial F1 
comples, beta polypeptide 
B2m_ Rn00560865_m1, beta2 microglobulin 
Tested primers: 
Alkaline phosphatase primer: Rn01516028-m1 (NCBI gene ref: NM_013059.1) 
Osteocalcin primer: Rn01455285_g1 (NCBI gene reference: NM_013414.1) 
Osteopontin primer: Gg03362459_m1 (NCBI gene reference: NM_204535.4) 
2.3 CELL CULTURE 
2.3.1 Osteoblasts 
 
Isolation of primary Rat Calvarial Osteoblasts: 
Newborn Wistar rats P1-3 (40-50) were killed by cervical dislocation, heads 
were immediately transferred to the tissue culture laboratory in transport 
medium (TM) supplemented with 15% NBCS; Calvarial bones were dissected 
and removed then digested by collagenase solution according to (Bellows, et al., 
1986). Each head was held with tweezers down side of face and a small nick in 
the skin was made over the bridge of the nose. The cut was continued over the 
calvarium and skin was reflected to expose the bone. A cut was made right 
through the calvaria from the external auditory meatus across behind parietal 
bones. A second cut was made across above the eye sockets. The calvaria was 
removed carefully, freed from the loosely adherent tissue and stored in PBS on 
ice. All calvaria that were isolated were minced with scissor, rinsed three times 
with PBS. 4ml of collagenase solution (described above) preheated to 37º C 
were added. The calvaria bones and the collagenase solution were incubated at 
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37º C for 10 minutes with continuous magnetic stirring. They were then removed 
from incubator, tissue fragments were allowed to settle. Supernatants were 
removed and added to 4ml NBCS on ice (designated as population 1). The 
same procedure was repeated with fresh collagenase for further 10 minute 
(Population 2) and three further periods of 20 minutes each (Populations 3-5). 
Supernatants were centrifuged at 1500 rpm for 5 minutes, and cell pellets were 
re-suspended in 10ml ME containing 15% NBCS. Each population was plated 
into T75 flask and incubated for 24-48 hours. Population 3-5 were trypsinized 
and pooled together and used as the osteoblastic cell population. Cells were 
then cultured and maintained in 75cm2 (T75) flasks and fed with ME 
supplemented with 10% NBCS. 
 
Rat bone marrow stromal cells (BMSCs) 
Rat bone marrow stromal cells (BMSCs) were isolated from male Wistar rats 
aged 4-6 weeks (weighing 100-120g) as described by (Maniatopoulos, et al., 
1988) as follows: 
The rats were rendered unconscious in CO2 chamber then were killed by 
cervical dislocation. Incision was made through the skin and the muscles and 
tendons were dissected to access the femora. The bone was removed and 
placed in TM. Excess tissues were removed and the epiphysis of the bone was 
removed by scalpel and disposed. With the medullary cavities exposed the 
diaphyses were placed in centrifuge tube and spun at 1500 rpm for 3 minutes to 
expel the bone marrow. The bone marrow was dispersed in culture medium 
(ME) and seeded in T75 flasks (one femur per flask). Cultures were washed and 
medium was changed every 2-3 days. 
 
Rat Osteosarcoma Cell line ROS17/2.8 (ROS) 
ROS cells were a gift from the Royal Veterinary College, London. Cells were 
cultured and maintained in 75cm2 flasks and fed with ME supplemented with 
10% NBCS. 
 
	   
72 	  
	  
Chapter	  Two	  Material	  and	  Methods	  
MC3T3-E1 Mouse (Mus musculus) cell line (MC3T3)  
MC3T3 mouse pre-osteoblastic cells were purchased from ATCC (catalogue 
number CRL-2593). Cells were cultured and maintained in 75cm2 flasks and fed 
with ME supplemented with 10% NBCS. 
2.3.2 Fibroblasts 
Isolation of primary rat gingival, periodontal ligament and skin fibroblasts:  
Adult wistar rats were rendered unconscious in CO2 chamber and killed by 
cervical dislocation. Samples of gingival and skin tissue were isolated and 
transferred in TM supplemented with 15% NBCS. Gingival and oral mucosa 
samples were cut with a scalpel into small fragments (approximately 1mm3) and 
let to air dry in very little medium in 10cm diameter tissue culture Petri dish for 
few minutes in sterile hood environment to allow the tissue fragments to begin to 
adhere to the plastic surface. A similar method was used for dermal samples 
after the removal of hair and the epithelium.  
 
To isolate periodontal ligament fibroblasts, molar teeth were extracted by gentle 
elevation using a scalpel blade. The periodontal ligament was carefully removed 
under a dissecting microscope (Zeiss) avoiding the cervical tissues that could 
include contaminating gingival fibroblasts. Small periodontal ligament fragments 
were let to air dry in sterile hood environment for few minutes then ME 
supplemented with 15% NBCS was added.  
 
All cells were grown in ME supplemented with 15% NBCS in 10 cm Petri dish for 
5-7 days then transferred to a T25 flask. As cells became confluent they were 
transferred, grown and maintained in T75 flasks in ME supplemented with 10% 
NBCS. Each isolated line used originated from one rat only. 
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2.4 SET-UP OF EXPERIMENTS  
2.4.1 Three-dimensional co-culture 
0.5 ml of the 3-D collagen solution (above) was applied to each well of 24-well 
plates and plates were incubated for 30 minutes at 37˚C in order to let the 
collagen gel and form the desired consistency before seeding the cells. 
Two different experimental set-ups were used: 
 
Set-up 1: Simultaneous seeding of osteoblasts and fibroblasts into the gel: 
Both osteoblasts and gingival fibroblasts were incorporated together into the 3-D 
collagen system simultaneously at a density of 5 x 105cells/well calvarial cells, 
5x105 or 1x106 gingival cells by adding each cell suspension in 500 µl of ME 
supplemented with 10% NBCS. Controls for this experiment consisted of gels 
seeded only with calvarial osteoblasts at a density of 10 x 106 cells/well in 1 ml 
ME supplemented with 10% NBCS. Gels were cultured for 72 hours, and then 
total ALP levels were measured in the cultures. Background levels of gingival 
cells ALP was tested and corrected in all combined treatments.  
 
Set-up 2: Sequential seeding of osteoblasts and fibroblasts into the gel: 
Osteoblasts were seeded into the setting gel at a density of 5 x 105 cells/well by 
adding 750µl of cell suspension in ME supplemented with 10% NBCS. 
Fibroblasts were seeded onto the surface of the gel 24 hours later at a density of 
5 x 105 or 1x106 cells/well in ME supplemented with 10% NBCS. In control 
cultures, osteoblasts were seeded instead of fibroblasts after 24 hours, or 
fibroblasts were seeded during both seeding the gel and after 24 hours. Gels 
were grown for 72 hours after the second seeding, and then total ALP was 
measured. 
 
In both experiments parallel plates were set to perform MTT assays for the 
correction of cell numbers. 
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2.4.2 Inserts co-culture 
Falcon ™ (falcon 24-well plate #3504, and matching inserts # 3095) cell culture 
insert system was used to grow cells in close proximity but without direct cell 
contact ensuring that the two types of cells are sharing the same medium. 
Osteoblasts were seeded onto the lower level of the well at a density of 5 x104 
cells/well in ME supplemented with 10% NBCS. The inserts were added 24 
hours later and fibroblasts were seeded onto the membrane of these inserts at a 
density of 5 x 104 cells/well ME supplemented with 10% NBCS. Controls 
consisted of cultures with osteoblasts in both wells and inserts in addition to 
cultures with wells grown with empty inserts. Cells were grown for 72 hours after 
seeding the fibroblasts on the inserts then osteoblasts were assayed for total 
ALP activity (figure 2.1). 
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Figure 2.1: Falcon insert system, A: diagram of the plate, B: diagram of insert 
well. 
 
 
2.4.3 Treatment of osteoblasts by conditioned media (CM), growth 
factors and combined treatment  
Osteoblasts (Calvaria, ROS or MC3T3) were cultured in 96-well plates and 24-
well plate at densities of 5x103 cells and 5x104 a well respectively, grown in CM 
supplemented with 10% NBCS for 24 hours. Medium was replaced by treatment 
	   
76 	  
	  
Chapter	  Two	  Material	  and	  Methods	  
solution supplemented with 10% NBCS (ME with a growth factor, CM, or 
combined treatment of CM and growth factor, in addition to control medium ME). 
Experiments were stopped after 72 hours by removing the medium and 
performing total ALP assay. 
2.4.4 Osteoblasts grown on the top of matrices of fibroblasts  
Fibroblasts were grown as a monolayer in 96 well-plates at a density of 5 x103 
cell/well for 72 hours using ME supplemented with 10% NBCS. Cells were then 
killed either by freezing in -80°C freezer or by UV irradiation. Medium was 
removed and wells were washed with PBS. Osteoblasts were seeded into wells 
where the fibroblast had previously been grown at a density of 5x103 cells/well 
for 72 hours in ME supplemented with 10% NBCS. Controls consisted of 
osteoblasts grown without matrices of fibroblasts. Medium was removed and 
total ALP assay was performed. 
2.4.5 Set-up for osteocalcin and osteopontin ELISA experiments and 
real-time PCR  
ROS cells were grown in 6-well plate at density of 5x105 cells/ well for 24 hours 
in ME containing 10% NBCS. Medium was replaced with test and control 
medium that contain 10% NBCS. Conditioned medium from three primary 
gingival fibroblastic lines and three primary PDL fibroblastic lines were used to 
treat ROS cells (2ml/well). 10ng/ml of BMP-2 treatment was performed as 
positive control and treatment with ME containing 10% NBCS was considered 
the negative control. All treatments were performed in triplicates.  
After 72 hours, supernatants were collected and stored in -20° C to be used in 
ELISA experiments (osteocalcin and osteopontin), RNA of ROS cells was 
isolated using RNeasy kit from Qiagen as described below and reverse 
transcription was done to obtain cDNA. This experiment was repeated twice and 
samples were used in ELISA experiments and qPCR.  
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2.5 METHODOLOGY 
2.5.1 Immunocytochemistry 
Gingival and PDL fibroblasts were investigated for expression of vimentin and 
S100A4 proteins according to the following protocol: 
Three Gingival and PDL fibroblast lines (in triplicates) were seeded in 24 well 
plates on the top of glass coverslips. The coverslips were sterilised by radiation 
for 1 minute. 5 x104 cells per well were seeded and cultured for 72 hours in ME 
supplemented with 10%NBCS. 
After the media was removed cells were rinsed with PBS and fixed with -20°C 
methanol. 
Cells were blocked with goat serum (5 % in buffer) for 1 hr with gentle rocking. 
Primary vimentin (ab20346) or S100A4 (ab27957) antibody was added to 
blocking buffer and incubated for 1 hr with gentle rocking.  After a thorough 
wash (4 x 10 min) with the buffer secondary antibody was added in buffer that 
has goat serum and incubated for 30 min with gentle rocking.  Cells were 
washed again (4 x 10 min) with buffer. Coverslips were mounted on slides using 
immuno-mount after wash and Dapi Stain for 10 minutes. 
2.5.2 Alkaline phosphatase (ALP) Histochemical staining 
Three gingival and PDL fibroblast lines (in triplicates) were seeded in 24 well 
plates at density of 5x104 cells/well and cultured for 72 hours in ME 
supplemented with 10%NBCS. Cells were then washed with PBS and fixed with 
fomalin for 10 minutes. Cells were washed again with 0.2 TRIS HCL buffer with 
pH of 9.0. Cells were then incubated for 30 minutes in substrate solution (60mg 
naphthol AS phosphate were dissolved in 1ml dimethyl fomamide then added to 
200ml of TRIS buffer). Cells were visualised under light microscope.  
2.5.3 Total alkaline phosphatase (ALP) assay  
ALP for osteoblasts grown in 3 dimension collagen-based culture 
The medium was removed from all wells leaving the collagen gel containing 
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osteoblasts embedded its 3-D structure. Wells were washed with PBS and the 
gel and cells were transferred to 1 ml eppendorfs. Gels containing cells were 
sonicated by (Soniprep 150) for 20 seconds. 100 µl of sonicates were pipetted 
into 96-well plate in duplicates. 100 µl of ALP reagent solution were added to the 
wells, incubated at 37˚C for 20 minutes in the dark. Plates were then read in a 
spectrophotometer at 405 nm. 
 
ALP for osteoblasts treated by CM, growth factors, combined treatment, for 
osteoblasts grown on the top of matrices of fibroblasts and for osteoblasts grown 
in inserts co-culture system  
Supernatants were removed (and inserts in co-culture experiments) and wells 
were washed with PBS. Total ALP reagent was applied to all wells (100µl/well 
for 96-well plate and 300µl/well for 24-well plate). Plates were incubated in 37˚C 
and protected from light for 10-20min in calvarial and MC3T3 cells and for 1-
5mins in ROS cells. Readings were taken with a plate reader at 405 nm. 
 
2.5.4 MTT assay for cell numbers.  
In addition to plates to be assayed for total ALP, parallel plates were set up to 
allow correction for differences in cell numbers. Relative cell numbers were 
assessed by MTT assay. To perform MTT test, supernatants were removed and 
wells were washed with PBS. 0.5mg/ml MTT solution (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) was applied to wells (100µl for 96-well plate 
and 300µl for 24-well plate). Plates were incubated at 37˚C for 2 hours in the 
dark. The MTT solution was removed, wells were washed with PBS and 
acidified isoproponal was added to wells (100µl/well for 96-well plate and 
300µl/well for 24-well plate). Plates were incubated for 1hour at 37˚ C. Plates 
were read in a spectrophotometer at 570nm. 
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2.5.5 Osteocalcin ELISA 
The experiment was performed as an overnight procedure as follow: 
Standards, control and samples were pipetted in the wells in dublicates 
(100µl/well) and the plate was incubated for 18 hours at 2-8°C. Wells were 
aspirated and washed three times with wash buffer and 100 µl/well of 
osteocalcin antiserum was added and the pate was incubated for 1 hour at 
37°C. After a second wash, 100 µl/well of donkey anti-goat IgG peroxidase was 
added to the wells and the plate was incubated for 1 hour at room temperature. 
TMB and hydrogen peroxide mixture was added (100µl/well) after a third wash 
and incubated in the dark at room temperature for 30 minutes. Stop solution was 
added (100 µl/well) and absorbance was measured at 450nm. 
2.5.6 Osteopontin ELISA 
Samples were diluted at 1:16 as recommended by the assay manufacturer. 
Diluted samples, control and standards were added to the wells in dublicates (50 
µl/well) and the plate was incubated shaking for 1 hour at room temperature. 
After a thorough wash, 50 µl/well of the secondary antibody was added to the 
plate and incubated shaking for 1 hour at room temperature. After a second 
wash, 50 µl/well of the conjugate was added to all wells except the blank well, 
and the plate was incubated shaking for 30 minutes at room temperature. 50 
µl/well of substrate solution was added after a third wash and a further 
incubation shaking for 30 minutes at room temperature. Final addition of 50 
µl/well of stop solution and reading at 450 nm was performed. 
2.5.7  Real-time PCR 
Extraction of RNA 
Cells in the 6 well plates were lysed by adding buffer RLT (350 µl/well) to the 
wells, and lysate were collected by a rubber policeman. Lysates were placed in 
QIAshredder spin column and centrifuged for 2 minute at full speed. One volume 
of 70% ethanol was then added to the lysate and was mixed well by pipetting. 
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The mixture was placed in RNeasy spin column and centrifuged for 15 seconds 
at 10.000rpm and the flow-through was discarded. 700 µl of buffer RW1 was 
added to the RNeasy spin column and further centrifuge for 15 seconds at 
10000 rpm to wash the spin column membrane. The flow-through was 
discarded. 500 µl of buffer RPE was added to the spin column and further 
centrifuge for 15 seconds at 10000rpm to wash the membrane. The RNeasy 
spin column was placed in a new 1.5 ml collection tube and 50µl of RNase-free 
water was added to the membrane and the column was centrifuged for 1 minute 
at 10000rpm to elute the RNA that is kept cold and frozen.   
 
Reverse Transcription (cDNA synthesis) 
Concentrations of RNA of each sample was measured using the NanoDrop. The 
following reagents were added to the tube (per sample): 
1µg RNA + H2O that make 14µl in total 
0.5 µg oligo dT primer: 1µl 
The tube was then heated to 70°C for 5 minutes and cooled at 6°C then 
centrifuged. 
11 µl of the following was added per sample: 
M-MLV RT buffer: 5 µl 
10 mM dNTPs: 1.25µl 
M-MLV RT (Rnase H minus): 1 µl 
H2O: 3.75 µl 
The tube was then placed in the PCR machine and the following programme 
was applied: 
Heat at 40°C  for 60 minutes 
Heat at 70°C for 15 minutes 
Cool to 6°C  
Samples were then stored at -20°C. 
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Quantitative Real-time PCR (TaqMan) 
Before testing ALP, osteocalcin and osteopontin genes, in order to select two 
control primers, we tested six candidate control primers for their stability with a 
range of our cDNA samples. Genorme software was used to test the most 
consistent expression profile (Figure 2.2). The selected primers are: 
ATP5b_Rn01756316_g1 and B2m_Rn00560865_m1 
 
Figure 2.2: Average expression stability values of six control genes. The more stable genes are 
the less value in the Y axis. 
 
Distilled water was added to the samples to make 40-fold dilution, then 5µl of 
cDNA samples (in triplicates) were pippeted in 384-well plates followed by 
mixture of 0.5µl of primer with 5µl of mastermix per well. The plates were sealed 
with adhesive films and centrifuged at 4000rpm. PCR reaction was then carried 
out in the PCR machine according to the thermal programme: 
95° C for 10 minutes 
60 cycles of 15 seconds at 95° C  
60° C for 1 minute 
Data was collected by SDS203 software, analysed and normalised to the 
endogenous controls mentioned above. 
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Characterization of conditioned media 
Heat treatment 
CM extracted from three gingival fibroblastic lines were used in this experiment. 
500µl of each line CM and of control were aliquoted into 2ml eppendorfs and 
immersed in boiling water for 1, 5 and 10 minutes.  Control samples were 
serum-free ME exposed to the same heat treatment.  Samples were then cooled 
to room temperature and NBCS was applied at 10%.  ROS cells were seeded in 
96 well-plates at 5x103 cells/well and fed with ME for 24 hours. The medium was 
then replaced with heat-treated samples and controls supplemented with 10% 
NBCS in triplicates.  Total ALP assay was applied as described above after 72 
hours. 
 
Trypsin treatment 
CM extracted from three gingival fibroblastic lines was incubated with 1mg/ml of 
trypsin (Sigma T5266) at 37°C for two hours. The trypsin was then inactivated 
with 2mg/ml trypsin inhibitor (Sigma T6522) at 37°C for two hours.  As a control, 
CM was incubated with 2mg/ml trypsin inhibitor for two hours.  ROS cells were 
seeded in 96 well-plate at 5x103 cells/well and fed with ME for 24 hours. The 
medium was then replaced with trypsin treated samples and controls 
supplemented with 10% NBCS in triplicates, total ALP assay was applied as 
shown above after 72 hours. 
 
Molecular weight fractionation 
Serum free media conditioned by gingival, oral mucosa and skin fibroblasts 
(three lines of each) was collected as described above.  Molecular weight filters 
were used to fractionate the media (100kDa, 50kDa and 30kDa filters, from 
Vivaspin, Sartorius group, Cat No VS06S1) by centrifuging at 3000rpm for 15 
minutes. Retentate and filtrate samples were reconstituted to the original 
concentration using serum free ME. ROS cells were seeded in 96 well-plate at 
5x103 cells/well and fed with ME for 24 hours. The medium was then replaced 
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with retentate samples, filtrate samples and controls supplemented with 10% 
NBCS in triplicates. Controls are serum free ME fractionated using the same 
filter size as the samples. Total ALP assay was applied as shown above after 72 
hours. 
2.6 STATISTICAL ANALYSIS 
In ALP and MTT assays, values of ALP varied between experiment repeats, 
therefore all values were normalised to control values. Number of repeats and 
replicates in each experiment is indicated in the graph legends. In this study all 
experiments result graphs had error bars that represent the standard deviation 
calculations. Comparisons between 2 groups were performed by student t-tests, 
For 3 or more groups 1-way ANOVA with Bonferroni post test was used. 
Significance was taken as P < 0.05. 
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CHAPTER THREE 
CHARACTERISATION OF FIBROBLAST CULTURES 
3.1 INTRODUCTION 
We hypothesize in this thesis that gingival fibroblasts as a superficial connective 
tissue may specifically produce factors that inhibit bone formation.  We also 
hypothesize that this effect may be distinct from periodontal ligament fibroblasts, 
which are a deep connective tissue with specific properties.  This study used rat 
primary gingival and PDL fibroblast lines that were harvested from different 
animals at different times. The studies described in this chapter validate the 
characteristic phenotypes of the gingival and periodontal ligament fibroblasts.  
PDL comprise a heterogeneous cell population and consists of several cell 
subsets that differ in their function.  The literature describes PDL fibroblasts as 
distinct from superficial connective tissue fibroblasts.  It is known that PDL 
fibroblasts produce osteoblast-related extracellular matrix proteins and show 
higher alkaline phosphatase activity compared to gingival fibroblasts, implying 
that PDL fibroblasts or a sub-poulation of them have osteogenic characteristics 
(Murakami, 2003; Wu et al, 2009). However, It has thus been speculated that 
PDL cells possess regulatory mechanisms to inhibit mineralization. Interestingly, 
under certain conditions, some cells within the PDL exhibit properties of 
osteoblasts and are capable of forming a mineralized matrix in vitro (Cho et al, 
1992). PDL is also reported to be rich in stem cells (Petrovic & Stefanovic, 2009)  
which have been used for tissue regeneration (Kim et al, 2009). The stem cells 
may be of neural crest origin, as they express neural crest markers (Huang et al, 
2009). Researchers have used a number of markers to differentiate between 
PDL and gingival fibroblasts.   Amongst these is S100A4 protein. This is a 
calcium binding protein that belongs to S100 protein family which, after binding 
to Ca2+, interact with target molecules and control various cellular processes 
such as differentiation and cell metabolism (Schafer et al, 1996) It has been 
observed that PDL express high level of S100A4 compared to other oral tissues.  
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Duarte et al found a significant difference of S100A4 expression between PDL 
and gingival fibroblasts and they proposed that this protein can be a useful 
marker for distinguishing cells from these two tissues (Duarte et al, 1998) 
Vimentin is a protein forming the vimentin filaments, a common type of 
intermediate filament which is widely used as a marker for cells derived from 
embryonic mesenchyme.  Previous studies have demonstrated vimentin 
expression in both primary periodontal ligament and in gingival fibroblasts.  
Vimentin staining is thus a useful method for the confirmation of fibroblast 
phenotype, without distinguishing between site of origin. (Mussig et al, 2005; 
Abiko et al, 2004; Di Domenico et al, 2003). 
The aim of the studies in this chapter is to characterise the gingival and 
periodontal ligament cell lines isolated for further studies in this thesis. 
Specifically, this chapter explores the morphological features for the two cell 
types including the formation of bone nodules, expression of ALP protein, S100a 
and vimentin.  
3.2 METHODS 
3.2.1 Observation of cell morphology and bone nodules 
Three PDL (passage 5) and gingival fibroblast (passage 4) lines were cultured in 
24 well-plate at a density of 5x104 cells/ well and fed with ME supplemented with 
10% NBCS. Cells were observed in different confluence and bone nodules were 
observed in over confluent cultures. 
3.2.2 Total and histochemical ALP assays 
Three gingival (passage 4) and PDL (passage 5) primary fibroblast lines were 
cultured in 24 well plates at density of 105 cells/well for 72 hours in ME 
supplemented with 10% NBCS. Total ALP assay and ALP histochemical assays 
were performed to parallel wells of the gingival and PDL cells as described in 
chapter 2. Three different cell lines of gingival and PDL fibroblasts were used in 
this assay. 
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3.2.3 Immunocytochemistry staining 
Three cell lines of PDL and gingival fibroblasts were cultured in 24 well-plate on 
the top of cover glass at density of 105 cells/ wells for 72 hours and were fed with 
ME supplemented with 10% NBCS. Cells were then fixed and permeablised as 
described in chapter 2.  Non-specific binding with goat serum and primary then 
secondary antibodies were applied and the slides were stained with DAPI and 
mounted with immunomount. Slides were visualised using immunoflourescent 
microscope.  Test groups were compared control groups in which primary 
antibody was omitted.  
3.3 RESULTS 
3.3.1 Observation under light microscopy 
Light microscopically, all fibroblast populations had the distinctive spindle-
shaped appearance typical of fibroblasts, and no consistent morphological 
differences were apparent between gingival fibroblasts and PDL fibroblasts.  
However, Some PDL cells are larger, flattened and develop multiple cell 
processes, some were elliptical and smaller than the fusiform cells and 
sometimes roundish cells. Gingival fibroblasts and PDL fibroblasts both showed 
good growth, each approaching confluence within 5–7 days after splitting at a 
1:4 dilution ratio.  
Despite their similar spindle-shaped appearance, periodontal ligament 
fibroblasts and gingival fibroblasts appeared to display distinct functional 
activities when cultured to confluence.  PDL fibroblasts appeared to form bone 
nodules in-vitro, this feature that made it distinct from gingival fibroblasts (Figure 
3.1) 
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B1 
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B2 
 
A3 
 
B3 
 
A4 
 
B4 
Figure 3.1: Morphology of PDL and gingival fibroblasts (four different primary cell lines), ability 
of PDL cells to form bone nodules was noted in cells A1-A4, whereas it was not noted in 
gingival cells B1-B4. Original magnification x100. 
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3.3.2 Expression of ALP  
In three independent experiments, gingival fibroblasts showed no significant 
difference in total ALP expressed when compared to background (total ALP to 
empty wells).  However, PDL fibroblasts showed increased total ALP expression 
when compared to background or gingival cell total ALP (figure 3.2) 
 
Figure 3.2: Total ALP of gingival and PDL cells compared to background (ALP to empty wells). 
Control: background, Gin: total ALP to gingival cells, PDL: total ALP to PDL cells. Marked 
comparisons to control are marked, ***: P<0.001. 
 
Histochemical staining for ALP in PDL and gingival fibroblasts showed that the 
two cell types have distinct phenotypes. Three PDL fibroblast lines showed 
significantly higher percentage of ALP positive cells than the three gingival 
fibroblast lines that showed occasional single ALP positive cells in each well 
(figure 3.3).    
 
***      ***       *** 
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A 
 
B 
Figure 3.3: ALP Histochemical staining of gingival and PDL cells (three different primary cells 
lines), Column A: PDL cells, Column B: gingival cells. Original magnification x100.  
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3.3.4 Immunocytochemical staining of the gingival and PDL cells 
Periodontal and gingival cells were analysed for the expression of two markers, 
Vimentin and S100A4 calcium binding protein.  
Immunocytochmeical staining of gingival and periodontal ligament fibroblasts 
showed that gingival and PDL fibroblasts express vimentin protein with no 
significant difference (figure 3.4). However, PDL fibroblasts showed expression 
of S100A4 protein, whereas gingival fibroblasts did not (figure 3.5). 
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Figure 3.4: Immunocytochemistry staining for the three PDL (Column A & B) and three gingival 
cell lines(Column C & D).  Columns A & C shows the Dapi staining of the nucleui and columns B 
& D shows the vimentin staining. Original magnification x200. 
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Figure 3.5: Immunocytochemistry staining for the three PDL (Column A & B) and three gingival 
cell lines(Column C & D).  Columns A & C shows the Dapi staining of the nuclei and columns B & 
D shows the S100 A4 staining. Original magnification x200 
 
3.4 DISCUSSION 
In this chapter, we analyzed differentially expressed proteins between PDL and 
gingival fibroblasts and examined their morphology as well as their ability to form 
bone nodules in vitro. 
We used immunohistochemistry to determine the expression of S100A4 and 
vimentin proteins between PDL and gingival fibroblasts. We also used 
histochemical ALP assay to visualise the differentially expressed ALP by both 
cell types. It was essential first to verify whether our cultured cells are different in 
their morphological phenotypes under light microscope in vitro.  
Although we have observed many irregularities in cell morphology of PDL 
fibroblasts under light microscopy, the morphology of the majority of the PDL 
cells was similar to fibroblasts. This is consistent with literature, it was observed 
by Nanci and Bosshardt that although all fibroblasts look alike microscopically, 
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heterogeneous cell populations exist between different connective tissues and 
also within the same connective tissue. The fibroblasts of the periodontal 
ligament are characterized by their rapid turnover of the extracellular 
compartment, in particular, collagen. Periodontal ligament fibroblasts are large 
cells with an extensive cytoplasm containing an abundance of organelles 
associated with protein synthesis and secretion. They have a well-developed 
cytoskeleton and show frequent adherens and gap junctions, reflecting the 
functional demands placed on the cells. Ligament fibroblasts are aligned along 
the general direction of the fiber bundles and extend cytoplasmic processes that 
wrap around them (Nancy & Bosshardt, 2006). 
Similar to all other connective tissues cells, PDL fibroblasts express extracellular 
collagenous and noncollagenous matrix constituents. Murakami et al showed 
that PDL fibroblasts produce osteoblast-related extracellular matrix proteins and 
show higher alkaline phosphatase (ALP) activity compared with gingival 
fibroblasts, implying that PDL fibroblasts have osteogenic characterisitics. 
(Murakami, et al.,  2003). This chapter shows that the PDL fibroblasts used in 
our study are highly responsive in the ALP histochemical staining, in contrast, 
gingival fibroblasts showed minimum response, which confirm the heterotypic 
difference between the two types of fibroblasts. Similarly PDL fibroblasts 
showed that they form bone nodule like matrices when they are over confluent. 
This is a known feature of the PDL cells (Chien et al., 1999). In another study, 
three-dimensional nodules containing mineralized matrices were formed only 
when the cells were cultured in the presence of mineralizing medium including 
ascorbic acid and dexamethasone (Cho et al., 1992). In our study PDL 
fibroblasts showed multilayered pattern forming the bone nodule, although it was 
not mineralized since we did not use mineralizing medium.  
This was not the case in gingival fibroblasts. This was also demonstrated in a 
study by Lekic et al; who showed that PDL fibroblasts has osteoblast-like 
properties, including the expression of bone-associated marker such as ALP 
(Lekic, et al., 1997). 
When the differential expression of vimentin by PDL and gingival fibroblasts 
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using immunocytochemistry was assayed, it was evident that vimentin was 
markedly up-regulated in gingival fibroblasts compared to PDL fibroblasts. 
However, literature shows that vimentin is expressed in both gingival and PDL 
fibroblasts (Sculean, et al., 2003) 
In the case of S100A4 we have shown that it is strongly up-regulated in PDL 
fibroblasts compared to gingival fibroblasts. This is consistent with previous 
studies as S100A4 was observed to be preferentially expressed in periodontal 
ligament, indicating its tissue specificity and was reported as an extracellular 
inhibitor of mineralization and may be one of the factors responsible for keeping 
PDL space free of mineralization (Duarte, et al., 1999). 
Previous research has shown that PDL fibroblasts and gingival fibroblasts are 
heterogeneous in vivo (Lekic, et al., 1997). Also previous studies have 
demonstrated that PDL and gingival fibroblasts displayed unique differences 
with respect to proliferation and wound fill (Oates, et al., 2001), and they 
responded differently to growth factors during wound-healing processes 
(Mumford, et al., 2001). This chapter confirm the above studies that PDL and 
gingival fibroblasts display distinct phenotype patterns that may reflect intrinsic 
functional differences of the two cell populations and may well coordinate with 
their tissue-specific activities. We speculate that despite their similar spindle-
shaped appearance, PDL and gingival fibroblasts differ in their biological 
functions that might mirror into differential functions which this study investigate 
in the following chapters. 
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CHAPTER FOUR 
EFFECTS OF CONNECTIVE TISSUE FIBROBLASTS ON OSTEOBLAST 
DIFFERENTIATION 
 
The aim of the studies described in this chapter was to test whether gingival 
fibroblasts can influence osteoblast differentiation. These studies used a three-
dimensional (3D) culture of cells since it has been used successfully with other 
osteoblasts experiments (Abbott, 2003; Hoffman, 1993). Other studies suggest 
that 3D cultures may provide a more physiological environment for osteoblasts 
cultures. Studies show that MC3T3-E1 cell line, primary osteoblasts, and the 
osteocytic cell line MLO-Y4 growing in 3D culture develop an elaborate 
morphology, including stellate-like shape and cytoplasmic projections; closely 
resembling those of osteocyte processes in vivo (Karsdal, et al., 2002; Kurata, et 
al., 2006; Vukicevic, et al., 1990). The culture system used in this chapter 
employed type I collagen gel as a 3-dimensional culture system. This material 
provides a conductive environment for osteoblastic differentiation. Masi et al 
(1992) showed that bovine collagen type I exhibits favorable effects on 
attachment and functional and growth activities of a human osteoblastic cell line 
(Masi, et al., 1992). In this assay fibroblasts and osteoblasts can be co-cultured 
in one environment enabling cellular contact between the cell types. Therefore 
gingival fibroblasts can produce signals to affect osteoblasts differentiation either 
by secreting factors in the combined medium or the matrix or by cell membrane 
receptors that require cell-cell contact. 
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4.1 GINGIVAL CELLS INHIBIT OSTEOBLAST DIFFERENTIATION WHEN 
CULTURED SIMULTANEOUSLY IN 3-D CULTURE  
This experiment tested the effects of gingival fibroblasts on differentiation of 
calvarial cells when they are co-cultured in 3-D culture system enabling cellular 
contact between the two types of cells.  Osteoblast differentiation was assessed 
by measuring total ALP expression.  
4.1.1 Methods 
Co-cultures were tested for ALP expression at various cell densities. 5x105 
calvarial osteoblasts were co-cultured with either 5x105 or 1x106 gingival 
fibroblasts in type I collagen (1ml) 3-D culture system for 72 hours in serum-
containing αMEM medium. All experiments were carried out in triplicate. Control 
values were taken as the ALP expression of 5x105 osteoblasts grown in the 
absence of fibroblasts but at the same final cell density for test experiments (i.e. 
1x106 and 1.5x106 cells). To obtain this ALP value, 1x106 or 1.5x106 calvarial 
cells were grown in type I collagen for 72 hours. The ALP values for cultures 
were then assayed, and this value was divided by a correction factor calculated 
according to actual cell numbers of cells. 
 
To ensure proper correction for final cell numbers, replicate wells were 
established and cell numbers determined by MTT assay. The results of this 
assay are shown in Table 4.1. 
 
Number of cells plated initially MTT value at 72 hours (mean ± sd) Correction Factor 
5 x105 0.032871 ± 0.00182  
1 x106 0.064533 ± 0.00318 1.97 
1.5 x106 0.10347 ± 0.00416 3.15 
 
Table 4.1 Estimation of final cell numbers by MTT assay at different initial plating densities, 
(simultaneous seeding). 
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The MTT assay demonstrated a linear relationship between initial plating density 
and final MTT assay. MTT value of 5x105 calvarial cells was not significantly 
different from MTT values of 1x106 calvarial cells divided by 2 or MTT values of 
1.5x106 calvarial cells divided by 3 after 72 hours of culture. 
 
It was not possible to separate the calvarial cells from fibroblasts in the co-
culture. Therefore ALP levels of fibroblasts grown in monoculture were 
measured and subtracted from ALP levels of the group of combined cultures.  
4.1.2 Results 
In this set of experiments, the results were normalized to controls and expressed 
as the percentage of the control values.   The results are the combination of 
three independent experiments that demonstrate consistent effects when 
calvarial osteoblasts were co-cultured with gingival fibroblasts (Figure 4.1).  In 
experiment one, there was a significant 48.8% inhibition of ALP production of 
calvarial cells when cultured with 5x105 fibroblasts (Control: 100 ± 22, co-
culture: 51.2 ± 5, P<0.05), however, when calvarial cells were co-cultured with 
double the number of fibroblasts there was a significant 76.6% inhibition of ALP 
production (co-culture: 32.4 ± 5, P<0.01). In experiment two, similar significant 
inhibition of ALP production occurred when calvarial cells were co-cultured with 
5x105 fibroblasts (Control: 100 ± 3.6, co-culture: 49.7 ± 6.6, 50% inhibition, P< 
0.001) and when co-cultured with double the number of fibroblasts (co-culture: 
22.6 ± 7.3, 77% inhibition, P<0.001). Similarly, experiment three results showed 
51.8% inhibition of ALP production of calvarial cells when cultured with 5x105 
fibroblasts (Control: 100 ± 3, co-culture: 48.2 ± 6.1, P<0.001) and 76.5% 
inhibition when co-cultured with double the number of fibroblasts (Co-culture: 
23.5 ± 7.2, P<0.001). The results show an average inhibition of 50.5% of ALP 
production of calvarial cells where co-cultured with 5x105 gingival fibroblasts, 
and an average of 76.7% inhibition when the calvarial cells were co-cultured 
with double the number of gingival cells (figure 4.1). 
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Figure 4.1: effects of gingival fibroblasts on osteoblasts differentiation in 3D culture system, 
measured by ALP expression, simultaneous seeding of both cell types control: ALP level of 5x105 
calvarial cells grown in 3D monoculture containing 1x106 calvarial cells. Cal +Gin: ALP level of 
5x105 calvarial cells grown in 3D clture with 5 x105 gingival fibroblasts, Cal + (2xGin): ALP level of 
5x105 calvarial cells grown in 3D culture with 1x106 gingival fibroblasts. All values were normalized 
to control. (The experiment was carried out in three independent occasions). Significant 
comparisons to control are marked, *: P<0.05, **: P<0.01, ***: P< 0.001. (SD, n=3x3) 
 
4.2 EFFECTS OF ADDING GINGIVAL CELLS TO GEL SURFACE OF 3-D 
CALVARIAL OSTEOBLAST CULTURES (SEQUENTIAL CULTURE) 
 
In this experiment, osteoblasts were cultured in type I collagen 3-D culture alone 
similar to the previous experiment. Fibroblasts were then added to the surface of 
the culture 24 hours later.  
4.2.1 Methods 
5x105 calvarial cells were added to the 3-D culture system. After 24 hours either 
the same number of gingival fibroblasts (5x105) or double (1x106) were added to 
the gel surface of the culture and maintained for a further 72 hours prior to 
measuring total ALP levels. As with the previous experiment ALP levels of 
gingival cells were subtracted from ALP level of co-cultures to eliminate the 
*** 
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background levels. The control group was represented by growing calvarial cells 
in the first day and adding calvarial cells in the subsequent day. ALP levels for 
the later groups were measured and corrected for cell number by MTT viability 
assay (Table 4.2). All tests were carried out in triplicate and were carried out in 
three independent occasions. 
Table 4.2 MTT value at 72 hours (mean ± sd)  
Number of cells plated initially Average MTT value Correction Factor 
5 x105 0.043 ± 0.002  
1 x106 0.089 ± 0.002 2 
1.5 x106 0.13 ± 0.003 3.1 
 
Table 4.2 Estimation of final cell numbers by MTT assay at different initial plating densities, 
(sequential seeding). 
 
4.2.2 Results 
The results here are also presented normalized to the control values. Total ALP 
levels of calvarial cells grown in 3-D culture and exposed to 5x105 fibroblasts 
after 24 hours were significantly lower in three independent experiments. 
Experiment one showed 55.1% inhibition (Mixed culture: 44.96±12.7 control:100 
± 8.1) when calvarial cells were cultured with 5x105 gingival cells. However, 
double number of gingival cells caused 81.5% inhibition in total ALP expression 
(mixed culture: 22.5±8). In experiment two, when calvarial cells were cultured 
with 5x104 of fibroblasts, there was 55.3% inhibition in ALP expression (44.7±9.7 
compared to control 100±2), and when we doubled the number of fibroblasts, 
the inhibition increased to 70.5% (29.5±3.9). Experiment three demonstrated 
more inhibition when calvarial cells were cultured with 5x105 of fibroblasts 
(71.7% inhibition, 28.26±4.1 compared to control 100±4) and showed further 
inhibition when the number of the fibroblasts were doubled (79.6% inhibition, 
mixed culture: 20.4±3.9). This set of experiments showed average inhibition of 
60.7% of ALP expression of calvarial cells when cultured with 5x105 fibroblasts, 
and an average of 77.2 % inhibition when calvarial cells were cultured with 106 
of gingival fibroblasts (Figure 4-2). 
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Figure 4.2: effects of gingival fibroblasts on osteoblasts differentiation in 3D culture system 
(sequential seeding), measured by ALP expression, control: ALP value of 5x105 calvarial 
osteoblasts grown in 3D culture that had similar number of calvarial osteoblasts after 24 hours, 
Cal +Gin: ALP value of the co-culture of calvarial osteoblasts and gingival fibroblasts (5 x105 cell 
each), Cal + (2xGin): ALP value of the co-culture of calvarial osteoblasts (5 x105) and gingival 
fibroblasts (1x106). All values were normalized to control. (The experiment was carried out in 
three independent occasions). Significant comparisons to control are marked. **: P< 0.01, ***: 
P< 0.001. (SD, n= 3x3) 
 
4.3 GINGIVAL FIBROBLAST MATRICES INHIBIT CALVARIAL 
OSTEOBLASTS DIFFERENTIATION 
The previous experiments demonstrated that fibroblasts inhibit osteoblast 
differentiation when they grow in combined cultures. This effect might be caused 
by a variety of signals such as secreted soluble molecules or sequestered matrix 
molecules. Therefore to test whether living fibroblasts were needed to cause the 
above effects, the matrices of fibroblasts were tested for their influence on the 
differentiation on osteoblasts. The following study investigated the effects of 
extra-cellular matrix (ECM) laid down by rat primary gingival fibroblasts and 
calvarial osteoblasts on the differentiation of rat primary calvarial osteoblasts 
assessed by ALP production. 
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4.3.1 Methods 
5x103 Primary rat gingival fibroblasts or calvarial osteoblasts were seeded 
directly onto the plastic wells of 96-well plate, cultured for 72 hours and then the 
cells were killed in situ. Two methods were used to devitalise the plates, either 
by freeze-thaw cycles or by irradiation. Devitalised matrices were then re-
seeded with calvarial cells at a density of 5x103 cells/well for 72 hours and ALP 
levels were assessed and compared to control values derived from the ALP 
levels of calvarial cells grown directly on plastic. All tests were carried out in four 
replicates and repeated once. 
 
4.3.2 Results 
Calvarial osteoblasts seeded onto the top of gingival fibroblast matrices 
expressed significantly less total ALP than controls. In three independent 
experiments, there was an average of 42.2% decrease in ALP expression when 
osteoblasts were grown on fibroblast matrices obtained by irradiation compared 
to control (experiment one: 55.8±2.2, compared to control 100±2, P<0.001; 
experiment two: 65.9±9 compared to control 100±14.9, P<0.01; experiment 
three: 51.8±14, compared to control 100±11.5, P <0.01). When the matrices 
were obtained by freeze-thaw cycles in three independent experiments, there 
was an average inhibition of 43.3% of ALP expression of calvarial cells 
(Experiment one: 64.1±2.8 compared to control 100±2, P<0.001; experiment 
two: 56±8 compared to control 100±14.9, P<0.01; experiment three: 49.3±2.3 
compared to control 100±11.5, P<0.001) (Figure 4.3). 
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Figure 4.3: effects of gingival fibroblasts matrices on calvarial osteoblasts differentiation, 
measured by ALP expression. Control: ALP value of calvarial osteoblasts grown on plastic with 
no matrix, Gin Irradiated Matrix: ALP value of the calvarial osteoblasts grown on gingival 
matrices obtained by irradiation, Gin Frozen Matrix: ALP value calvarial osteoblasts grown on 
gingival matrices obtained by freeze/thaw cycles. All values were normalized to control. 
Experiment was carried out in three independent occasions. Significant comparisons only are 
marked. **: P <0.01, ***: P <0.001. (SD, n= 4x3) 
 
 
In contrast, matrices laid down by calvarial osteoblasts did not show a significant 
effect on ALP expression of calvarial osteoblasts after either devitalising 
treatment in three independent experiments (Figure 4.4). 
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Figure 4.4: effects of calvarial osteoblasts matrices on calvarial osteoblasts differentiation 
measured by ALP expression. Control: ALP value of calvarial osteoblasts grown on plastic with 
no matrix, Cal Irradiated Matrix: ALP value of the calvarial osteoblasts grown on calvarial 
matrices obtained by irradiation, Cal Frozen Matrix: ALP value calvarial osteoblasts grown on 
calvarial matrices obtained by freeze/thaw cycles. All values were normalized to control. 
Experiment was carried out in three independent occasions, n=4x3. 
 
4.4 DISCUSSION 
Osteoblast responses of 3D-cultures may be more like those of cells in vivo than 
those of cells in two-dimensional (2D) culture. Also the 3-D matrix in vitro allows 
a more physiological representation of osteoblastic behaviour (Cukierman, et al., 
2001; Elsdale & Bard, 1972; Hotary, et al., 2003). This culture system enabled 
us to test the effects of gingival fibroblasts on differentiation of calvarial 
osteoblasts measured by ALP expression.  
 
Gingival fibroblasts inhibited ALP expression of calvarial osteoblasts by more 
than 50% when they were grown together. By doubling the number of gingival 
fibroblasts in the co-culture, a further inhibition of ALP expression was seen to 
about a quarter of the control level. An additional co-culture model was applied 
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to this experiment where we seeded the fibroblasts 24 hours after seeding the 
osteoblasts in the 3-D gel. This might leave the fibroblasts growing on the top of 
the gel rather than migrating throughout the gel. Thus this model maintained the 
3-D culture of the osteoblasts, but reduced the effects of cell-cell contact. Once 
again a marked inhibition of ALP expression of osteoblasts was seen by the 
added fibroblasts. It is clear from the above results that the presence of gingival 
fibroblasts significantly suppressed osteoblast differentiation. These effects 
might be cell contact based or dependent on factors released into the co-culture 
medium or embedded in the matrix or combined factors.  
 
To begin to address the nature of the inhibition, we designed the experiments 
that we performed on the matrices. Contacts between cells of the osteoblast 
lineage and surrounding ECM might play a pivotal part in the mechanisms that 
dictate cellular behaviour. Functional ECM components are necessary for 
osteoblast differentiation and maturation which is achieved not only through the 
regulation of cell shape and migration but also by differential intracellular 
signalling crosstalk triggered by ECM stimuli (Salasznyk, et al., 2004). Using this 
model, factors relating directly to direct cell-cell contact or continued secretion of 
soluble molecules were excluded. The results obtained demonstrated that 
signals can persist in matrices of gingival fibroblast matrices which remain 
inhibitory to calvarial osteoblast ALP production. Comparing these results to the 
results obtained from using calvarial matrices instead of gingival matrices 
demonstrated that the inhibition caused is specific to the fibroblasts. 
Although previous studies have shown that bone cell matrices enhance 
osteoblastic differentiation of BMSC measured by ALP (Datta, et al., 2005), in 
the current study the effects of calvarial matrices on ALP production by calvarial 
osteoblasts was not significantly different from controls. This might be due to 
shorter culture periods applied in this assay. 
 
In summary this chapter focused on the role of cell-cell and cell-extracellular 
matrix interactions and role in regulating osteoblasts differentiation. The results 
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indicated that gingival fibroblasts and their extra-cellular matrix synthesized in 
vitro can suppress osteoblastic differentiation of calvarial cells. Whether this 
suppression is dependent on the matrix proteins or based on released factors in 
the medium that would be embedded in the matrix required further experimental 
work.  
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CHAPTER FIVE 
THE EFFECTS OF SECRETED FACTORS FROM CULTURED 
FIBROBLASTS ON OSTEOBLAST DIFFERENTIATION IN VITRO 
 
In Chapter 4 it was shown that rat primary gingival fibroblasts inhibited the 
differentiation of calvarial osteoblasts, as measured by ALP expression, in a 3-D 
co-culture system. This observation led to testing if the inhibitory effects were 
dependent on cell contact or whether they were the result of the action of 
soluble factors secreted by the fibroblasts.  The experiments described in this 
chapter were therefore designed to test the ability of soluble factors secreted 
into the culture medium by fibroblasts to alter ALP expression by osteoblasts.  
 
5.1 OSTEOBLASTS AND FIBROBLASTS GROWN TOGETHER BUT 
PHYSICALLY SEPARATED BY PERMEABLE MEMBRANES 
This experiment consisted of growing two types of cell grown in the same 
medium in different compartments, ensuring no contact between cells of one 
type with cells of the other type, using an “inserts” co-culture system. This 
system has been used successfully to test the indirect effects of one cell type on 
another (Kim, et al., 2003).  For example co-culture of human astrocytes with 
human brain capillary endothelial cells separated by a membrane has shown 
that the astrocyte has a role in the regulation of brain capillary endothelial 
expression of the key hemostasis factors tissue plasminogen activator (tPA) and 
its inhibitor, plasminogen activator inhibitor-1 (PAI-1).  This indicates that factors 
can pass through the membrane from one cell type to the other (Kim, et al., 
2003).  Beierle et al have also used the insert co-culture system to test the 
effects of hepatocytes on neuroblastoma cells (Beierle, et al., 2002; Chen, et al., 
1999). 
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5.1.1 Methods 
In this set of experiments a polycarbonate membrane at the base of a plastic 
inserts served as the culture surface for the soft tissue fibroblasts. The 
membrane has pores of 0.4 µm size that enable released cytokines and other 
molecules to diffuse through, but prevents the cells from passing through, as 
described in chapter 2. The system has a gap of 0.8mm between the lower 
surface of the membrane and the cells growing in the culture disk. 
 
Osteoblastic cells (5x104 cells/well) were grown on the bottom surface of a 24-
well plate.  A range of different osteoblast cell models were tested in different 
experiments.  These included primary calvarial osteoblasts, primary rat bone 
marrow stromal cells (BMSC) or cells from the murine osteoblastic line MC3T3-
E1 cells, while gingival fibroblasts (5x104 cells/well) were added on the top of a 
membrane inserts placed in the same wells 24 hours later. Control cultures had 
osteoblasts grown on the bottom surface without cell co-cultures on the inserts. 
A third group was added that had osteoblasts grown on both surfaces to test 
whether osteoblasts on the top surface can have the same influence of 
fibroblasts. All cultures were grown for 72 hours after adding the fibroblasts then 
ALP activity in the responsive cell populations (osteoblast cultures) was 
assayed. 
5.1.2 Results 
Calvarial and BMSC showed higher basal levels of ALP expression than MC3T3 
cells (Cal: 4.5 ± 0.56 pnp/ml/hr, BMSC: 4.4 ± 0.28 pnp/ml/hr, MC3T3: 2.6 ± 0.12 
pnp/ml/hr). However, in all osteoblast types ALP levels were significantly 
reduced when co-cultured with fibroblasts. These experiments were repeated in 
three separate independent experiments, and the results shown were 
normalised to control cultures (osteoblasts cultured alone with empty inserts) 
(Figure 5.1). Calvarial cells showed the greatest change in ALP expression in 
test cultures in three experiments (Averages Cal only: 100% ± 12.15%, Cal + 
Gin: 47.99 ± 4.9%, P<0.001). Similar results were obtained when BMSCs were 
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tested in three experiments (BMSC only: 100% ± 5.8%, BMSC +Gin: 56.4% ± 
7.4%, P<0.001). There was a significant inhibition (in two experiments of three) 
also when MC3T3 cells were tested (averages MC3T3 cells only: 100% ± 4.2%, 
MC3T3 cells+Gin: 76.8% ± 10.9%, P<0.05). Addition of osteoblasts to the insert 
surface did not significantly alter differentiation of cells on bottom surface.  
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Figure 5.1: Inhibition of total ALP activity of osteoblasts (calvaria, BMSC and MC3T3) when 
cultured in the presence of gingival fibroblasts on a membrane insert. (Mean ± S.D. results from 3 
independent experiments, n = 6 samples for each group in each experiment), normalised 
percentage to control values. Significant comparisons only are marked, *: p<0.05, **: p <0.01, ***: 
p <0.001 (by 1-way ANOVA and Bonferoni post test).  
** 
*** 
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5.2 EFFECTS OF FIBROBLAST CONDITIONED MEDIA (CM) ON 
DIFFERENTIATION OF OSTEOBLASTS MEASURED BY ALP EXPRESSION 
In section 5.1 the experimental results suggest that the inhibitory effect seen 
was the result of the secretion of soluble factors into the culture medium by the 
fibroblasts.  In order to extend these observations, the aim of the set of 
experiments described here was to demonstrate that the inhibitory effects on 
osteoblasts were due to the presence of soluble factors released by the 
fibroblasts and thus contained in the conditioned medium (CM). 
 
The use of CM collected from growing cells in testing effects on other cells is 
well described in the literature.  Karsdal et al (2008) collected CM from human 
osteoclasts cultured on either bone or plastic and tested their effects on bone 
nodule formation by osteoblasts and found that both types of CM were shown to 
dose-dependently induce bone nodule formation.   They therefore showed that 
osteoclasts secreted non-bone derived factors, which induce pre-osteoblasts to 
form bone-like nodules (Karsdal, et al., 2008). Vezeridis et al (2006) also used 
CM from osteocytes to treat osteoblasts.  They found that osteocyte CM inhibits 
osteoblast proliferation and stimulated differentiation as measured by increased 
ALP expression (Vezeridis, et al., 2006).  
 
The experiments here were initially performed on primary rat calvarial 
osteoblasts and subsequently were applied to the rat osteosarcoma cell line 
ROS 17/2.8 to establish a reproducible model of the system that showed a good 
response in term of the inhibition of ALP synthesis. The ROS cell line was 
selected after trying a number of different cell lines including MC3T3 cells.  ROS 
cells showed the highest ALP production and best response after treatment with 
conditioned media. 
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5.2.1 Methods 
Gingival, oral mucosa, skin and PDL fibroblasts and calvarial osteoblasts were 
seeded into T75 flasks at a density of 1x106 cells in 10ml of ME (αMEM medium 
supplemented with 10% NBCS; penicillin G 50 unit/ml, streptomycin 50 µg/ml 
and amphotericin B 0.3 µg/ml) for 24 hours, then the medium was replaced by 
5ml of serum free ME for 48 hours. Serum free supernatants (CM) were 
collected from gingival fibroblast, oral mucosa fibroblast and skin fibroblast 
cultures to test their ability to inhibit ALP production by calvarial cells. 
Supernatants extracted from other cell types were used as control for 
comparison (PDL and Calvarial conditioned medium). CM was filtered to remove 
cell debris and frozen at -20° C. 
 
Collected CM was subsequently supplemented with 10% NBCS and used to 
treat primary calvarial cells or ROS cells seeded in 96-well plates at a density of 
5x103 cells/well. Test groups were compared to control (osteoblasts treated with 
ME). The assay was performed for 72 hours as in the co-culture assay and total 
ALP was measured as described in chapter 2. Parallel plates using calvarial 
cells treated with CM and controls were prepared for MTT assay for cell number 
correction.  
5.2.2 Results 
Gingival CM showed a significant inhibition of calvarial ALP synthesis in three 
independent experiments using CM collected from 3 distinct gingival cell lines 
(53% reduction, P<0.001; 52.5% reduction, P<0.001; 38.1% reduction, P< 0.05 
in experiments 1, 2 and 3 respectively). ALP activity of calvarial cells was 
unaltered when treated with PDL CM in three experiments compared to control 
(P≥0.05). Calvarial CM also caused a significant inhibition of calvarial osteoblast 
ALP secretion in two experiments (35.6% reduction, P<0.001 and 39.25 
reduction, P<0.001) compared to control, the third experiment showed pattern of 
inhibition but was not statistically significant (P=0.163) (Figure 5.2). 
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Figure 5-2: Inhibition of ALP activity of Calvarial cells when treated with different CM, Control: 
no treatment. Gin con media: treatment with gingival CM. PDL con media: treatment with 
periodontal ligament CM. Cal con media: treatment with calvarial osteoblasts CM. (Mean ± S.D.  
Results from 3 independent experiments, N = 4 for each experiment). Significant comparisons 
to control are marked, *: p <0.05, ***: p <0.001. 
 
 
Parallel MTT assays for calvarial cells treated with the same CM showed no 
significant effect on osteoblast proliferation when they were treated with either 
gingival or PDL CM. However there was a significant stimulation of osteoblast 
proliferation when they were treated with calvarial CM compared to control 
(P<0.001 in experiment 1 and P<0.05 in experiments 2 & 3) (Figure 5.3). This 
may explain the ability of calvarial CM to inhibit ALP production of calvarial 
osteoblasts. ALP levels are consistent with the osteoblasts becoming less 
differentiated when they increase their proliferative activity. Calvarial cell ALP 
inhibition after treatment with gingival conditioned medium was not due to 
alteration in osteoblast proliferative activity alteration, as MTT was not altered. 
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Figure 5.3: MTT assay of calvarial cells treated with different CM. Control: no treatment. Gin con 
media: treatment with gingival CM. PDL con media: treatment with periodontal ligament CM. Cal 
con media: treatment with calvarial osteoblasts CM. (Mean ± S.D.  Results from 3 independent 
experiments, N = 5 for each experiment). Significant comparisons only are marked, *: p <0.05 
***: p <0.001. 
 
 
When ROS cells were treated with gingival CM, ALP levels of ROS cells were 
significantly reduced compared to control in four independent experiments (CM 
was extracted from 4 different cell lines): 53% ± 3.5% in experiment 1 (P<0.001), 
by 32% ± 7.9% in experiment 2 (P= 0.0014), by 50% ± 6.6% in experiment 3 (P= 
0.002) and by 30% ± 11.7% in experiment 4 (P= 0.01). Overall this was a mean 
of 41.25% ± 7.4% inhibition (Figure 5.4). 
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Figure 5.4: ALP assay of ROS cells treated with gingival CM, four separate experiments 
compared and normalised to control (Mean ± S.D. n= 4 in each experiment). Significant 
comparisons to control are marked, *: p<0.05, **: p<0.01, ***: p <0.001. 
 
Similarly, CM from oral mucosa fibroblasts was used to treat ROS cells in four 
different experiments there was significant inhibition of ALP synthesis of ROS 
cells (CM was extracted from 4 different cell lines). In experiment 1, there was 
48% ± 2.1% inhibition (P<0.001), and in experiment 2, there was 78% ± 1.6% 
inhibition (P<0.001), in experiment 3 there was 56% ± 0.9% inhibition (P<0.001) 
and in experiment 4 there was 41% ± 11.39% inhibition of ALP production 
(P<0.01) that makes an average of 55.75% ± 4% inhibition (Figure 5.5). 
 
*** 
*** 
* 
** 
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Figure 5.5: ALP assay of ROS cells treated with Oral Mucosa CM, four separate experiments 
compared and normalised in percentage to control (mean ± S.D. n= 4 in each experiment). 
Significant comparisons to control are marked, **: p<0.01, ***: p <0.001. 
 
CM from skin fibroblasts also inhibited ALP production in ROS cells. Significant 
inhibition of ALP synthesis in four experiments compared to control was noted 
(CM was extracted from 4 different cell lines): experiment 1 and 2 both showed 
46% inhibition ± 6.355% & ± 2.4 respectively (P<0.001), in experiment 3 there 
was 41% ± 15.99% inhibition (P<0.01) and in experiment 4 there was 49% ± 
12.14 inhibition (P= 0.002) an average of 45.5% ± 9.3% inhibition (Figure 5.6). 
 
*** 
*** 
*** 
** 
	   
115 	  
	  
Chapter	  Five	  The	  Effects	  Of	  Secreted	  Factors	  from	  Fibroblasts	  On	  Osteoblast	  Differentiation	  in	  vitro	  
 
Figure 5.6: ALP assay of ROS cells treated with Skin CM, in four separate experiments 
compared and normalised to control (mean ± SD. n= 4 in each experiment). Significant 
comparisons to control are marked, **: p< 0.01, ***: p< 0.001. 
 
In contrast, PDL cell CM showed opposite effects to that of the other fibroblasts 
cultures. When PDL CM was used to treat ROS cells in four different 
experiments (CM was extracted from 4 different cell lines) there was a 
significant stimulation of ALP production of the ROS cells compared to controls. 
In 4 different experiments, there was 25% ± 5.4% increase in ALP production of 
ROS cells treated with PDL CM (P<0.001). However, there was a greater 
stimulation in the other experiments of 41% ± 16.85% (P<0.001), 50% ± 13.5% 
(P<0.001) and ALP was more than doubled in the last experiment 131% ± 
7.68% increase (P<0.001) (Figure 5.7). 
** 
*** 
*** 
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Figure 5.7: ALP assay of ROS cells treated with PDL CM, four separate experiments compared 
and normalised in percentage to control (mean ± S.D. n= 4 in each experiment). Significant 
comparisons to control are marked, ***: p< 0.001. 
 
5.3 EFFECTS OF FIBROBLAST CONDITIONED MEDIA (CM) ON 
OSTEOCALCIN AND OSTEOPONTIN PRODUCTION BY OSTEOBLASTS  
In chapter 4 and sections 5.1 and 5.2 it was shown that gingival, oral mucosa 
and skin fibroblasts inhibit osteoblast expression of ALP, a classic marker of 
osteoblast differentiation.  In contrast, PDL fibroblasts stimulated osteoblast 
differentiation measured by ALP. Furthermore, it was demonstrated that these 
effects were the result of factors released into the supernatants of the fibroblast 
cultures. To investigate further this observation, additional experiments were 
carried out to test if the CM also inhibited expression of additional markers of 
osteoblast differentiation, osteocalcin and osteopontin.  These experiments were 
carried out firstly to determine effects on protein production by ELISA, and 
secondly on gene expression by qPCR (described in section 5.4)  
 
*** 
*** *** 
*** 
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5.3.1 Methods 
ROS cells were cultured in 6-well plates at a density of 5x105 cells/well for 24 
hours in ME containing 10% NBCS. Medium was then replaced with test and 
control medium containing 10% NBCS. Conditioned medium from three primary 
gingival fibroblastic lines and three primary PDL fibroblastic lines were used to 
treat ROS cells (2ml/well). 10ng/ml of BMP-2 treatment was performed as a 
positive control and treatment with ME containing 10% NBCS was the negative 
control. All treatments were performed in triplicates.  
After 72 hours, supernatants were collected and stored at -20° C prior to 
analysis by ELISA for osteocalcin and osteopontin as described in chapter 2. 
 
5.3.2 Results 
Supernatants collected from gingival and periodontal fibroblasts were tested for 
osteocalcin and showed minimal background. ROS cells expressed osteocalcin; 
however although gingival CM appeared to decrease osteocalcin expression 
and PDL CM appeared to increase expression, these differences were not 
statistically significant.  BMP-2 treatment had no significant effect on osteocalcin 
expression. (Figure 5.8) 
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Figure 5.8: Osteocalcin ELISA assay of ROS cells treated with CM of three gingival (G1, 4 &5) 
and three PDL (P2, 3 &4) fibroblast lines. Treatment with 10ng/ml of BMP-2 was performed as 
positive control, Three independent experiments were performed that show consistent results. 
n=3. 
 
In the osteopontin experiment, BMP-2 treatment and gingival CM did not 
significantly change osteopontin expression pattern of ROS cells in three 
independent experiments. However, PDL CM of three cell lines stimulated 
osteopontin expression of ROS cells in experiments 1 and 3 (mean increase of 
59.5 ± 5% in experiment 1 and a mean increase of 30.9 ± 5.7 in experiment 3, 
P<0.05 in both) (figure 5.9). 
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Figure 5.9: Osteopontin ELISA assay of ROS cells treated with CM of three gingival (G1, 4 &5) 
and three PDL (P2, 3 &4) fibroblast lines. Treatment with 10ng/ml of BMP-2 was performed as 
positive control, Three independent experiments were performed that show consistent results. 
n=3.  
 
5.4 EFFECTS OF FIBROBLAST CONDITIONED MEDIA (CM) ON 
DIFFERENTIATION OF OSTEOBLASTS MEASURED BY GENE 
EXPRESSION OF ALP, OSTEOCALCIN AND OSTEOPONTIN (REAL-TIME 
PCR) 
Although it was shown above that CM from gingival, oral mucosa and skin 
fibroblasts inhibit osteoblast ALP expression, and PDL fibroblasts caused 
opposite effects, gingival CM did not significantly affect the expression pattern of 
osteocalcin and osteopontin of these markers. However, in addition the positive 
control treatment of BMP-2 also did not affect expression of osteocalcin and 
osteopontin. To investigate further the effects of the superficial connective tissue 
fibroblasts versus PDL fibroblasts on differentiation of osteoblasts, further 
experiments were carried out to measure the gene expression of ALP, 
osteocalcin and osteopontin of ROS cells in response to the treatment with CM 
from gingival and PDL fibroblasts. 
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5.4.1 Methods 
ROS cells were cultured in 6-well plates at density of 5x105 cells/well for 24 
hours in ME containing 10% NBCS. Medium was replaced with test and control 
medium that contain 10% NBCS. Conditioned medium from three primary 
gingival fibroblastic lines and three primary PDL fibroblastic lines were used to 
treat ROS cells (2ml/well). 10ng/ml of BMP-2 treatment was performed as a 
positive control and treatment with ME containing 10% NBCS was the negative 
control. All treatments were performed in triplicates.  
After 72 hours, RNA of ROS cells was isolated using RNeasy kit from Qiagen as 
described in chapter 2 and reverse transcription was done to obtain cDNA. This 
experiment was repeated twice and collected cDNA samples were used in 
qPCR. Six house-keeping (HK) genes were tested in order to select 2 stable 
genes for qPCR then the samples were tested for ALP, osteocalcin and 
osteopontin genes. 
5.4.2 Results 
Gene expression of ALP, osteocalcin and osteopontin was measured in ROS 
cells treated with CM extracted from three primary gingival fibroblast lines and 
three primary PDL fibroblast lines. For positive control 10ng/ml of BMP-2 was 
used to treat ROS cells, and relative expression was investigated compared to 
control (ROS cells treated with ME). Expression of ALP showed significantly 
lower levels when the ROS cells were treated with gingival CM (48% ± 7.6% 
reduction in experiment 1, 35% ± 14 %reduction in experiment 2, and 40% ±15 
% in experiment 3). There was no significant change in expression of ALP 
genes when ROS cells were treated with CM from PDL fibroblasts; however, 
treatment with 10 ng/ml of BMP-2 showed significant increase to expression of 
ALP gene (52%, 63% & 94% increase in experiments 1, 2 and 3 respectively). 
Expression of osteocalcin gene did not show a significant change when ROS 
cells were treated with gingival CM or with BMP-2.  However, treatment with 
PDL CM showed significant increase in expression of osteocalcin expression by 
ROS cells (98%±3% increase in experiment 1, 87%±14% increase in 
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experiment 2 and 220%± 117% increase in experiment 3). Similarly expression 
of osteopontin did not show significant change when ROS cells were treated 
with either gingival CM or 10ng/ml of BMP-2, and showed significant increase 
when treated with PDL CM in two of three performed experiments (62%±17% 
increase in experiment 1, 43%±15 in experiment 2 and 114% ± 110% increase 
in experiment 3). (Figure 5.10) 
 
Figure 5.10: ALP (ALP), osteocalcin (OSC) and osteopontin (SPP) genes expression of ROS 
cells treated with three gingival (G1, 4 &5) and three PDL (P2, 3 &4) fibroblast lines. Treatment 
with 10ng/ml of BMP-2 was performed as positive control, Three independent experiments were 
performed that show consistent results. 
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5.5 DISCUSSION 
It was shown in chapter 4 that combined culture of primary gingival fibroblasts 
and calvarial osteoblasts influenced osteoblast differentiation measured by ALP 
production. It was not possible from these experiments to assess if direct cell-
cell contact is required for the inhibitory effects.  
 
To test if fibroblasts released factors that influence osteoblasts differentiation an 
in vitro bi-compartment culture system was used as a model. Primary 
osteoblasts were seeded into tissue culture plates, whereas gingival fibroblasts 
were seeded into cell-culture inserts. Many previous studies have used this 
method in testing the influence of a cell type on another (Spector, et al., 2002; 
Tan, et al., 2007; Yang, et al., 2001). Bunyaratavej et al used CM from breast 
cancer cell line to treat MC3T3 cell line and found that CM inhibited osteoblast 
differentiation; however they were able to antagonise these effects by adding 
noggin to the CM suggesting that their CM contains BMP proteins 
(Bunyaratavej, et al., 2000).  
 
The transwell co-culture system has membranes with 0.4 µm pores, which 
permitted the two cell populations to grow together in the same well, but it 
prevented direct cell-to-cell contact. Therefore, we were able to determine 
whether paracrine signalling from fibroblasts could influence the biologic activity 
of osteoblasts. In this experiment, three osteoblast cell types were tested; 
primary rat calvarial osteoblasts, bone marrow stromal cells and MC3T3 cell 
line. The co-culture system demonstrated that co-cultured osteoblasts with 
gingival fibroblasts showed a significantly decreased ALP production than did 
osteoblasts cultured alone. This was the case in all three cell types used, 
however primary calvarial cells showed the highest response. Collectively these 
results verify that gingival fibroblasts can influence the differentiation activity of 
osteoblasts independent of physical contact. Moreover, these results suggest 
that this influence is specific to certain types of fibroblasts as PDL cells had the 
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opposite effects on ALP to other fibroblasts tested.  
 
The conditioned media assay is a method that has been successfully used by 
researchers (Maxson & Burg, 2008). This assay confirmed the hypothesis that 
gingival conditioned media inhibited calvarial osteoblast differentiation. The 
specificity to superficial tissue fibroblasts (gingival) was evident when CM from 
periodontal ligament fibroblasts (deep tissue) failed to cause the same inhibition. 
Although CM from calvarial osteoblasts caused similar inhibitory influence on 
calvarial osteoblasts differentiation, this may have been due to the increased 
proliferative activity of the osteoblasts and this is consistent with osteoblast 
behaviour given the inverse relationship between proliferation and ALP 
expression and differentiation (Granchi, et al., 2008). MTT assay of calvarial 
osteoblasts treated with calvarial CM demonstrated increased levels of MTT 
compared to control suggesting increased proliferation. In contrast, MTT assay 
of calvarial osteoblasts treated with gingival or periodontal ligament fibroblasts 
showed no significant difference to controls. 
The results of the studies here are consistent with the previous findings 
described in Chapter 3. The inhibition in calvarial osteoblast ALP production in 
3-D cultures with cells in contact was 55-57% (chapter 4). In the experiments 
here, we showed that the inhibition caused by no-contact co-culture and by the 
conditioned media was 52% and 51% respectively.  
 
Different conditioned media experiments on ROS cells confirmed that CM 
extracted from superficial connective tissues including gingival, oral mucosa and 
skin fibroblasts are all inhibitory to ALP production of ROS cells. In addition this 
effect seems to be consistently seen by using different cell lines derived from 
different animals. In contrast, the CM from PDL stimulated ALP production of 
ROS cells. All experiments performed using superficial connective conditioned 
media in this project showed inhibitory influence on osteoblasts differentiation 
measured by ALP. The conditioned media was a stable source of inhibitory 
activity to study this influence in a reproducible model, and demonstrated the 
	   
124 	  
	  
Chapter	  Five	  The	  Effects	  Of	  Secreted	  Factors	  from	  Fibroblasts	  On	  Osteoblast	  Differentiation	  in	  vitro	  
same effects whenever used on osteoblasts and retained its activity even after 
freezing. 
 
To confirm the results from the total ALP experiments, real-time PCR assay was 
performed to investigate the influence of gingival and PDL CM on expression of 
ALP protein of ROS cells. In this experiment, BMP-2 was as a positive control 
for its known characteristics of stimulating ALP expression that caused increase 
in ALP protein expression in three independent experiments (average of 69.6% 
increase). qPCR showed that gingival CM inhibited the expression of ALP genes 
in three different experiments with an average of 41 % reduction. However, 
when PDL conditioned media was used to treat ROS cells, there was no 
significant difference in ALP protein production of ROS cells measured by real-
time PCR, which is contrary to the results we had above when we used the total 
ALP assay.  This might be due to the presence of modulatory factors that 
degrade ALP proteins in ROS cells during the PCR assay. Another explanation 
is that a feed back loop can cause an endogenous inhibition of ALP protein in 
ROS cells. This feed back loop can be caused by the presence of an inhibitor in 
the supernatants of ROS cells that can affect ALP protein production. Rawadi et 
al (2003) showed that antagonizing the Wnt/LRP5 pathway leads to a decrease 
of ALP activity. The use of Noggin in their study revealed that the induction of 
ALP by Wnt is independent of bone morphogenetic proteins.  
 
Further experiments were performed to investigate whether CM from gingival 
and PDL cells was able to cause similar effects to other differentiation markers, 
namely osteocalcin and osteopontin. ELISA and qPCR assays were performed 
for both markers; however, when osteocalcin ELISA assay was performed to 
supernatants of ROS cells treated with gingival CM, PDL CM or BMP-2, there 
was no significant difference to control. In the case of osteopontin ELISA, 
gingival CM and BMP-2 showed no difference of protein expression compared 
to control, however, PDL CM showed significant increase of osteopontin in the 
supernatants in two of three experiments, and a similar pattern of increase in the 
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third experiment, although the difference was not statistically significant. This 
may be due to the relatively large standard deviation seen with the data, 
suggesting an inconsistent effect which may explain the lack of statistical 
significance. 
 
Interestingly, using qPCR assay to investigate osteocalcin and osteopontin 
changes with the above treatments showed that PDL CM significantly increased 
the level of expressed osteocalcin protein in three independent experiments 
(average of 135% increase) and similar osteopontin increase in two of three 
experiments. Also, the results showed that BMP-2 treatments did not show 
significant difference to osteocalcin or osteopontin protein production, which 
suggests that PDL CM might be affecting expression of osteocalcin and 
osteopontin in a pathway independent from BMP pathway.  
 
We have shown above that gingival CM and BMP-2 influenced the expression of 
ALP protein measured by total ALP assay and by qPCR; however, gingival CM 
or BMP-2 appear to make no difference to osteocalcin or osteopontin measured 
by ELISA and qPCR. This was surprising given the consistency and magnitude 
of the effect of CM on ALP expression. This result might be explained by the 
possibility that influence on these markers can occur at different time points 
during differentiation. The relationship between expression or repression of ALP 
activity was studied by Beck et al who found that Induction of ALP expression 
can be dissociated from expression of late-stage markers such as osteocalcin 
and osteopontin. They suggested that osteopontin induction is dependent on at 
least a minimal level of alkaline phosphatase activity, and that osteopontin 
induction it is not dependent on induction of alkaline phosphatase at the RNA 
level. If alkaline phosphatase is supplied exogenously, osteopontin expression 
can be induced in conditions in which endogenous alkaline phosphatase is 
severely repressed. In addition, the use of the ROS cell line might increase the 
likelihood of “decoupling” of ALP and other bone markers as the line is derived 
from an osteosarcoma which would increase the likelihood of the cells not 
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showing a normal progressive pathway of osteoblastic differentiation.  This is 
supported by the fact that the positive control treatment, BMP-2, also failed to 
show any effects on osteocalcin and osteopontin expression.  
 
Previous studies have shown the ability of gingival fibroblasts to stimulate bone 
resorption by a mechanism of factor release that affects osteoclasts (Lerner, et 
al., 1990; Sjostrom, et al., 2000). However, this is the first study to report the 
potential inhibitory activity of superficial connective tissue fibroblasts and the 
stimulatory activity of periodontal ligament fibroblasts on osteoblast 
differentiation measured by ALP production. 
 
In summary, these studies confirm that modulation of osteoblast differentiation 
by fibroblasts may differ according to where the fibroblasts originate from. Deep 
tissue fibroblasts stimulate osteoblast differentiation whereas superficial tissue 
fibroblasts have opposite effects. This work also shows that the influence of 
fibroblasts occurs without the need for any physical contact between the two 
types of cells. This can be interpreted as demonstrating that fibroblasts release 
soluble factors that can influence osteoblast differentiation as measured by ALP 
expression. 
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CHAPTER SIX 
PRELIMINARY CHARACTERISATION OF OSTEOBLAST INHIBITION BY 
CONDITIONED MEDIA 
 
 
In chapter 5 it was shown that media conditioned by gingival and other 
superficial fibroblasts is able to inhibit ALP activity of calvarial and ROS cells. 
The aim of the studies described in this chapter is to carry out preliminary 
investigations of whether the inhibition is caused by the activity of proteins.  
Furthermore, experiments were carried out to determine the approximate 
molecular weight range of the factors involved in this inhibition. The first set of 
experiments in this chapter was carried out to test the effects of heat inactivation 
and treatment with trypsin to the gingival conditioned media and whether this 
treatment removes the inhibitory activity. The second set of experiments used 
an exclusion fractionation of the different conditioned media to determine the 
approximate molecular weight of factors responsible for the activity.  
ROS cells were treated with media exposed to the treatment with heat, trypsin 
and filtration process for 72 hours and total ALP assay was used as described 
previously. 
6.1 HEAT TREATMENT OF THE CONDITIONED MEDIA 
6.1.1 Methods 
CM extracted from three gingival fibroblastic lines (G1, G4 and G5) were used in 
this experiment. 500µl of each line CM and of control were aliquoted into 2ml 
eppendorfs and immersed in boiling water for 1, 5 and 10 minutes.  Control 
samples were serum-free ME exposed to the same heat treatment.  Samples 
were then cooled to room temperature and NBCS was applied at 10%.  ROS 
cells were seeded in 96 well-plates at 5x103 cells/well and fed with ME for 24 
hours. The medium was then replaced with heat-treated samples and controls 
supplemented with 10% NBCS in triplicates.  Total ALP assay was applied as 
described in chapter 2 after 72 hours. 
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6.1.2 Results 
Total ALP of ROS cells treated with gingival CM was significantly lower than 
control (average 45% inhibition in three lines). Treatment with heated ME 
(boiling for 1, 5 & 10 minutes) did not affect total ALP of ROS cells. When CM 
was boiled for 5 or 10 minutes the inhibitory activity of gingival conditioned 
media disappeared. However, boiling the CM for 1 minute did not significantly 
affect the inhibitory activity (Figure 6.1) 
 
Figure 6.1: Total ALP of ROS cells treated with ME and gingival CM treated with heat (1-
10minuts). Control: ROS cells treated with ME (heated by placing in boiling water for 1,5 &10 
minutes, and non-heated), G1, G4, G5: ROS cells treated with CM of three gingival lines,  
(heated by placing in boiling water for 1, 5 &10 minutes, and non-heated). All numbers were 
normalised to control. Three independent experiments (N=5, SD). Significant differences to non-
heated control are marked, **: P<0.01, ***: P<0.001. 
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6.2 TREATMENT OF THE CONDITIONED MEDIA WITH TRYPSIN 
6.2.1 Methods 
CM extracted from three gingival fibroblastic lines (G1, G4 and G5) was 
incubated with 1mg/ml of trypsin at 37°C for two hours. The trypsin was then 
inactivated with 2mg/ml trypsin inhibitor at 37°C for two hours.  As a control, CM 
was incubated with 2mg/ml trypsin inhibitor for two hours.  
ROS cells were seeded in 96 well-plate at 5x103 cells/well and fed with ME for 
24 hours. The medium was then replaced with trypsin treated samples and 
controls supplemented with 10% NBCS in triplicates, total ALP assay was 
applied as shown in chapter 2 after 72 hours. 
6.2.2 Results 
Total ALP of ROS cells treated with gingival CM was significantly lower than 
control (49%, 51.8% & 52.8% inhibition in G1, G4 & G5 respectively compared 
to treatment with ME).  Trypsin treatment of CM completely removed the 
inhibitory activity in all cases.  Trypsin treatment of control medium had no 
effects throughout.   (Figure 6.2) 
 
 
Figure 6.2: Total ALP of ROS cells treated with ME and gingival CM exposed to trypsin. Control: ROS cells 
treated with ME (exposed to no treatment, trypsin and inhibitor or inhibitor only treatment), G1, G4, G5: 
ROS cells treated with three gingival lines CM. All numbers were normalised to control. N=5 replicates per 
treatment, three experiments (SD). Significant differences to non-treated control are marked, ***: P<0.001. 
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6.3 MOLECULAR WEIGHT FRACTIONATION 
6.3.1 Methods 
Serum free media conditioned by gingival, oral mucosa and skin fibroblasts was 
collected as described in chapter 2.  Molecular weight filters were used to 
fractionate the media (100kDa, 50kDa and 30kDa filters) by centrifuging at 
3000rpm for 15 minutes. ROS cells were seeded in 96 well-plate at 5x103 
cells/well and fed with ME for 24 hours. The medium was then replaced with 
retentate and filtrate samples and controls supplemented with 10% NBCS in 
triplicates, total ALP assay was applied as shown in chapter 2 after 72 hours. 
6.3.2 Results 
The influence of gingival CM was confirmed in this set of experiments as it 
caused an inhibition of ROS cells ALP activity by 49.4% ± 9.2% in experiment 1 
(P<0.001), 53% ± 2.7% in experiment 2 (P<0.001) and by 69.8% ± 18% in 
experiment 3 (P<0.001). Gingival CM 100kDa retentate did not retain the 
inhibitory activity of total ALP of ROS cells after the fractionation process 
(93.7±13% in experiment 1, 109.3 ±10.6 in experiment 2 and 94±17.7% in 
experiment 3) compared to 100 % control; however, gingival CM 100kDa filtrate 
carried the inhibitory activity of ROS cells total ALP (58% ±12% inhibition in 
experiment 1, 59% ± 10.8% inhibition in experiment 2 and 69% ± 18.3% 
inhibition in experiment 3, P< 0.001 compared to control in all experiments) 
(Figure 6.3). 
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Figure 6.3: Total ALP of ROS cells treated with gingival CM fractionated at 100kDa. Control: 
ROS cells treated with ME, Gin CM: ROS cells treated with gingival CM, Gin CM above 100: 
ROS cells treated with gingival CM (100 kDa retenate), Gin CM below 100: ROS cells treated 
with gingival CM (100kDa filtrate). This graph represents three independent experiments (Exp1, 
Exp2 & Exp3). N=5 replicates (SD). Significant differences to control are marked, **: P<0.01, ***: 
P<0.001. 
 
Similar results were obtained when media conditioned by skin and oral mucosa 
fibroblasts fractionated at 100kDa (Figure 6.4 and 6.5 respectively). 
 
 
Figure 6.4: Total ALP of ROS cells treated with skin CM fractionated at 100kDa.  
Control: ROS cells treated with ME, Skin CM: ROS cells treated with Skin CM, Skin CM above 
100: ROS cells treated with Skin CM (100 kDa retenate), Skin CM below 100: ROS cells treated 
with Skin CM (100 kDa filtrate). This graph represents three independent experiments (Exp1, 
Exp2 & Exp3). N=5 replicates (SD). Significant differences to control are marked, *: P<0.05, **: 
P<0.01, ***: P<0.001. 
 
***    ***     **         ***    ***    ** 
***    ***     *         ***    ***    * 
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Figure 6.5: Total ALP of ROS cells treated with OM CM fractionated at 100kDa. Control: ROS 
cells treated with ME, OM CM: ROS cells treated with OM CM, OM CM above 100: ROS cells 
treated with OM CM (100 kDa retenate), OM CM below 100: ROS cells treated with OM CM 
(100 kDa filtrate). This graph represents three independent experiments (Exp1, Exp2 & Exp3). 
N=5 replicates. (SD). Significant differences to control are marked, *: P<0.05, **: P<0.01. 
 
Similar to the results above, fractionation of the conditioned media (gingival, skin 
and OM) with 50kDa filters showed that 50kDa filtrate retained the inhibitory 
activity of ROS cells total ALP in the three cells types; however, 50kDa retentate 
lost the inhibitory activity.  When gingival CM 100kDa retentate were used, the 
inhibitory effects disappeared in three independent experiments, (96.2% ± 15%, 
123% ± 11% and 77% ± 23% compared to control of 100% ± 15.1%, P>0.05) 
however 50kDa filtrate retained the inhibitory activity (41.6% ± 17.8% compared 
to control, P<0.001) (Figure 6.6).  
 
 
 
***    ***     *      ***    ***    * 
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Figure 6.6: Total ALP of ROS cells treated with gingival CM fractionated at 50kDa. Control: ROS 
cells treated with ME, Gin CM: ROS cells treated with gingival CM, Gin CM above 50: ROS cells 
treated with gingival CM (50 kDa retenate), Gin CM below 50: ROS cells treated with gingival 
CM (50 kDa filtrate). This graph represents three independent experiments (Exp1, Exp2 & 
Exp3). N=5 replicates (SD). Significant differences to control are marked, ***: P<0.001. 
 
 
Similarly, when skin conditioned media was fractionated by 50kDa filter, 50kDa 
retenate did not show a significant inhibition of total ALP activity of ROS cells in 
three independent experiments (114% ±13%, 86% ± 17% and 83% ±25% 
P>0.05). 50kDa filtrate retained the inhibitory activity in three independent 
experiments (47% ± 11%, 38.2% ± 21% and 27.6% ± 15.6%, P<0.001 
compared to 1005 control) (Figure 6.7) 
 
 
 
 
 
 
 
 
 
 
***    ***     ***      ***    ***    *** 
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Figure 6.7: Total ALP of ROS cells treated with skin CM fractionated at 50kDa.  Control: ROS 
cells treated with ME, Skin CM: ROS cells treated with Skin CM, Skin CM above 50: ROS cells 
treated with Skin CM (50 kDa retenate), Skin CM below 50: ROS cells treated with Skin CM (50 
kDa filtrate). This graph represents three independent experiments (Exp1, Exp2 & Exp3). N=5  
replicates (SD). Significant differences to control are marked, ***: P<0.001. 
  
When oral mucosa CM was fractionated, 50kDa retenate did not retain the 
inhibitory activity in three independent experiments (83.6% ± 11.7%, 98% ± 7% 
and 127.6% ± 13% P>0.05 compared to control). However, 50kDa filtrate 
carried the inhibitory activity similar to the other CM in three independent 
experiments (40.8% ± 9.8%, 56.2% ± 13.5% and 45.7% ± 12%, P<0.001 
compared to control of 100%) (Figure 6.8) 
 
 
***    ***     ***      ***    ***    *** 
	   
135 	  
	  
Chapter	  Six	  Preliminary	  Characterisation	  of	  Osteoblast	  Inhibition	  by	  Conditioned	  Media	  
 
Figure 6.8: Total ALP of ROS cells treated with OM CM fractionated at 50kDa. Control: ROS 
cells treated with ME, OM CM: ROS cells treated with OM CM, OM CM above 50: ROS cells 
treated with OM CM (50 kDa retenate), OM CM below 50: ROS cells treated with OM CM (50 
kDa filtrate). This graph represents three independent experiments (Exp1, Exp2 & Exp3). N=5 
replicates (SD). Significant differences to control are marked, ***: P<0.001. 
 
Fractionation of the conditioned media of gingival fibroblasts using 30kDa filters 
showed that the 30kDa retentate was inhibitory to ROS cells ALP production in 
three independent experiments (71.5 ± 20.5 % in experiment 1, P<0.05, 61.2 ± 
20.6% in experiment 2, P<0.01 and 64.8 ± 19.4 % in experiment 3, P <0.05). 
Statistical analysis shows more significant differences (P<0.001) when the 
results of the three experiments are combined and compared to control (Figure 
6.9). 30kDa filtrate did not significantly affect ALP activity of ROS cells 
compared to control (P>0.05) in three independent experiments. 
 
***    ***     ***      ***    ***    *** 
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Figure 6.9: Total ALP of ROS cells treated with gingival CM fractionated at 30kDa. Control: ROS 
cells treated with ME, Gin CM: ROS cells treated with gingival CM, Gin CM above 30: ROS cells 
treated with gingival CM (30 kDa retenate), Gin CM below 30: ROS cells treated with gingival 
CM (30 kDa filtrate). This graph represents three independent experiments (Exp1, Exp2 & 
Exp3). N=5 replicates. (SD). Significant differences to control are marked, *: P<0.05, **: P<0.01, 
***: P<0.001. 
 
Fractionation of the skin CM with 30 kDa filters shows that 30kDA retentate 
retained the significant inhibitory activity in one experiment (53.8 ± 16.3 in 
experiment 2, P<0.01). Although, the inhibition showed in the other two 
experiments was not statistically significant (70.3 ± 27.6% with P=0.07 in 
experiment 1 and 65.9±28.8% with P=0.057 in experiment 3), statistical 
difference is evident when the results of the three experiments were combined 
(P<0.01) (Figure 6.10). 30kDa filtrate did not show significant change to ALP 
activity of ROS cells similar to gingival CM. 
 
**    **     ***           *    *      * 
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Figure 6.10: Total ALP of ROS cells treated with skin CM fractionated at 30kDa. Control: ROS 
cells treated with ME, Skin CM: ROS cells treated with Skin CM, Skin CM above 30: ROS cells 
treated with Skin CM (30 kDa retenate), Skin CM below 30: ROS cells treated with Skin CM (30 
kDa filtrate). This graph represents three independent experiments (Exp1, Exp2 & Exp3). N=5 
replicates (SD). Significant differences to control are marked, **: P<0.01, ***: P<0.001. 
 
 
When the fractionation (30kDa filters) process was applied to the oral mucosa 
CM, 30kDa retentate was significantly inhibitory to ROS cells ALP activity of 
ROS cells in three independent experiments. The difference was more 
significant statistically when the results of the three experiments were combined 
(42.9 ± 19.4% in experiment 1, P<0.001, 47.6 ± 21.3% in experiment 2, P<0.01, 
and 60.9 ±15.8% in experiment 3, P<0.01). Similar to the gingival and skin 
conditioned media, 30kDa filtrate did not show a significant effect on ROS cells 
ALP activity (Figure 6.11). 
 
***    ***     ***                    ** 
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Figure 6.11: Total ALP of ROS cells treated with OM CM fractionated at 30kDa.  Control: ROS 
cells treated with ME, OM CM: ROS cells treated with OM CM, OM CM above 30: ROS cells 
treated with OM CM (30 kDa retenate), OM CM below 30: ROS cells treated with OM CM (30 
kDa filtrate). This graph represents three independent experiments (Exp1, Exp2 & Exp3). N=5 
replicates. (Mean ± Std) Significant differences to control are marked, *: P<0.05, **: P<0.01, ***: 
P<0.001. 
 
6.4 DISCUSSION 
The studies in this chapter were designed to carry out preliminary 
characterization of the media conditioned by the fibroblasts. It was shown earlier 
that superficial fibroblasts secret factors that inhibit ALP expression of 
osteoblasts.  By heating the conditioned media and by treatment with trypsin, it 
was tested whether these factors are likely to be of proteinaceous nature.  
Heat treatment of CM at 100°C for 5 and 10 minutes totally abolished ALP-
suppression activity, whereas heat treatment for at 100°C for 1 minute had no 
significant effect on gingival CM.  Also treatment with trypsin completely 
obliterated the effects of gingival CM when it was applied to the CM and 
compared to control. 
This response to heat and trypsin, a protein hydrolase, indicates that the factors 
involved in this response have characteristics of proteins. This approach is 
familiar and has been used by many scientists. Ikeda et al (2003) treated the 
hepatic cells culture supernatant was treated with trypsin (25 mg/ml) at 37° for 3 
***    ***     ***       **       **    ** 
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hours and also with heat at 50-90° C and investigate the effects of this CM on 
lymphoid cells before and after the treatment. They found that the conditioned 
media of hepatocytes had an anti-proliferative effect on lymphoid cells. Its 
suppressive activity was sensitive to trypsin and heat treatment. 
In another study by Redondo et al, conditioned media of endothelial cells were 
found to increase smooth muscle cell sodium pump activity; however, these 
effects were trypsin sensitive heat stable when the CM was placed in boiling 
water for 3 minutes but heat sensitive when the treatment was for 10 minutes. 
They suggested the factor involved to be a growth factor (Redondo et al, 1995). 
This indicates that different factors get inactivated by different level of heat 
treatment.  
 
Furthermore, fractionation of the conditioned media according to their molecular 
weight investigated the range of the molecular weight of the factors involved in 
causing an inhibition of osteoblasts ALP activity. Media conditioned by three 
different superficial connective tissue fibroblasts were subject to molecular 
weight-exclusion filtration process. Three sizes were selected, 100, 50 and 30 
kDa, however media 50kDa retentate (conditioned by three cell types) showed 
no significant influence on ROS cells differentiation measured by ALP activity, 
and media 50kDa filtrate (conditioned by three cell types) retained the inhibitory 
activity of ROS cells ALP activity. 
However the 30kDa filtrate did not show inhibitory activity. The results indicate 
that the inhibitory activity of the conditioned media of the three cell types is 
retained in the fractions between 30kDa and 50kDa.  
Although this method is not accurate enough to determine the exact molecular 
weight of the factor, it can be speculated that the inhibitory activity is likely to be 
a relatively small protein or polypeptide molecule and allows us to discount 
many factors and implicate a subgroup of factors involved in the regulation of 
bone growth by influencing the differentiation of osteoblasts.  A more precise 
determination of the factor molecular weight could be obtained by performing 
high-performance liquid chromatography (HPLC) that separates the CM 
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according to the molecular weight. However, this would give a large number of 
samples that needs to be tested a biological assay. An alternative approach is to 
test known possible candidate factors on the basis of the information obtained 
here which could be tested for their action on osteoblasts. 
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CHAPTER SEVEN 
ROLE OF BONE MORPHOGENETIC PROTEINS (BMPS) AND THEIR 
INHIBITORS ON OSTEOBLAST DIFFERENTIATION 
 
As discussed in chapter 1, BMPs are strong stimulators of osteoblast 
differentiation and their actions can be modulated by a range of specific 
antagonists. The expression of BMP antagonists is thus a good candidate 
mechanism which may account for the secreted bone inhibitory activity of 
fibroblast CM. Thus the studies in this chapter aimed to investigate the effects of 
BMPs on the differentiation of osteoblasts measured by ALP expression, and 
test whether they can be antagonised by their inhibitors. These studies were 
carried out as a preliminary study prior to investigation of the potential BMP 
antagonistic activity of fibroblast CM, which will be described in chapter 8. 
7.1 METHODS 
This set of experiments was initially carried out on primary calvarial osteoblasts. 
This pilot experiment suggested the use of a cell line instead of the primary 
calvarial cells since the established cell line may show less experimental 
variation between experiments. Therefore ROS 17/2.8 (ROS) cells were tested 
in subsequent experiments. Primary Calvarial osteoblasts or ROS cells were 
seeded into 96-well plates at a density of 5x103 cells/well. Treatment with BMP 
proteins with or without inhibitors (Noggin, chordin, follistatin) was applied in 
NBCS-containing ME for 72 hours and compared to controls that had received 
no treatment. Total ALP expression was measured as discussed in chapter 2. 
50 ng/ml of BMP-2 was used to test the effects on primary calvarial osteoblasts 
however, a range of BMP-2 and activin doses were used to establish a dose 
response curve on ROS cells. Also different dosages of their inhibitors (Noggin 
0-500ng/ml, follistatin 0-100ng/ml) alone and in combination with BMP-2 or 
activin were used to verify a dose-response in respect of ALP expression of 
ROS cells. 
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7.2 RESULTS 
7.2.1 BMP-2 influences ALP expression of rat primary calvarial 
osteoblasts 
Calvarial osteoblasts were treated with 50ng/ml of BMP-2. Exact levels of 
induced ALP varied according to the different passage of the primary cells used; 
however they always showed a significant increase in ALP production in a 
consistent pattern. We list here results of three experiments that showed 
increased ALP production of 71.8% ± 3% (P< 0.001) in the first experiment, 
19.2% ± 7% increase in the second experiment (P< 0.05) and 38±11.8 (P< 
0.001) in experiment 3 (Figure 7.1). 
 
 
Figure 7.1: ALP assay of Calvarial cells treated with 50ng/ml BMP-2 in three separate 
experiments compared and normalised to control (mean ± S.D. n= 5 in each experiment). 
Significant comparisons to control are marked, *: p< 0.05, ***: p< 0.001. 
 
 
 
 
 
*** 
*** 
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7.2.2 BMP-2 Dose Response Curve in ROS cells 
Range of BMP-2 doses were used to verify the therapeutic limits of BMP-2 on 
ROS cells. ROS cells responded to BMP-2 treatment at a much lower dose 
compared to calvarial osteoblasts, since ALP production of ROS cells increased 
steeply with BMP treatment of 0-10 ng/ml (Figure 7.2 and 7.3); however higher 
BMP-2 doses did not result in further significant increases in ALP production 
(Figure 7.2). 5ng/ml of BMP-2 increased ALP production of ROS cells by more 
than 2.5 fold. 10ng/ml of BMP-2 resulted in 3-4 fold increase compared to un-
stimulated cells (Figure 7.2). 
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A 
 
B 
 
Figure 7.2: ALP assay of ROS cells treated with 0-100ng/ml BMP-2. Graph A shows three 
independent experiments and graph B shows averages of three experiments in a dose response 
curve, each treatment point is an average of three experiments. All were normalised to control 
(SD. n= 3 in each experiment). All treatments cased a significant increase in ALP (P<0.001 
compared to control). Treatments above 10ng/ml did not show significant difference to treatment 
with 10ng/ml of BMP-2. 
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A 
 
B 
Figure 7.3: ALP assay of ROS cells treated with 0-10ng/ml BMP-2, Graph A shows three 
independent experiments and graph B shows averages of three experiments in a dose response 
curve, each treatment point is an average of three experiments. All were normalised to control 
(SD. n= 3 in each experiment). Compared to control, all treatments in three experiments showed 
significant difference (apart from experiment 1 in 0.1ng/ml treatment). P<0.001 in all treatments 
with 5 and 10ng.ml, P<0.01 in treatments with 0.5 and 1ng/ml, P<0.05 in treatment with o.1 
ng/ml. Treatment with o.5ng/ml was not significant from 0.1ng/ml in experiments 2 and 3. 
Treatments with 1ng/ml did not show significant difference to treatments with 0.5 ng/ml in three 
experiments. Treatments with 5ng/ml showed significant difference to 1ng/ml and treatment with 
10ng/ml was significantly different from 5ng/ml (P<0.01). 
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7.2.3 Effects of treatment of activin on ROS 17/2.8 cells 
Cells were treated with a range of dosages of activin up to 50ng/ml. Three 
independent experiments showed that treatment of ROS cells with 2.5ng/ml 
activin or less did not cause a significant alteration to ALP expression of ROS 
cells compared to control, however activin treatment of 5ng/ml showed 
increased ALP expression by average of 18% ± 5.1% (P< 0.01). Treatment with 
dosages of higher than 5ng/ml did not show significant further increase in ALP 
production of ROS cells, which suggest that activin maximal response had been 
reached at 5ng/ml of treatment (Figure 7.4). 
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A 
 
 
B 
Figure 7.4: ALP assay of ROS cells treated with 0-50ng/ml activin. Graph A shows results of 
three independent experiments and graph B shows the results in dose response curve, each 
treatment point is an average of three experiments. All were normalised to control (SD. n= 3 in 
each experiment). 
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7.2.4 Effects of Noggin on BMP-induced differentiation of ROS 17/2.8 
cells 
Noggin did not significantly alter ALP production of unstimulated ROS cells, 
however, when noggin was added to BMP-2 containing media before applying to 
the cells, changes in ALP production were seen. 500ng/ml of noggin completely 
suppressed the stimulation caused by 25ng/ml BMP-2, but only partly inhibited 
the response to 50ng/ml BMP-2 (from 332% ± 18% to 263% ± 17%) (P< 0.01). 
100ng/ml of noggin suppressed the stimulation of 5ng/ml BMP-2 to control level 
and partly but significantly inhibited the stimulation of BMP-2 at 10ng/ml (from 
330% ± 12% to 148% ± 6.8%) and 25ng/ml (from 337% ± 6.6% to 219% ± 14%); 
however 100ng/ml of noggin did not significantly alter stimulation of 50ng/ml of 
BMP-2. 50ng/ml of noggin completely suppressed stimulation of 5ng/ml of BMP-
2 and partly but significantly inhibited stimulation of 10ng/ml of BMP-2 on ROS 
cells; however 50ng/ml of noggin did not alter the effects of 25ng/ml BMP-2. 
Lower dosages of noggin were not able to alter significantly the influence of 
BMP-2 at 5ng/ml or above (Figure 7.5). 
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Figure 7.5: Noggin effects on differentiation of ROS cells treated with BMP-2, noggin dose (0, 
50,100 & 500ng/ml). Each treatment point is an average of three experiments. All were 
normalised to control (S.D. n= 3 in each experiment). 
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7.2.5 Effects of Chordin on BMP-induced differentiation of ROS 
17/2.8 cells 
Chordin treatment of 100ng/ml and below was unable to significantly alter ALP 
production of ROS cells and was unable to inhibit stimulation of ALP by BMP-2 
at dosages of 0-10ng/ml (Figure 7.6). However, chordin treatment of 500ng/ml 
did significantly inhibit stimulatory effects of 5ng/ml BMP-2 (from 290% ± 5.1% 
to 167% ± 7.6%), and BMP-2 of 10ng/ml (from 307% ± 22.7% to 213.5% ± 12%) 
(Figure 7.7). Also treatment with chordin of 1µg/ml and 2 µg/ml suppressed ALP 
production of ROS cells stimulated by BMP-2 of 0.5ng/ml, 1ng/ml, 5ng/ml and 
10ng/ml to control level (Figure 7.7). 
 
 
 
Figure 7.6: Chordin effects (0- 100 ng/ml) on differentiation of ROS cells treated with BMP-2, 
chordin dose (0- 100 ng/ml). Each treatment point is an average of three experiments. All were 
normalised to control (SD. n= 3 in each experiment). 
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Figure 7.7: Chordin effects (0- 2000ng/ml) on differentiation of ROS cells treated with BMP-2, 
chordin dose (0- 2000ng/ml). Each treatment point is an average of three experiments and 
normalised to control (SD. n= 3 in each experiment). 
7.2.6 Effects of Follistatin on differentiation of ROS 17/2.8 cells 
The results suggest that follistatin (0-100ng/ml) did not have a significant 
inhibitory effect on the stimulatory effects of BMP-2 (0-10ng/ml) (Figure 7.8). 
Also follistatin (0-500ng/ml) caused no significant alteration to the stimulation 
caused by activin (0-50ng/ml) (Figure 7.9). 
 
 
Figure 7.8: Follistatin effects on differentiation of ROS cells stimulated with BMP-2, Follistatin 
dose (0, 50,100 ng/ml). Each treatment point is an average of three experiments. All were 
normalised to control (SD. n= 3 in each experiment). 
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Figure 7.9: Follistatin effects on differentiation of ROS cells stimulated with activin, follistatin 
dose (0, 50,500 ng/ml). Each treatment point is an average of three experiments. All were 
normalised to control (SD. n= 3 in each experiment). 
 
7.6 DISCUSSION  
BMPs have been shown to have a stimulatory effect on the differentiation of 
bone marrow stromal cells into osteoblasts (Lecanda, et al., 1997; Rickard, et 
al., 1994). Their effects on different osteoblast cultures have been shown in 
many studies. Chen et al (1997) in their study on rat calvarial osteoblasts 
showed that BMP-2 increases the expression of bone cell differentiation marker 
genes (Chen, et al., 1997). Gimble et al (1995) have also stated that only high 
concentrations of BMP-7 caused an increase in the number of ALP positive 
osteoblast-like cells (Gimble, et al., 1995). The stimulatory effects of BMP-2 on 
ALP activity were previously shown by (Fromigue, et al., 1998). This effect is 
believed to be due to the inducing effect of BMPs on cell lineage toward the 
osteoblastic cell line. Takuwa et al (1991) have shown that ALP levels are 
increased by the administration of BMP-2 to the osteoblast cell cultures in vitro 
(Takuwa, et al., 1991). Another study by Laflamme and Rouabhia (2008) 
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measured osteocalcin expression by osteoblasts treated with BMP-2, BMP-7 
and mixture of both. They found that BMP-2 and the BMP-2/-7 mixture 
enhanced osteocalcin expression more than BMP-7 alone (Laflamme & 
Rouabhia, 2008).  
 
In the experiments here, we established a model system for BMP 
responsiveness that can demonstrate the antagonistic activity of BMP inhibitors. 
We used BMP-2 to stimulate differentiation of rat primary calvarial osteoblasts 
and subsequently ROS 17/2.8 cells. There was a significant increase of ALP 
production of the calvarial cells after treatment with 50ng/ml of BMP-2. The 
increase was variable between experiment repeats; this was possibly due to the 
calvarial cell culture plate containing different passage cells and it varied 
between batches. ROS 17/2.8 cells were used in subsequent experiments and 
showed a more predictable response in reaction to treatment with BMPs and 
their inhibitors. ALP production in ROS cells reached saturation when treated 
with BMP-2 at a dose of 10ng/ml and at dose of 5ng/ml when activin was used.  
BMP-2 caused a significantly higher increase in ALP expression of ROS cells 
compared to activin (Three fold with BMP-2 treatment, 1.5 fold with activin), 
which indicates that ROS cells are more responsive to BMP-2 in respect to ALP 
production than activin. This is possibly due to the high affinity of BMP-2 
receptor binding in ROS cells compared to the activin, that needs a heteromeric 
complex of type II and type I activin receptors in which type I receptors are 
phosphorylated by type II receptors to initiate the intracellular signalling (del Re, 
et al., 2004). Although type II receptors show high affinity binding for their ligand 
when transiently expressed, type I receptors do not appear to bind ligand on 
their own (Attisano, et al., 1993; Ebner, et al., 1993; Mathews & Vale, 1991). 
However, it is not known whether ROS cells express both type I and type II 
activin receptors. 
 
It was reported that the effects of activin are complex and strongly cell-type 
dependent (de Jong, et al., 2002). It has been shown to induce bone formation 
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when injected near bone (Oue, et al., 1994). In contrast, other in vitro studies 
have indicated that they may impede bone formation by inhibiting the early 
differentiation of osteoblasts (Breen, et al., 1994; Ikenoue, et al., 1999). In our 
study we demonstrate that activin weakly (compared to BMP-2) stimulated ROS 
cell differentiation as measured by increased ALP production. These effects 
could be obtained by treating the cells with 5ng/ml of activin; however, 
increasing dose of treatment did not induce higher levels of ALP production of 
ROS cells. 
 
Noggin has been extensively studied for its ability to bind to BMP-2, -4, and -7 in 
a manner that inhibits the BMPs from binding to their receptors (Zimmerman, et 
al., 1996). This action of noggin has been most extensively studied in many 
models where bone development can be examined in the context of transgenic 
mice overexpressing either a BMP or noggin or both (Glaser, et al.; Wijgerde, et 
al., 2005; Wu, et al., 2003). Such studies have determined that noggin does play 
a pivotal role in the development of bone by regulating the action of BMPs in a 
spatial/ temporal manner (Nakamura, et al., 2003; Peng, et al., 2005). 
 
In this study we investigated the influence of noggin on ALP production in ROS 
cells and demonstrated that noggin alone does not inhibit ALP production; 
however, when noggin was applied to the medium containing BMP-2 which 
showed stimulation to ALP, this combination lowered ALP and eliminated the 
stimulation caused by BMP-2. These effects were shown to be dose dependent, 
total suppression of 10ng/ml of BMP-2 stimulation required more than 100ng/ml 
of noggin; however 50ng/ml of noggin was able to eliminate stimulatory effects 
of 5ng/ml of BMP-2. This is consistent with work performed by (Zimmerman, et 
al., 1996). They pre-incubated BMP-4 with 16 nM noggin protein for 1 hr which 
abolished its activity over a range of BMP-4 doses from 0.1 pM to 6.66 nM. In 
their experiment noggin alone had a small but reproducible inhibitory effect in 
the absence of added BMP-4, suggesting that it may antagonize activities 
present in serum or secreted by the cells.  
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Chordin is another protein that binds BMPs and thus antagonizes their activities 
(Piccolo, et al., 1994). We demonstrate in this study that chordin is able to block 
BMP-2 stimulation similar to noggin; however, the dose of chordin needed to 
antagonize BMP-2 of 10ng/ml was higher than the required noggin dose. In this 
experiment on ROS cells we show that chordin works against BMP-2 at high 
concentrations. 
 
Follistatin was identified as a natural antagonist that binds activin with high 
affinity and neutralizes its biological activities by preventing activin interaction 
with its membrane receptors (Hemmati-Brivanlou, et al., 1994; Michel, et al., 
1990; Nakamura, et al., 1990). It has also been shown that follistatin binds BMP-
2, -4, and -7, with higher affinities for BMP-7 (Iemura, et al., 1998; Yamashita, et 
al., 1995), although the affinity of follistatin for BMPs is lower than that of 
follistatin for Activin (Iemura, , et al., 1998; Michel, et al., 1990; Nakamura, et al., 
1990). Lemura et al. demonstrated that follistatin can inhibit the effect of BMP-2, 
-4, and –7 in a manner different from that of the other organizer factors, noggin 
and chordin, by binding to BMP receptors through BMPs, forming a trimeric 
complex. In this study follistatin did not block BMP-2. We also showed that 
follistatin did not antagonize its high affinity ligand, activin. Although the reasons 
for this result are uncertain, this might indicate the need for a third factor that 
forms a complex to enable the binding and then can block activin effects. It is 
crucial to understand the structural features of the molecules binding that could 
account for differences in ligand specificity between follistatin and BMP or activin 
proteins. Follistatin types vary in respect to their N-terminal domain and 
therefore influence the ligand binding specificity (Stamler, et al., 2008).  
 
In summary, our findings are consistent with earlier literature suggesting that 
BMP antagonists of this type regulate osteoblast differentiation and bone 
formation (Aspenberg, et al., 2001; Devlin, et al., 2003; Gazzerro, et al., 1998). 
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This chapter describes the effects of BMP-2 and activin on differentiation of 
primary calvarial and ROS cells. We investigated the effects of the BMP 
inhibitors (noggin, chordin and follistatin) and showed that the actions of BMPs 
can be regulated by extracellular proteins that bind BMPs and block parts of the 
BMP signalling pathway. We were able to block the effects of BMP-2 by noggin 
and chordin, although considerably higher dose of chordin. We were not 
successful in blocking BMP-2 or activin using follistatin in this system on ROS 
cells. 
 
To date, biological methods of enhancing bone regeneration in clinical use have 
centred on the promotion of osteoinduction via the delivery of BMPs. However, 
targeting BMP inhibitors, such as noggin and chordin may provide means of 
improving regeneration and fulfilling other relevant osteogenic needs. This 
chapter points to the possible local feedback mechanisms that are based on 
BMPs and their inhibitors and might be available in the gingival-alveolar bone 
complex that maintain an ideal balance between bone breakdown and 
regeneration 
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CHAPTER EIGHT 
MEDIA CONDITIONED BY FIBROBLASTS INFLUENCES EFFECTS OF 
BONE MORPHOGENETIC PROTEINS 
 
 
We have shown in chapter 5 that conditioned media extracted from superficial 
tissue fibroblasts (gingival, oral mucosa and skin) significantly inhibits 
osteoblasts differentiation as measured by ALP expression. In contrast, 
conditioned media from periodontal ligament fibroblasts stimulates osteoblasts 
differentiation. We have also demonstrated in chapter 7 that BMP-2 significantly 
enhanced differentiation osteoblasts as measured by ALP synthesis, in contrast, 
noggin and chordin was able to inhibit BMP-2 effects and totally suppressed at 
sufficient doses. This chapter tests whether the conditioned media can modulate 
the effects caused by BMP-2 or their inhibitors.  
 
8.1 METHODS 
Serum free CM of gingival, oral mucosa; skin and periodontal ligament 
fibroblasts were collected as detailed in chapter 2. Osteoblasts were seeded in 
96-well plate at density of 5x103/well in 10% serum added αMEM medium. 
Medium was replaced after 24 hours with 10% serum added CM (test groups) or 
ME (control group). Test and control groups were treated with BMP-2 or noggin 
from 0-100ng/ml, and the assay was stopped 72 hours later. Total ALP activity 
was assessed as detailed in chapter 2. 
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8.2 RESULTS 
8.2.1 Conditioned media harvested from superficial connective 
tissue inhibits the effect of BMP-2 on ALP production in calvarial 
cells 
In this set of experiments calvarial osteoblast cultures were treated with BMP-2. 
BMP-2 stimulated ALP expression in a dose-dependent manner. 100ng/ml 
BMP-2 increased ALP levels by approximately 2.7 fold compared to control (269 
± 14%, P<0.001). In contrast, gingival CM significantly inhibited ALP expression 
of calvarial osteoblasts by 26.8% (P<0.001). Furthermore gingival CM inhibited 
the effects of BMP-2 at all concentrations tested (Figure 8.1) and it completely 
blocked the effects of 50ng/ml BMP-2 (109.2 ± 5.2%, P= 0.15 compared to 
control). At higher concentrations of BMP-2 conditioned medium only partially 
blocked the activity (Figure 8.1). 
 
 
Figure 8.1: ALP assay of Calvarial cells treated with BMP-2 (0-100ng/ml), gingival CM and 
combined treatment of both gingival CM and BMP-2. All results were normalized to control, 
three independent experiments. (S.D. n= 4 in each experiment). 
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Experiments using skin CM combined with BMP-2 caused a similar effect to the 
gingival CM. 25ng/ml BMP-2 reversed the inhibitory effect of Skin CM and 
blocked its inhibitory action (96.9 ± 4%, P<0.05 compared to treatment with skin 
CM only, P= 0.93 compared to control). Also, skin CM inhibited ALP activity of 
calvarial cells by 23.2 ± 7.5% (P<0.05 compared to control), and it totally 
blocked the stimulation caused by 50ng/ml BMP-2 (108.4 ± 5.5, P< 0.001 
compared to treatment with BMP-2 only, P= 0.12 compared to control). Skin CM 
also partially inhibited the effects of 100ng/ml BMP-2 (195.7 ± 12.7%, P<0.001 
compared to treatment with BMP-2 alone and compared to control) (Figure 8.2). 
 
   
 
Figure 8.2: ALP assay of Calvarial cells treated with BMP-2 (0-100ng/ml), skin CM and 
combined treatment of both skin CM and BMP-2. All results were normalized to control, three 
independent experiments. (S.D. n= 4 in each experiment). 
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Experiments using CM from oral mucosa fibroblasts combined with BMP-2 
caused a similar effect to the skin CM. 25ng/ml BMP-2 antagonised the oral 
mucosa CM and blocked its inhibitory action (102.9 ± 12%, P<0.01 compared to 
treatment with OM CM only, P= 0.96 compared to control). Also, oral mucosa 
CM inhibited ALP activity of calvarial cells by 19 ± 5.5% (P< 0.005 compared to 
control), and it totally blocked the stimulation caused by 50ng/ml BMP-2 (108.5 ± 
5%, P< 0.001 compared to treatment with BMP-2 only, P= 0.19 compared to 
control). Oral mucosa CM also significantly modulated effects caused by 
100ng/ml BMP-2; however, this was not total suppression of the activity (231.9 ± 
8.4%, P< 0.001 compared to treatment with BMP-2 alone and compared to 
control) (Figure 8.3). 
 
 
 
Figure 8.3: ALP assay of Calvarial cells treated with BMP-2 (0-100ng/ml), oral mucosa 
conditioned media and combined treatment of both OM conditioned media and BMP-2. All 
results were normalized to control, three independent experiments. (S.D. n= 4 in each 
experiment). 
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8.2.2 Effects of superficial soft tissue fibroblast conditioned media 
on BMP-2 dose-response in ROS cells 
To test the effects of the combined treatment of BMP-2 and different conditioned 
media in a reproducible model, a set of experiments identical to those using 
calvarial cells were performed assessing changes in ALP activity of ROS cells 
treated with BMP-2, CM and combined treatment of CM and BMP-2. 
BMP-2 stimulation caused a dose-dependent increase in ALP up to 10ng/ml of 
BMP-2. Higher doses of BMP-2 did not show a significant increase of ALP 
production of ROS cells (Figure 8.4). Gingival fibroblast CM inhibited ALP 
activity of ROS cells not exposed to BMP-2 treatment (38% reduction ± 7.3%). 
This inhibition was maintained even when the cells were treated with BMP-2 of 
10 ng/ml; however, gingival CM did not inhibit ALP production in the presence of 
BMP-2 treatment above 10 ng/ml (Figure 8.4). 
 
 
Figure 8.4: ALP assay of ROS cells treated with 0-50ng/ml of BMP-2, combined treatment with 
conditioned media of gingival fibroblasts. All were normalised to control, three independent 
experiments (S.D. n= 3 in each experiment). 
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Similar experiments were performed testing effects of conditioned media 
harvested from oral mucosa and skin fibroblasts on ALP production stimulated 
by up to 10ng/ml BMP-2. CM extracted from oral mucosa fibroblasts was 
inhibitory to ALP production (75.3% ± 4.1%, P<0.001 compared to control). This 
inhibition was maintained even when cells were treated with BMP-2 of 1ng/ml 
(75.5% ± 12.6%, P<0.001 compared to matching BMP-2 treatment), treated with 
5 ng/ml (88 ± 18.1%, P<0.001 compared to matching BMP-2 treatment) and 
when treated with 10 ng/ml (124% ± 12.9%, P< 0.001 compared to matching 
BMP-2 treatment) (Figure 8.5). Broadly, similar effects were obtained using CM 
extracted from skin fibroblasts to test ROS cells with or without added BMP-2 
(Figure 8.5). 
 
 
 
Figure 8.5: ALP assay of ROS cells treated with 0-10ng/ml of BMP-2, combined treatment with 
CM of oral mucosa and skin. All were normalised to control, three independent experiments. 
(S.D. n= 6 in each experiment). 
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8.2.3 Influence of periodontal ligament fibroblast conditioned media 
on BMP-2 dose response in ROS cells 
We have shown above that CM from superficial connective tissue fibroblasts 
(gingival, oral mucosa and skin) antagonised the effects of BMP-2 on ALP in 
primary calvarial and ROS cells. Also in chapter 4 it was shown that CM from 
periodontal ligament (PDL) fibroblasts stimulated ALP activity, in contrast to the 
other superficial tissue CM. In this experiment we tested the influence of PDL 
CM on the effects of BMP-2 treatment on ALP production by ROS cells. ROS 
cells were treated with BMP-2, at concentrations from 0-10ng/ml of BMP-2. 
There was maximum three-fold increase in ALP synthesis with 10ng/ml BMP-2 
treatment. PDL conditioned media stimulated ALP activity in ROS cells not 
exposed to BMP-2 treatment (58% increase ± 5%). This stimulation was 
significantly additive (185% increase in combined treatment with 5ng/ml BMP-2 
compared to 139% increase in BMP-2 only treatment P= 0.001) combined 
treatment of PDL CM and higher doses of BMP-2 did not show any further 
increase in ALP production compared to treatment with BMP-2 only (Figure 8.6).  
 
 
Figure 8.6: ALP assay of ROS cells treated with 0-10ng/ml of BMP-2, combined treatment with 
CM from PDL fibroblasts, each treatment point is an average of three independent experiments. 
All were normalised to control (S.D. n= 4 in each experiment). 
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8.2.4 Influence of noggin on the effects caused by periodontal 
ligament fibroblast conditioned media in ROS cells 
The data in figure 6-6 shows that CM from periodontal ligament fibroblasts 
together with BMP-2 stimulates ALP activity of ROS cells. Experiments in 
chapter 5 showed that noggin could suppress the action of BMP-2 in stimulating 
ALP activity in ROS cells. In this set of experiments the effects of noggin (0-500 
ng/ml) on the activity of PDL CM was tested. Periodontal ligament (PDL) CM 
significantly stimulated ALP production of ROS cells (49.4 ± 5% increase). 
However, addition of noggin to the PDL CM suppressed this stimulation. Total 
suppression of PDL effects was achieved with treatment with noggin at 
100ng/ml and higher. (Figure 8.7) 
 
 
 
Figure 8.7: ALP assay of ROS cells treated with PDL conditioned media and noggin (0-
500ng/ml). Three independent experiments, All were normalised to control (S.D. n= 6 in each 
experiment). 
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8.3 DISCUSSION  
Results from previous chapters indicate that conditioned media harvested from 
superficial connective tissue fibroblasts inhibits differentiation of calvarial and 
ROS osteoblasts measured by total ALP assay. In this chapter we hypothesised 
that factors contained in CM of superficial tissue fibroblasts and involved in 
inhibiting osteoblast differentiation might act by inhibition of BMP. Therefore we 
tested the ability of CM harvested from gingival, oral mucosa and skin fibroblasts 
to inhibit the stimulatory effects of BMP-2 on calvarial and ROS cells. Previous 
studies have used similar systems to test the antagonistic potential of CM on 
osteogenic medium (Meury, et al., 2006). In those studies it that shown that CM 
of human umbilical vein endothelial cells can inhibit dexamethasone induced 
differentiation of bone marrow stromal cells measured by different markers 
including ALP. 
 
In this chapter, calvarial and ROS cells were exposed to series of BMP-2 
dosages and were treated by combination of BMP-2 and conditioned media from 
different source. Although calvarial and ROS cells reacted to BMP-2 treatment 
by significant increase of ALP synthesis, ROS cells responded at a lower dose 
than calvarial cells. However, in both calvarial and ROS cells, CM from gingival, 
oral mucosa and skin fibroblasts suppressed ALP production stimulated by 
BMP-2. Our experiments on calvarial cells showed that CM of superficial 
connective tissue fibroblasts (gingival, oral mucosa and skin) can cause total 
suppression of 50ng/ml BMP-2 activity; however the superficial connective 
tissue CM caused only partial inhibition of the enhanced ALP activity caused by 
100ng/ml BMP-2. Similarly, in ROS 17/2.8 cells, superficial connective tissue 
fibroblasts CM antagonised effects caused by BMP-2 on ALP activity. Similar to 
the current work described here, a study by Oshima et al showed that 
conditioned media of human multiple myloma cell lines (RPMI8226 and U266) 
contains factor that inhibit BMP-2 activity in both MC-3T3E1 cells and bone 
marrow derived osteoblasts (Oshima, et al., 2005). 
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We have shown in chapter 5 that BMP-2 activity could be blocked by addition of 
excess Noggin. Although the stoichiometry of the interaction of BMP-2 with 
noggin has not been described, in our experiments on ROS cells 100ng/ml 
noggin totally inhibited up to 10ng/ml BMP-2. In contrast, 50ng/ml Noggin only 
partially blocked BMP-2 concentrations above 5ng/ml. In this chapter, 
experiments performed on ROS cells also show that addition of gingival, oral 
mucosa or skin CM totally blocked BMP-2 activity up to 5ng/ml, but did not fully 
block BMP-2 above 10g/ml. This is consistent with the superficial tissue CM 
having the equivalent activity of 50ng/ml noggin. Suppression caused by CM 
from superficial connective tissue fibroblasts was dependent on the BMP-2 dose 
as higher concentrations of BMP-2 overcame the effects of the CM. CM 
harvested from periodontal ligament fibroblasts stimulated ALP production in 
ROS 17/2.8 cells. However, this chapter demonstrates that PDL conditioned 
media additively enhanced ALP activity stimulated by BMP-2 (0-10 ng/ml) in 
ROS cells. Similar work was done by Champagne et al using different CM and 
osteoblasts cultures. They harvested the conditioned media of human and 
murine macrophages and tested their effects on human mesenchymal stem 
cells (hMSCs) (Champagne, et al., 2002). They demonstrated that the CM 
contains factors that stimulate ALP activity of hMSCs. ALP induction was 
blocked by anti-BMP-2 antibody and by anti-transforming growth factor-beta1 
(TGF-beta1) antibody. The results here suggest that periodontal ligament 
fibroblasts secret factors which stimulate differentiation of ROS cells. We 
hypothesized that this stimulation is similar to BMP-2 stimulation; therefore, 
noggin was tested for its ability to block ALP activity enhanced by PDL 
conditioned media. We demonstrate that 50ng/ml noggin partially blocked the 
stimulation caused by PDL CM; however, 100ng/ml noggin and above totally 
suppressed it. 
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In summary, we have shown that superficial connective tissue fibroblasts 
express factors that inhibit osteoblasts differentiation enhanced by BMP-2. We 
demonstrate that these factors can block BMP-2 similar to its antagonist, noggin. 
This indicates factors involved might be one or more of BMP antagonists. In 
contrast to this, it was shown that deep connective tissue fibroblasts express 
factors that, additively with BMP-2, stimulate osteoblast differentiation. These 
factors were blocked with the specific BMP inhibitor noggin, suggesting that the 
factors may be one or more of the BMP proteins.  
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CHAPTER NINE 
ROLE OF GINGIVAL CONDITIONED MEDIA ON OSTEOBLAST MIGRATION 
AND CHEMOTAXIS 
 
9.1 INTRODUCTION  
Cell migration is a dynamic, cyclical process in which a cell extends a protrusion 
at its front, which in turn attaches to the substratum on which the cell is 
migrating. This is followed by a contraction that moves the cell body forward 
toward the protrusion, and finally the attachments at the cell rear release as the 
cell continues to move forward. The cycle is initiated by external signals 
(chemotactic molecules), which are sensed and communicated to the cell’s 
interior by receptors in the cell membrane. In response to these signals, cells 
extend protrusions, by polymerizing actin, that act as feelers, seeking out new 
terrain and sensing the direction from which they are receiving signals. Adhesive 
complexes needed for traction collect at the front of the protrusion, tethering the 
protrusion to the substratum. Actomyosin filaments contract at the front of the 
cell and pull the cell body toward the protrusion. Release of adhesive 
connections in the rear of the cell and retraction of the tail completes the cycle. 
The orchestration of this complex process resides in many molecules that serve 
to distinguish the front from the rear of the cell and whose actions are carefully 
timed (Horwitz & Parsons, 1999; Lauffenburger & Horwitz, 1996). 
 
The process of cell migration regulates cellular movements during development 
and directs many links between the cells in the nervous system in a growing 
embryo (Rubel & Cramer, 2002). Numerous guidance molecules and 
chemoattractants steer cells to proper locations in the forming animal. In mature 
organisms, cell movements are required for tissue maintenance and restoration, 
as seen during the remodelling of the vascular system and in wound healing 
(Martin & Parkhurst, 2004). In addition, the cells of the immune and 
inflammatory systems shuttle between the vascular and lymphatic systems and 
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migrate from circulation towards sites of infection (Moser & Loetscher, 2001; 
Thelen, 2001). Besides these roles in normal physiology, improper cell migration 
is seen in many pathological conditions, including cancer metastasis, and 
various chronic inflammatory diseases (Condeelis, et al., 1992; Condeelis, et al., 
2005; Le, et al., 2004; Murphy, 2001; Tarrant & Patel, 2006; Wardlaw, et al., 
2000). 
 
By definition, chemotaxis is the characteristic movement or orientation of a cell 
along a chemical concentration gradient either toward or away from the 
chemical stimulus. In a homogeneous medium cells move randomly. However, 
in a heterogeneous medium many of them are able to perform tactic 
movements. They move in response to the direction and intensity of a stimulus. 
If they move towards or away from the source of stimulus we call it positive or 
negative bias, respectively. Chemokinesis is the reaction by which the speed or 
frequency of locomotion of cells or the frequency and magnitude of turning 
(change of direction) of cells or organisms moving at random is determined by 
substances in the environment (Keller, et al., 1977). The response elicited is not 
vectorial, but rather is random movement. Neither amplitude nor frequency of 
motion has characteristic, directional components as this behaviour provides 
more scanning of the environment than migration between two distinct points. 
From these definitions it becomes clear that undirected information causes 
kinetic behaviour and a directed information causes tactic behaviour. However, 
there are undecided cases. As pointed out by Dunn (Dunn & Brown, 1987). The 
same stimulus and the same receptor kinetics can lead to directed or undirected 
changes in the individual movement patterns.  
 
Bone development, remodelling, and repair involve the recruitment of 
mesenchymal progenitor cells and their differentiation to osteoblasts. The 
process of migration is believed to be regulated, in part, by growth factors stored 
within the bone matrix and released during bone resorption (Fiedler, et al., 
2002). Mundy et al (1982) investigated the mechanisms by which bone-forming 
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cells are attracted to areas of bone resorption during bone remodelling. They 
have used in-vitro methods to identify chemotactic signals released by resorbing 
bone. Cultured rat osteosarcoma cells, showed unidirectional migration in 
response to a signal released by resorbing bones. These cells also migrated 
uni-directionally in response to Type I collagen, which comprises 95% of the 
bone matrix (Mundy, et al., 1982). 
 
BMPs are established as chemoattractive proteins for osteoblasts. Fiedler et al 
(2002) showed that migration of primary human progenitor cells and osteoblasts 
was stimulated by rhBMP-2, rhBMP-4, and rhPDGF in a dose-dependent 
manner (Fiedler, et al., 2002). Gonnerman et al (2006) used a micro Boyden 
chamber to study the migration of two cell lines (UMR and MC3T3-E1) under the 
influence of different concentrations of BMP-2 (1-1000 ng/ml) and showed that 
in both cell types, the highest chemotactic effect was observed at 10 ng/ml of 
BMP-2 (Gonnerman, et al., 2006). Other studies have shown that primary 
human mesenchymal stem cells and MC3T3-E1 osteoblasts demonstrate a 
chemotactic response to recombinant human BMP-7 (rhBMP-7) (Lee, et al., 
2006).  They found that the migration speed and distance of the MC3T3-E1 
cells, or primary human mesenchymal stem cells, co-cultured with BMP-7 
producing COS-7 cells were significantly increased compared to those of the 
MC3T3-E1 cells (or stem cells) only, using a computer-aided, time-lapse video-
microscopy system. 
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9.1.1 Measurement of chemotaxis 
A wide range of techniques are available to evaluate chemotactic activity of cells 
or the chemoattractant character of ligands. The most commonly used are: 
 
Agar plate assays:  
This way of evaluation deals with agar-agar or gelatine containing semi-solid 
layers made prior to the experiment. Small wells are cut into the layer and filled 
with cells and the test substance. Cells can migrate towards the chemical 
gradient in the semi solid layer or under the layer as well (Kohidai, 1995). 
 
Two-chamber techniques:  
Chambers isolated by filters are proper tools for accurate determination of 
chemotactic behaviour. The pioneer type of these chambers was constructed by 
Boyden (Boyden, 1962). The motile cells are placed into the upper chamber, 
while the test substance containing fluid is filled into to lower one. Efficiency of 
the measurements was increased by development of multiwell chambers (e.g. 
NeuroProbe), where 24, 48, 96, 384 samples are evaluated in parallel. 
Advantage of this variant is that several parallels are assayed in identical 
conditions. Positive responder cells are counted from the lower chamber (long 
incubation time) or from the filter (short incubation time). For detection of cells 
general staining techniques (e.g. trypan blue) are used. Labelled (e.g. 
fluorochromes) cells have also been used. In some assays cells get labelled 
during transmigration across the filter. 
 
Boyden chamber was used in this assay based on creating a gradient of the 
chemotactic agent and allowing cells to migrate through a membrane towards 
the chemotactic agent. If the agent is not chemotactic for the cell, then the 
majority of the cells will remain on the upper surface of the membrane. If the 
agent is chemotactic, then the cells will migrate through the membrane and will 
be seen on the lower surface of the membrane. This method was chosen for the 
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advantages of being a simple analysis, does not need image analysis 
techniques in addition to giving quantitative results by multi-well chambers using 
48 parallel running samples.  
9.1.2 Aims. 
We showed in chapters 3 and 4 that gingival fibroblasts release factors inhibitory 
to osteoblast differentiation. Conditioned media extracted from gingival 
fibroblasts confirmed that it could significantly inhibit ALP expression of primary 
calvarial and ROS17/2.8 osteoblasts. As recruitment of osteoblasts is an 
important process in bone remodelling, in the studies here we tested whether 
gingival fibroblasts release factors which might also be inhibitory to osteoblasts 
migration, thus suggesting another mechanism in which gingival superficial 
connective tissue is involved in regulating bone regeneration. Our previous 
experiments also showed that BMP-2 has stimulated differentiation of 
osteoblasts as measured by ALP synthesis. An excess amount of Noggin, a 
BMP inhibitor, could antagonise BMP-2. Gingival conditioned media was also 
able to antagonise the effects of BMP-2. In the studies here we tested the 
antagonistic effects of noggin against BMP-2 in respect of osteoblast migration 
and tested the ability of gingival conditioned media to inhibit the chemotactic 
action of BMP-2 on osteoblasts.  
 
PDGF is another chemotactic factor that operates via a distinct receptor 
signalling pathway. We investigated its stimulatory effects on osteoblasts 
migration. Influence of gingival conditioned media on PDGF effects were also 
investigated. These studies should help to determine whether factors in 
conditioned media are BMP inhibitors or can also inhibit PDGF, therefore 
demonstrate whether the inhibition is generalised or specific to BMP. 
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9.2 MATERIAL AND METHODS 
9.2.1 Chemotaxis chamber 
A Neuro Probe AP48 chemotaxis chamber was used in this set of experiments 
consisting of precision-machined acrylic top and bottom plates and a silicone 
gasket. The bottom plate has 48 wells with a diameter of 3.2mm and each 
holding 25µl. Corresponding holes in the top plate form the upper wells when 
the chamber is assembled. A single 25x80mm piece of polycarbonate filter 
membrane was placed between the top and bottom plates, and a gasket is 
positioned over the filter to create a seal. Narrow raised rims around mating 
surfaces of top and bottom wells enhance the seal. 
 
Figure 9.1: Neuro Probe chemotaxis chamber assembled. 
 
Figure 9.2: Neuro Probe chemotaxis chamber, lower and upper plates and sealing gasket. 
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Osteoblasts 
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Figure 9.3: Diagram of Chemotaxis chamber  
 
9.2.2 Preparation of the filter membrane 
Polyvinylpyrolidine-free polycarbonate filters with a 10µm thickness and a pore 
of 8 µm were used (Receptor Technologies Limited #475947). The filters were 
pre-coated with type I collagen to promote cell attachment, as described by 
(Hughes & McCulloch, 1991). 
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9.2.3 Chamber preparation and experiment set-up 
Using a micropipette and a 1mm gel-loading tip, lower wells were filled with the 
chemoattractant or controls that had been previously warmed to 37˚ C. Each 
well contained 30µl, in order to give a slight positive meniscus to prevent air 
bubbles from being trapped when the filter was applied. The filter membrane 
was applied on the lower plate followed by the silicone gasket paying attention 
to the correct orientation with the lower plate. The top plate was applied and 
fixing screws were firmly tightened. 
 
Adding the osteoblast suspension 
Primary calvarial cells were suspended in αMEM serum free medium at a 
density of 3x105 cells/ml. the cells were pipetted into each upper well (55µl 
/well). Care was taken to avoid formation of air bubbles. The chamber was 
incubated at 37°C for 6 hours.  
 
Preparing and staining the filter membrane  
Wells were emptied by inverting the chamber over a sink. The thumbnuts were 
removed and the chamber was inverted onto a paper towel. The lower plate was 
separated from the system and the filter was carefully held and lifted with pair of 
forceps. The membrane had been cut on its corner to indicate its orientation. 
The cells were fixed by immersing of the membrane in ice-cold methanol for 10 
minutes. The filter was rinsed in PBS and the upper surface where cells were 
seeded was scraped across the edge of a glass slide six times, and rinsed with 
PBS to remove cells left on the upper surface. The membrane was stained by 
DAPI stain (4’-6-Diamidno-2-phenylindole), cut in two halves and mounted on a 
glass slides. 
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9.2.4 Cell Counting 
A fluorescence microscope was used (Nikon Eclips, TE2000-S) to visualise the 
cells migrated through the membrane. Images were taken (X40 objectives) 
using an attached digital camera. Five fields in each well were taken (5 
replicates), and three wells were used for each treatment resulting in 15 fields 
for each treatment. All images were transferred to the PC and counting was 
performed. 
A  B  
Figure 9.4: Calvarial osteoblasts migration, cells migrated through the membrane and stained 
with DAPI showing the difference in cell migration between A (Control) and B (treatment with 
1ng/ml BMP-2). Original magnification x40. 
9.2.5 Statistics 
In migration assays, the number of migrated osteoblasts varied between 
experiments.  Therefore all values were normalised to control values. The 
number of replicates in each experiment and the number of  
independent experiments are indicated in the figure legends.  
Error bars represent the standard deviation calculations. Comparisons between 
2 groups were performed by student t-tests, For 3 or more groups 1-way 
ANOVA with Bonferroni post test was used. Significance was taken as P < 0.05. 
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9.3 RESULTS 
9.3.1 PDGF is a chemotactic factor to primary rat calvarial 
osteoblasts 
PDGF was tested as a chemotactic factor for primary rat calvarial osteoblasts. A 
range of concentrations of PDGF was used (0.01 pg/ml, 0.1 pg/ml, 1pg/ml, 
10pg/ml, 100pg/ml & 1ng/ml). The number of osteoblasts migrated through the 
membrane was significantly higher when PDGF was used in lower well of the 
chamber in concentration of 0.1 pg/ml (35% ± 4% increase). Further increases 
in PDGF concentration above 0.1pg/ml did not result in any further significant 
stimulation to osteoblasts migration. PDGF concentration of 0.01pg/ml did not 
significantly influence the number of migrated osteoblasts compared to control 
(Figure 9.5).  
 
 
Figure 9.5: PDGF effects on calvarial osteoblasts chemotaxis. The results represent averages of 
two independent experiments in triplicates. Five counts were done for each well. All numbers 
were normalised to control. ***: P< 0.001. 
*** 
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9.3.2 BMP-2 is a chemotactic factor to primary rat calvarial 
osteoblasts 
A range of concentrations of BMP-2 were tested for chemotactic effects on 
primary rat calvarial osteoblasts (0.01ng/ml, 0.1ng/ml, 1ng/ml, 10ng/ml and 
100ng/ml). Concentration of 0.01ng/ml of BMP-2 did not significantly influence 
the migration of osteoblasts compared to control, (test: 0.3 ± 9.3%, control: 100 
± 9.7). BMP-2 caused a dose-dependent increase in migration at concentration 
between 0.1 and 10ng/ml. However, 100ng/ml of BMP-2 did not further increase 
migration compared to treatment with 10ng/ml (Figure 9.6). 
  
Figure 9.6: BMP-2 effects on calvarial osteoblasts chemotaxis. The results represent averages 
of two independent experiments in triplicates. Five counts were done for each well. All numbers 
were normalised to control. ***: P< 0.001. 
 
 
 
 
 
*** 
 
*** 
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9.3.3 BMP-2 is a chemokinetic factor for primary rat calvarial 
osteoblasts 
BMP-2 was tested for chemokinetic effects on primary rat calvarial osteoblasts, 
that is the stimulation of random migration independent of concentration 
gradients.  BMP-2 was applied to both the top and bottom wells of the chamber. 
A range of concentrations was used (0.01ngl/ml, 0.1 ng/ml, 1ng/ml and 
10ng/ml). We therefore tested the ability of BMP-2 to alter amount of random 
movement exhibited by osteoblasts.  BMP-2 concentration of 0.01ng/ml in both 
lower and upper wells of the chamber did not significantly change number of 
migrated cells compared to control (3% increase ± 9%). Concentrations of 
0.1ng/ml in both chambers significantly increased osteoblasts migration by 28% 
± 6% compared to control, however increasing the concentrations to 1ng/ml and 
10ng/ml did not cause any further increase in osteoblast migration (Figure 9.7). 
 
 
 
Figure 9.7: BMP-2 effects on calvarial osteoblasts chemokinesis. The results represent averages 
of two independent experiments in triplicates. Five counts were done for each well. All numbers 
were normalised to control. ***: P< 0.001. 
*** 
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9.3.4 Noggin is a BMP-2 inhibitor in migration assay 
Noggin (50ng/ml) was applied alone and combined with BMP-2 (0.1ng/ml & 
1ng/ml) in the lower wells of the chamber to investigate whether noggin can 
antagonize the effects of BMP-2 on osteoblast migration.  Adding noggin alone 
to the lower wells in the migration chamber did not significantly alter the 
migration of osteoblasts; however, noggin was able to completely block the 
effects of BMP-2 on osteoblast migration (Figure 9.8). 
 
 
  
Figure 9.8: Effects of noggin (50ng/ml) on calvarial osteoblasts chemotaxis enhanced by BMP-2. 
The results represent averages of two independent experiments in triplicates. Five counts were 
done for each well. All numbers were normalised to control. ***: P< 0.001. 
 
 
 
 
 
*** 
 
*** 
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9.3.5 Gingival conditioned media opposes effects of BMP-2  
Gingival conditioned media was applied alone and in combination with different 
concentrations of BMP-2 to the lower wells of the chemotaxis chamber. Gingival 
conditioned media did not significantly alter the migration pattern of the primary 
osteoblasts compared to control (actual number of cells migrated and 
considered background and all numbers were normalised to was 29.6 ± 5.3); 
however when gingival conditioned media was used with low concentrations of 
BMP-2 (1ng/ml &10ng/ml) in the lower wells, this significantly altered the 
migration behaviour compared to treatment with BMP-2 only. BMP-2 stimulate 
migration of osteoblasts at concentrations of 1-100ng/ml, gingival conditioned 
media was able to completely suppress this stimulation and to control level 
when treatment was combined with concentrations of BMP-2 up to 10ng/ml. 
Treatment with 100ng/ml of BMP-2 still stimulated migration of osteoblasts 
compared to control in the presence of gingival conditioned media (Figure 9.9).  
 
 
Figure 9.9: Effects of gingival CM on calvarial osteoblasts chemotaxis enhanced by BMP-2. The 
results represent averages of two independent experiments in triplicates. Five counts were done 
for each well. All numbers were normalised to control. ***: P< 0.001 to relevant BMP-2 treatment 
only. +++: P< 0.001 compared to baseline. 
*** 
 
*** 
 
+++ +++ +++ 
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9.3.6 Gingival conditioned media does not interfere with chemotaxis 
induced by PDGF  
Addition of Gingival CM combined with PDGF had no effects on PDGF mediated 
cell migration at all concentrations of PDGF tested (Figure 9.10). 
 
 
Figure 9.10: Effects of gingival CM on calvarial osteoblasts chemotaxis stimulated with PDGF. 
The results represent averages of two independent experiments in triplicates. Five counts were 
done for each well. All numbers were normalised to control. 
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9.4 DISCUSSION 
BMPs have mainly been suggested to stimulate differentiation and proliferation 
of mesenchymal stem cells toward an osteoblastic lineage. Thus they are 
believed to be involved in the basic pathophysiology of bone including healing 
and remodelling, where they are thought to increase the number of differentiated 
osteoblasts capable of forming bone. This stimulatory effect on osteoblastic 
differentiation by the BMPs is of particular importance during bone healing in 
which extensive bone formation capacity from differentiated osteoblasts is 
needed. As well as proliferation and differentiation effects, it has been 
suggested that stimulation of osteoblast chemotaxis by BMP-2 could be another 
mechanism for recruitment of bone forming cells. The chemotactic recruitment of 
osteoprogenitor cells and osteoblasts by BMP-2 could be of importance at both 
local bone formation during remodelling and during extensive formation in the 
bone healing process (Fiedler, et al., 2002; Gonnerman, et al., 2006). Studies 
support this hypothesis by demonstrating BMPs to be expressed and present in 
the early phases of fracture healing (Jin, et al., 1994; Nakase, et al., 1994). The 
maximal metabolic effects of BMPs on mouse and rat osteoblast cultures have 
previously been demonstrated around 10-100 ng/ml (Hiraki, et al., 1991; 
Sampath, et al., 1992). Lind et al (1996) stimulated migration of human 
osteoblasts, human marrow stromal osteoblasts, and U2-OS osteosarcoma cells 
with BMP-2. In their study maximal stimulation was seen at 1 ng/ml for human 
osteoblasts, human marrow stromal osteoblasts, and U2-OS osteosarcoma cells 
and at higher concentrations of 10 ng/ml and above the migration decreased to 
control levels (Lind, et al., 1996).  
 
In our study, the migratory effects of BMP-2 were seen at a relatively low 
concentration around 0.1ng/ml, maximal effects seen at 10ng/ml, and continued 
effects at high concentration of 100ng/ml.  The study also showed that BMP-2 
stimulated primary rat calvarial osteoblast chemokinesis in addition to its 
chemotactic effects. The chemokinetic response was maximal at 0.1ng/ml of 
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BMP-2 treatment and resulted in a 28% increase in the number of migrated cells 
compared to control. However, the chemotactic response continued to increase 
to make more than double the control level and reached maximum effect at the 
higher concentration of 10ng/ml. 100ng/ml BMP-2 also showed the maximal 
migration. This is slightly different to the results of Lind et al who showed a 
decline in migratory response in supra-optimal concentrations.  
In the present experiments noggin alone did not affect osteoblast migration; 
however, as expected it antagonized the chemotactic stimulation of osteoblasts 
by BMP-2 and suppressed it to control level. The noggin concentration used 
here was 50ng/ml and was used against 1ng/ml of BMP-2. Our results are 
consistent with experiments done by Sotobori et al (2006), who showed that 
treatment with noggin (1µg/ml) blocked the stimulatory effect of exogenously 
added rhBMP-2 (100ng/ml) on chemotaxis. In their experiment treatment with 
noggin only also did not alter the migration compared to control (Sotobori, et al., 
2006). 
 
A range of doses of PDGF were tested in the chemotaxis assay as it has been 
shown by researchers to be a potent chemotactic factor for various bone cell 
lines (Rasubala, et al., 2003).  Maximum significant response was achieved with 
0.1pg/ml of PDGF. Higher concentrations up to 1ng/ml were tested with no 
further alteration. These data are consistent with previous work which showed 
that effects have been demonstrated to be maximal at 100-fold lower 
concentrations than the maximal metabolic effects in rat calvaria and 
osteosarcoma cells (Hughes, et al., 1992); nevertheless other researchers have 
used relatively high doses of PDGF to increase migration of cells (Mehrotra, et 
al., 2004). 
 
It was previously demonstrated that gingival conditioned media contains factors 
inhibitory to BMP-2 in respect of differentiation of osteoblasts (Calvarial and 
ROS17/2.8 cells). Here it was shown that gingival conditioned media also blocks 
the effects of BMP-2 on osteoblast migration. However these inhibitory effects 
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were not seen when gingival conditioned media was applied to PDGF. This 
result provides evidence that the inhibition caused by gingival conditioned media 
is specific against BMP-2, rather than a general inhibitory effect on cell migration 
or chemotactic response.  
 
In summary, gingival CM contains factors that inhibit BMP-2 signalling in 
osteoblast chemotaxis in a similar pattern to noggin. The same conditioned 
media was not able to inhibit osteoblast migration when it was applied alone and 
it was not inhibitory to PDGF signalling on chemotaxis. This is evidence that 
gingival fibroblasts release factors that negatively regulate BMP-2, not only on 
osteoblasts differentiation as demonstrated in previous chapters, but also on 
osteoblasts migration behaviour. 
Since BMPs are thought to be one of the key regulators of bone formation, these 
results contribute to the understanding of the role superficial connective tissue 
may play in regulating osteogenesis and bone physiology. 
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CHAPTER TEN 
GENERAL DISCUSSION AND CONCLUSIONS 
 
10.1 GENERAL DISCUSSION 
The studies in this thesis have tested the hypothesis that the superficial 
connective tissue cells release factors which may inhibit coronal growth of 
alveolar bone. The anatomical and biological considerations of this region 
present unique challenges in respect of clinical regeneration of the lost bone. 
One of the most challenging problems is the failure to induce coronal bone 
regeneration.  When this bone is lost, it is claimed that the epithelium and 
superficial soft connective tissue (gingiva) grow at a rate considerably faster 
than the rate of periodontal ligament and bone forming cells. This means that 
the void created by bone loss becomes filled with connective tissue before the 
osteoblasts can repopulate the site.  Guided tissue regeneration (GTR) and its 
corollary, guided bone regeneration (GBR) involve placing a thin barrier 
membrane between the osseous defect and the overlying soft tissues. This 
restricts cells to colonize the defect to those from the bone tissue compartment. 
However, whilst these techniques can be relatively effective in regenerating 
bone laterally, induction of coronal bone growth is generally much more limited 
(Roos-Jansaker, et al., 2003). Although GBR/GTR techniques separate the 
different tissue compartments these techniques may also limit the movement of 
factors released by gingival fibroblasts thus reducing any inhibition of the bone 
forming cells in the adjacent alveolar bone.  Therefore, the aims of this project 
were to study the influence of superficial tissue fibroblasts on the behaviour of 
osteoblasts. The differentiation and migration of osteoblasts cultured with 
fibroblasts or treated with supernatants conditioned by fibroblasts were tested. 
It was demonstrated in chapter 4 using a 3-D culture system that superficial 
connective tissue fibroblasts significantly inhibit osteoblast differentiation. The 
two types of cells were grown in the same well so they could directly contact 
each other. The main shortcoming of this system is that ALP is assayed for the 
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entire mixed cell population; changes are compared to either fibroblasts or 
osteoblasts cultured alone. In addition the changes in ALP levels are 
complicated by changes in absolute and relative cell proliferation in mixed 
populations and the influence of cell density on ALP expression. Zhou et al 
(2006) found that human alveolar osteoblasts express more ALP when they are 
at 2x105 cells density than 4x105 or 8x105 cell density in 3x4x4 mm 3D scaffolds 
(Zhou, et al., 2006). Although it was difficult to separate the osteoblasts from the 
combined 3D culture to measure their ALP production, the results showed levels 
of inhibition (56%) consistent with that subsequently demonstrated in other 
model systems.  
 
It was also demonstrated that matrix deposited by gingival fibroblasts caused 
similar inhibitory effects. This indicated that live fibroblasts are not required to 
cause this influence and factors involved in this action can become embedded in 
the matrix or are cell membrane-bound factors that do not require living 
fibroblasts. A comparison of the effects of gingival fibroblasts or their matrices 
(test groups) with effects of osteoblasts or their matrices (control groups) on the 
differentiation of calvarial osteoblasts demonstrated that the inhibitory activity 
was specific to fibroblasts. These initial experiments only used gingival 
fibroblasts and the testing of other fibroblast types of superficial and deep tissue 
might give more insight into the specificity of the inhibition and whether 
differences existed between superficial and deep tissue fibroblasts in respect of 
inhibition of osteoblast differentiation. Therefore, we tested additional cell lines 
derived from a range of connective tissue sites in the other models.  
 
To investigate whether inhibitory molecules required cell-cell contact, two 
experimental systems were used in chapter 5 which both showed that superficial 
tissue fibroblasts could cause the above effects to osteoblasts without the 
requirement of direct cell-cell contact. The first model used a bi-compartment 
system that enabled the two cell types to grow whilst sharing the culture medium 
without cellular contact between the two cell types. The second system used 
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conditioned media from fibroblasts to treat the osteoblasts.  Both models 
showed that superficial connective tissue fibroblasts released factors that inhibit 
osteoblast differentiation. The conditioned media collected from different cell 
types was a successful model to study the influence on osteoblast 
differentiation. It formed a stable source to produce reproducible effects 
whenever used.  The conditioned media was collected in the absence of serum 
which meant that conditioning the media did not involve selective depletion of 
the serum.  Using media conditioned by different cells to treat calvarial and ROS 
cells it was shown that CM collected from superficial connective tissues, namely 
gingiva, oral mucosa and skin, was inhibitory to calvarial and ROS cell 
differentiation in a predictable and reproducible manner.  For the gingival cells 
particularly this effect was seen consistently throughout the many similar 
experiments carried out through out these studies, and using different 
conditioned media deriverd from different cell lines at different times.  This effect 
was demonstrated by measuring osteoblast ALP expression using total ALP 
assay and real-time PCR. In contrast, fibroblasts from the periodontal ligament, 
stimulated ROS cell differentiation measured by total ALP assay.  Although this 
stimulation was not evident when ALP was measured by rtPCR, this might be 
explained by the presence of modulatory mechanisms in the conditioned media. 
 
Although conditioned media of calvarial osteoblasts inhibited ALP production of 
calvarial osteoblasts, it stimulated cell proliferation. This stimulation of cell 
proliferation also suggests an alternative mechanism of inhibitory activity since 
osteoblasts are blocked from differentiating when they are actively proliferating 
(Granchi, et al., 2008), and suggest the production of mitogenic growth factors 
by the osteoblasts.   
 
When further studies were conducted (by ELISA and qRT-PCR) to test the 
effects of CM on the expression of other osteoblast differentiation markers, 
namely, osteocalcin and osteopontin, gingival CM did not significantly affect the 
expression of these markers, although there was a pattern of similar effects to 
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ALP, the results did not reach statistical significance due to the relatively large 
standard deviations seen with this data.  The differences in the results between 
ALP and other markers may be due to the existence of osteoblasts at different 
differentiation stage in the culture.  In addition, the use of the ROS 
osteosarcoma cell line might increase the likelihood of “decoupling” of ALP and 
other bone markers which would increase the likelihood of the cells not showing 
a normal progressive pathway of osteoblastic differentiation.  In support of this, 
positive control experiments using BMP-2 stimulation, an osteotropic factor 
known to stimulate osteoblast differentiation, also failed to regulate osteocalcin 
and osteopontin expression although did strongly stimulate AlP expression in 
the ROS cells.    Interestingly PDL CM caused a significant stimulation to 
osteocalcin and osteopontin expression as measured by RT-PCR in keeping 
with the findings with PDL CM on ALP. 
 
Despite the absence of significant effects of other osteoblast markers tested, the 
ALP assay was a good and easy model to study assess osteoblast 
differentiation and was therefore used in subsequent experiments.  The 
subsequent studies justified this interpretation as it was shown that the gingival 
medium has specific effects by antagonizing the action of BMPs (as seen in both 
ROS cell cultures and in primary cultures with both ALP assays and with 
chemotaxis assays. 
 
The studies then concentrated on the investigation of BMP antagonists as 
potential inhibitory factors that limit bone growth. Application of BMPs to a bone 
defect will initiate local bone formation and growth (Ripamonti, et al., 2001). 
Given the critical role that BMPs play in normal bone growth, inhibitors of BMPs 
were obvious candidates to test for the negative regulation of bone growth. By 
using BMPs a very sensitive model system to assay antagonistic potential of the 
conditioned media was developed. In this test system it was shown that ROS 
cells responded to as little as 1ng/ml of BMP. Using this ROS cell-based assay 
the effects of BMP-2 and activin were compared. Both caused a significant 
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increase in osteoblast differentiation (three fold with BMP-2 treatment, 1.5 fold 
with activin) as judged by changes in total ALP levels. The influence of 
antagonists of these factors was also investigated. The activity of noggin, 
chordin and follistatin were all compared to block BMP-2 activity. It was 
demonstrated that noggin could effectively block the activity caused by BMP-2. 
However, did not significantly reduce the basal (un-stimulated) ALP activity of 
osteoblasts.  Although chordin was also able to block BMP-2, a much larger 
dose of chordin (5 folds) was needed to cause the same effects as noggin.  This 
is probably in part due to the relatively higher molecular weight of chordin 
(101.5kDa) compared to 26kDa for noggin.  It may also reflect the differences in 
relative affinity or the need for multiple binding co-factors that regulate chordin 
action (Larrain, et al., 2003). Tests using follistatin showed that it did not block 
BMP-2 or activin activity. This is consistent with studies indicating that the 
specificity and binding affinity of follistatin is different from noggin or other BMP 
antagonists (Nakamura, et al., 1990; Michel, et al., 1990; Iemura, et al., 1998). 
Follistatin binds BMP-2, -4, and -7, with highest affinities for BMP-7 (Yamashita, 
et al., 1995), although the affinity of follistatin for BMPs is lower than that for 
Activin (Iemura, et al., 1999; Nakamura, et al., 1990). Follistatin binding to BMP 
receptors might need the generation of a trimeric complex involving key co-
factors (Iemura, et al., 1998). It is also possible that differences in the 3 follistatin 
isotypes (FS288, FS315 and follistatin-like 3 FSTL3) can influence binding 
specificity and affinity (Stamler, et al., 2008). In that study, binding studies 
revealed that replacing the FSTL3 N-terminal domain with the corresponding FS 
domain considerably lowers the affinity to activin A.  
 
In chapter 8 it was shown that the conditioned media harvested from superficial 
connective fibroblasts can block the effects of BMP-2 on calvarial or ROS cell 
differentiation. In addition it was shown that periodontal ligament fibroblasts 
(deep tissue) secreted factors which enhanced the activity of BMP-2 on 
osteoblast differentiation.  This stimulation was partially blocked by noggin. This 
confirmed the opposing action of the two anatomically distinct tissues 
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(superficial and deep).  BMP inhibitors might therefore be the factors released 
by the gingival fibroblasts that cause the inhibition of alveolar coronal bone 
growth. This is consistent with the result of a study by Jin et al (Jin, et al., 2003) 
that showed that periodontal tissue engineering can be performed by ex vivo 
gene transfer of BMP-7 gene delivery and osteogenesis can be inhibited by 
increased levels of noggin. 
 
It was also shown that BMP-2 can stimulate osteoblast recruitment as well as 
differentiation. In these studies conditioned media from superficial connective 
tissue fibroblasts inhibited the chemotactic activity of BMP-2, as did noggin. The 
antagonism of the gingival conditioned media was specific to BMP-2 since it was 
unable to inhibit cell migration induced by PDGF. Thus it was demonstrated that 
gingival fibroblasts release factors that antagonize BMP-2 activity, not only on 
osteoblast differentiation as demonstrated in chapter 6, but also on osteoblast 
migration behaviour as shown in chapter 7. The chemotactic recruitment of 
osteoprogenitor cells and osteoblasts by BMP-2 could be of importance at sites 
of local bone formation during remodelling and the bone healing process 
(Fiedler, et al., 2002; Lee, et al., 2006). Therefore, BMP inhibitors possibly 
released by gingival fibroblasts could inhibit both the recruitment and 
differentiation of osteoblasts at the coronal margin of the alveolar bone. 
  
This project provides direct evidence that an inhibitory signal to bone growth is 
produced by superficial connective tissue fibroblasts and has answered some of 
the questions with regards to identifying the nature of signals involved in this 
inhibition. Although this study suggests that maybe the inhibition is caused by a 
single factor, the results do not exclude a role for multiple factors acting 
together. Further pilot experiment was performed in attempt to identify the 
soluble molecules involved, i.e. the proteins expressed by the superficial tissue 
fibroblasts and involved in the inhibitory effects. Preliminary experiments were 
done to characterise the factors using selective filtration with molecular weight 
cut-off filters (5-100 KD) applied to the different conditioned media. Filtered 
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media was used to treat ROS 17/2.8 cells and compared to non-filtered media, 
then the changes were assessed by measuring total ALP assay. The results 
showed that media containing factors of molecular weight larger than 50kDa 
was not inhibitory to ALP production of ROS cells. However, media with factors 
of molecular weight smaller than 50kDa was inhibitory to ALP production of ROS 
cells. According to these preliminary results, it can be assumed that BMP 
antagonists larger than 50kDa are unlikely to be involved. However, these 
results do not positively help to identify the factors involved since most BMP 
inhibitors are smaller than 50kDa. Table 8.1 shows the molecular weight of 
some BMP antagonists. 
Molecules above 50kDa MW Molecules below 50kDa MW 
Chordin 101.5kDa Noggin 26kDa 
  Gremlin 19.6kDa 
  Follistatin 31kDa 
  Sclerostin 22.5kDa 
  DAN 18.9kDa 
  PRDC 17.1kDa 
Table 10.1: The molecular weight of some BMP antagonists 
 
Different techniques can be applied to characterize factors contained in the 
conditioned media. Preliminary work currently underway in our group by M 
Ghuman has investigated the expression of a range of inhibitors using 
quantitative PCR and Western blotting assays. This has shown that gingival 
fibroblasts express significant levels of Gremlin, PRDC, DAN and Noggin. The 
expression of these factors needs to be investigated further in both cultured cells 
and intact tissues. 
 
BMPs are major factors involved in abnormal ectopic bone formation and indeed 
this bone formation can be induced by application of BMPs to sites such as 
muscles in rat experiments, resulting in complete bone formation in an ectopic 
site. However, this ossification does not happen in superficial connective tissue 
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except in extremely rare cases (Kaplan, et al., 2004; Spronk, et al., 2001). 
The mechanisms which prevent ossification in superficial tissues are largely 
unknown. However the studies here provide strong evidence that this is due to 
the inhibition of BMP activity in superficial connective tissues and is likely to be 
the result of expression of specific BMP inhibitor proteins by the superficial soft 
connective tissue fibroblasts. At present there is little information regarding the 
presence of any of these potential BMP inhibitory factors in the gingival or other 
superficial connective tissues, and finding these factors in the forementioned 
tissues is thus the subject of proposed future studies.  
 
There are some limitations to the studies described here which need to be 
considered when interpreting the data and considering future work required in 
this area. Although the studies described show clear evidence of strong BMP 
inhibitory activity, this does not exclude the possibility that inhibition of bone 
formation might involve other mechanisms also. Indeed two pieces of evidence 
specifically support this suggestion. Firstly early experiments showed that non-
vital matrix also had osteoblast inhibitory activity, and it is not known if BMP 
antagonists are indeed sequestered in matrix.  Secondly although gingival CM 
inhibited basal ALP activity of ROS cells, this was not the case with the BMP 
antagonist noggin. 
 
In addition, by using cell culture models some caution should be exercised in 
extrapolating results to the situation in vivo. However these in vitro models are 
extremely useful in determining basic mechanisms and pathways before testing 
ideas in models in vivo. The studies have also concentrated on the use of one 
marker of osteoblast differentiation, ALP. ALP is widely use as an osteoblast 
differentiation marker and is possibly one of the most studied regulatory 
molecules in bone (Hughes & Aubin, 1998). In the studies here it proved to be a 
reproducible and simple assay to use as a “readout” of osteoblast responses 
although further studies might also use additional markers such as osteocalcin 
production. 
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10.2 FUTURE STUDIES 
A number of studies would be very useful to advance this area or research. 
As discussed above, there is a need to identify the expression of the range of 
BMP antagonists by fibroblasts, and to determine their relative concentrations 
and activity. As discussed previously some of these studies are already ongoing 
in our laboratory, but a fuller picture of this issue will also allow further testing of 
the specificity of inhibitory activities. 
The relative role of BMP antagonists versus other potential inhibitory activities 
also needs to be established. This might usefully be done in vitro using RNA 
silencing to block expression of relevant BMP inhibitors, followed by re-testing of 
the conditioned medium (which should then be absent of BMP inhibitory activity) 
for inhibitory activity. 
Extension of these studies to in vivo models would also be important to plan in 
order to translate the findings in vitro to a physiologically relevant system. Again, 
use of conditional knock out or knockdown models of the appropriate BMP 
inhibitors could provide definitive evidence of the role of this postulated activity. 
It is hope that these data could result in clinical studies to avoid or diminish the 
BMP inhibitory activity, possibly by blocking antagonist expression, stimulating 
exogenous BMPs which are not susceptible to specific antagonists, or even by 
chemically modifying BMP to prevent binding to antagonist locally. In the longer 
term it may be possible to produce modified BMP molecules for therapeutic 
application which take account of these findings.  In general it is thought that the 
antagonist binding domains of BMP proteins are not the same as the receptor 
binding domains of these molecules and thus it may be possible to engineer 
modified BMPS which are not susceptible to their extracellular antagonists but 
which retain their biological activity 
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10.3 CONCLUSIONS 
Bone normally has a high regenerative capacity. For example following fractures 
apposition and immobilisation of the fracture ends normally results in complete 
healing. However if damage to the alveolar bone occurs beyond a critical limit, it 
cannot regenerate completely. In this situation, clinical intervention aims to 
restore the lost bone therapeutically (Dunn, et al., 2005).  
 
In the longer term information provided in this project will lead to more definitive 
experiments on candidate inhibitor mechanisms and in-vivo regional distribution 
of BMP inhibitors. Ultimately, establishing the balance between BMPs and their 
inhibitors may lead to novel therapeutic interventions to promote bone growth 
and solve problems of pathological bone loss. Guided bone regeneration (GBR), 
is currently the technique of choice with or without graft material to treat bone 
loss.  Since current techniques do not usually induce coronal bone growth 
(Roos-Jansaker, et al., 2002; Stenport, Roos-Jansaker, et al., 2003), applying 
tissue engineering using bone enhancement molecules like BMPs or therapeutic 
modifications to block the inhibitory molecules released by the superficial 
connective tissue may direct bone formation favourably.  This may be through 
the application of topical drugs or combining BMP inhibitor blocking therapy with 
guided tissue regeneration, by attaching blocking agents to the side of the 
membrane facing the soft tissues and BMP proteins to the side facing bone. 
This could be an important step to solving several clinical problems associated 
bone loss problems. These include not only periodontal disease, but also for 
those considering dental implants, would-be denture wearers and children with 
congenital facial deformities. 
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